Investigating the immunomodulatory properties of human embryonic stem cell-derived mesenchymal stem cells by Lin, Wenyu & Lin, Wenyu
Investigating the immunomodulatory properties 
of human embryonic stem cell-derived 
mesenchymal stem cells 
 
 
 
 
 
 
 
Wenyu Lin 
 
 
Thesis submitted for the Degree of Doctor of Philosophy 
Imperial College London 
 
 
 
 
 
 
 
 
Department of Immunology, Division of Medicine 
Imperial College London, Hammersmith Campus 
 
November 2010 
  
2
Abstract 
The immunosuppressive property of mesenchymal stem cells (MSC) has been utilised to 
ameliorate autoimmune reactions such as graft-versus-host disease. However, variation exists in 
primary MSC isolated due to differences in donor age and tissue of origin. Alternatively, human 
embryonic stem cells (hESC) can be differentiated to homogeneous populations of MSC (hESC-
MSC), thus providing an unlimited source of MSC for cell therapy.  
In this study, the immunomodulatory properties of two hESC-MSC lines, hESC-MSC1 and 
hESC-MSC2, were compared with adult bone marrow-derived MSC (BM-MSC) and neonatal 
foreskin fibroblast (Fb). hESC-MSC were able to suppress the proliferation of anti-CD3/CD28-
stimulated CD4+ T cells in contact and transwell systems. The immunosuppression was 
demonstrated by both the carboxyfluorescein diacetate succinimidyl ester (CFSE) and [3H]-
thymidine proliferation assays. However, hESC-MSC were less potent and twice the number of 
adherent hESC-MSC (as measured by IC50) compared to BM-MSC and Fb were required to 
suppress T cell proliferation by 50%.  
Supernatants collected from transwells of MSC or Fb with T cells were shown to suppress T cell 
proliferation, suggesting that suppressive factors were only produced in the presence of activated 
T cells. Among several candidates, endothelial monocyte-activating polypeptide-II (EMAP-II) 
was identified as a potential suppressive factor. T cells also induced indoleamine-2,3-
dioxygenase (IDO) expression in MSC and Fb. IDO led to the depletion of tryptophan, an 
essential amino acid, and/or the production of tryptophan metabolites (kynurenines), thereby  
inhibiting T cell proliferation. Interestingly, blocking of IDO with 1-methyltrytophan reversed 
the suppressive effect, implicating IDO as a potential mediator in T cell suppression. 
Concomitantly, several candidate suppressive factors in the supernatants have also been 
identified using antibody arrays. However, their functions require validation. In conclusion, 
hESC-MSC share similar suppressive properties as BM-MSC and represent a potential cell 
source for clinical purposes.  
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1 Introduction 
Firstly, the characteristics and potential uses of stem cells (human embryonic stem cells (hESC), 
induced pluripotent stem cells (iPSC), adult stem cells (ASC), mesenchymal stem cells (MSC) 
and hESC-derived MSC (hESC-MSC)) and fibroblasts (Fb) will be described. Secondly, the 
immunological hurdles for stem cell therapy will be discussed. Finally, the literature regarding 
the immune characteristics of stem cells and Fb will be covered. 
1.1 Human embryonic stem cells (hESC) 
1.1.1 Derivation and characteristics of hESC 
hESC are derived from the inner cell mass (ICM) of the blastocyst, one of the earliest stages of 
the development of the embryo. After fertilisation, a series of cleavage divisions occur (Figure 
1-1). Each cell (blastomere) is uncommitted to any specific cell lineage. By day 4, the morula is 
formed, containing a collection of around 30 cells. 
 
Figure 1-1. Derivation of hESC. 
The human oocyte is fertilised in vitro 
by a sperm on day 0. At 24-25 h, the 
fertilised egg undergoes the first 
cleavage to generate a 2-cell 
embryo. By day 3, the 8-cell stage is 
formed. By day 5, the cavity of the 
blastocyst is completed. The ICM 
separates from the outer layer of 
cells. This is the first observable sign 
of cell differentiation in the embryo. 
The ICM of the blastocyst can be 
maintained in culture and generates 
hESC in the centre with trophoblast-
like cells in the periphery. 


2-cell stage
24-25 h
4-cell stage
Day 2 
8-cell stage
Day 3
Blastocyst
Day 5
Cultured pluripotent stem cells
Inner cell 
mass
Blastocoel
Trophectoderm
Blastomere


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Prior to implantation, the cells of the morula differentiate to form the blastocyst. The blastocyst 
contains an outer layer of cells and an inner cluster of cells termed the ICM. The outer layer of 
cells of the blastocyst gives rise to the trophectoderm and subsequently the placenta and other 
extraembryonic tissues while the ICM gives rise to all the other tissues in the body.  Cells of the 
ICM can be removed from the embryonic environment and cultured continuously in vitro under 
suitable conditions (Reubinoff et al., 2000; Thomson et al., 1998). These ICM-derived cells are 
thus termed as hESC. 
hESC can self-renew and are pluripotent, meaning that they can give rise to cells from all three 
germ layers: endoderm, ectoderm and mesoderm (Itskovitz-Eldor et al., 2000; Reubinoff et al., 
2000) (Figure 1-2). Pluripotency of hESC can be demonstrated in vivo by injecting hESC into 
immunodeficient mice to form teratomas containing the three germ layers (Reubinoff et al., 
2000). 
hESC derived from ICM can 
undergo self-renewal
Blastocyst
EndodermMesodermEctoderm
Pluripotency
Neurone Blood cells Pancreatic cells
 
Figure 1-2. Characteristics of hESC.  
hESC are derived from the ICM of the blastocyst. They can self-renew for prolonged periods of time and 
remain pluripotent with the ability to differentiate to the three germ layers. 
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1.1.2 Potential uses of hESC 
As hESC can proliferate indefinitely, they offer an unlimited source of cells which can be 
differentiated to any cell type in the body. Therefore, they have enormous potential for use in 
regenerative medicine to produce tissues for cell replacement therapy. Donated organs and 
tissues from live donors or cadavers are commonly used to replace the damaged tissue. However, 
the demand for these organs and tissues exceeds the available supply (Hauptman and O'Connor, 
1997; Steinbrook, 2007). For example, during myocardial infarction, the loss of cardiac muscle 
cells (cardiomyocytes) occurs. The adult heart has a limited regenerative capacity and this cell 
loss is mostly irreversible, leading to heart failure and eventual death (Lewis et al., 2003). Cell 
therapy may potentially restore the function of the heart. The potential of hESC-derived 
cardiomyocytes has been demonstrated in animal models. When hESC-derived beating 
myocardial tissue was injected into the infarcted myocardium of athymic nude rats, left 
ventricular function was preserved (Leor et al., 2007). However, most of the transplanted cells 
did not survive or integrate with the host myocardium. The improvement in ventricular function 
could be due to paracrine factors which prevented cardiac apoptosis. 
The use of hESC-derived cells for cell therapy is moving closer to reality with the recent 
announcement pertaining to the testing of GRNOPC1® for spinal cord injury in clinical trial 
phase I (Geron Corporation, 2010). GRNOPC1® contains hESC-derived oligodendrocyte 
progenitor cells and has been demonstrated to restore function in animal models of acute spinal 
cord injury through its remyelinating and nerve growth stimulating properties. hESC-derived 
cells and tissues can also be used for the testing of new drugs and improving their safety and 
efficacy for use in humans. For instance, hESC-derived heart cells may be used for toxicology 
studies, thus minimising the risk to humans due to inter-species differences when tested in 
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animals (Andersson et al., 2010). Such drug testing can be extended to other cell types such as 
neural cells and hepatocytes. 
1.2 Induced pluripotent stem cells (iPSC) 
A breakthrough in stem cell research occurred in 2006. Takahashi and Yamanaka showed that  
mouse Fb could be reprogrammed into pluripotent stem cells following the retroviral 
transduction of the four transcription factors – Octamer-binding transcription factor 3/4 (Oct3/4), 
sex determining region Y-box 2 (Sox2), krüppel-like factor 4 (Klf4) and c-myc into the Fb. 
These iPSC were similar to embryonic stem cells (ESC) in morphology, growth properties, 
surface expression of ESC markers and teratoma formation (Takahashi and Yamanaka, 2006). 
However, the iPSC generated were different from ESC in terms of gene expression and 
methylation patterns and failed to produce adult chimeras when injected into blastocysts. 
Subsequently, fully pluripotent iPSC were generated by increasing the stringency of the selection 
process and selecting for cells with reactivation of the master pluripotency transcription factors 
Oct4 and Nanog (Maherali et al., 2007; Okita et al., 2007). These iPSC had fully demethylated 
Oct4 and Nanog promoters and could form germline-competent chimeras upon injection into the 
blastocysts.  
Human iPSC can also be generated from adult human dermal Fb with the same four factors (Park 
et al., 2008; Takahashi et al., 2007). However, the reactivation of the c-myc retrovirus increased 
the formation of tumours in the chimeras (Okita et al., 2007). Subsequently, c-myc was found to 
be dispensable for iPSC generation.  When only the three factors, Oct3/4, Sox2 and Klf4, were 
used, there was no tumour formation (Nakagawa et al., 2008; Wernig et al., 2008). However, 
there was reduced efficiency in iPSC generation. The replacement of c-myc with Lin28 could 
successfully reprogramme Fb into ESC as well (Yu et al., 2007).  
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In a bid to make iPSC more patient-friendly, iPSC can be generated without the use of viruses. 
One approach makes use of polycistronic vectors carrying the four factors that could integrate 
into the genome when cotransfected with a transposase (Kaji et al., 2009; Woltjen et al., 2009; 
Yusa et al., 2009). After the iPSC lines were established, the vectors could be excised from the 
genome with a second round of exposure to transposases. Others have eliminated the need for 
gene delivery and have alternatively used small molecules (Feng et al., 2009). 
In conclusion, iPSC are a potential alternative to hESC in cell therapy. Furthermore, they 
overcome the ethical constraints that hESC face since iPSC are created without the destruction of 
embryos.  
1.3 Adult stem cells (ASC) 
1.3.1 Characteristics of ASC 
ASC are similar to hESC. They can proliferate for long periods of time and give rise to 
specialised cells. However, as compared to hESC, ASC are multipotent with limited 
differentiation ability to cell types of their tissue of origin. The main functions of ASC in an 
organism are to maintain the steady-state functioning of the cells and repair the tissues due to 
injury or disease. Typically, an intermediate cell type(s) called a precursor or progenitor cell is 
first generated. The precursor or progenitor cells are partially differentiated cells which are 
committed to a particular cell lineage. They divide and eventually form the differentiated cells. 
To determine if the isolated cell population is made up of ASC, the most stringent assay involves 
the transplantation of a single purified cell into an acceptable host without first culturing it in 
vitro and then observing for self-renewal and tissue, organ or lineage reconstitution (Cowen, 
2006). The single ASC should generate a line of genetically identical cells as clonality eliminates 
doubts about contamination with other cell types.  However, the in vivo reconstitution assay is 
not well-defined for many types of ASC. Therefore, in vitro clonal assays have been used as an 
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alternative. A single ASC is able to form a colony of cells and the purified population of these 
stem cells can home to a given tissue and repopulate it after transplantation into an animal. 
1.3.2 Sources and differentiation of ASC 
ASC are found in a specific area of each tissue, termed the “stem cell niche”. They stay 
quiescent for extended periods of time until they are activated by normal homeostasis or tissue 
injury to replicate in a bid to maintain tissues. The diversity of ASC is demonstrated by the 
various types of cells identified in many organs and tissues, including brain, bone marrow, 
peripheral blood, blood vessels, skeletal muscle, skin, teeth, heart, gut, liver, ovarian epithelium 
and testis (Czyz et al., 2003; Pfendler and Kawase, 2003). One example of an ASC is the 
haematopoietic stem cells (HSC) derived from the bone marrow. HSC can differentiate into all 
types of blood cells: red blood cells, T lymphocytes, B lymphocytes, natural killer cells, 
neutrophils, basophils, eosinophils, monocytes and macrophages (Weissman et al., 2001).  
Another example is the epithelial stem cells in the digestive tract. Epithelial stem cells can give 
rise to absorptive cells, goblet cells, paneth cells and enteroendocrine cells (Barker et al., 2008). 
1.4 Mesenchymal stem cells (MSC) 
1.4.1 In vitro characteristics of MSC 
In addition to HSC, non-haematopoietic progenitor cells capable of self-renewal and 
differentiation are also found in the bone marrow. These cells are termed ‘mesenchymal stem 
cells’ and were first described by Friedenstein. Friedenstein et al. (1968) reported that whole 
bone marrow fragments isolated from mice could form bone. After placing whole bone marrow 
cells in plastic culture dishes and then removing the non-adherent cells (which were 
haematopoietic cells), the adherent cells became more homogeneously fibroblastic in appearance 
with subsequent passages (Friedenstein et al., 1968). These plastic-adherent cells were rare 
(approximately 1 in 10,000 of the mononuclear cells in the bone marrow) and could form 
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colonies. The clones at the origin of each colony expanded into colonies composed of 
fibroblastic-looking cells and were thus termed as colony-forming unit-fibroblasts (CFU-f). The 
authors also found that the cells could differentiate into aggregates that resembled deposits of 
bone or cartilage. It was later shown that the single-cell forming colonies exhibited trilineage 
differentiation to adipocytes, osteoblasts and chondrocytes (Pittenger et al., 1999). 
There are conflicting reports on the homogeneity of MSC. Pittenger et al. (1999) reported that 
bone marrow-derived MSC (BM-MSC) constitute a single phenotypic population forming 
symmetric, spindle-shaped colonies (homology up to 98% by flow cytometric analysis) 
(Pittenger et al., 1999). On the other hand, it has also been indicated that single-cell derived 
colonies are morphologically heterogeneous, containing at least two different cell types: small, 
spindle-shaped cells and large cuboidal or flattened cells (Bruder et al., 1997). Recently, single-
cell analysis of mesenchymal progenitors obtained from another source, the knee joint synovium, 
also showed that variation exists in the individual clones (Karystinou et al., 2009).  The clones 
isolated took between 44 and 130 days to undergo 20 population doublings. A third possible 
fraction in BM-MSC was described as small, rapidly self-renewing cells which could be the 
earliest progenitors and could possess the greatest potential for multilineage differentiation 
(Colter et al., 2001).  
Besides the BM, MSC can also be expanded from a wide variety of adult tissues such as 
periodontal ligament (Wada et al., 2009), scalp tissues (Shih et al., 2005), lung (Karoubi et al., 
2009) and adipose tissue (Gronthos et al., 2001) and fetal tissues (Campagnoli et al., 2001; in 't 
Anker et al., 2003). Since MSC can be isolated from various sources using different methods, the 
Mesenchymal and Tissue Stem Cell Committee (MTSCC) of the International Society for 
Cellular Therapy (ISCT) (MTSCC-ISCT) proposed a set of minimal criteria to define human 
MSC (Dominici et al., 2006). Firstly, MSC must be plastic-adherent when maintained under 
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standard culture conditions. Secondly, although there is no single cell surface marker which can 
specifically identify MSC, the MTSCC-ISCT recommended that MSC must express CD73, 
CD90 and CD105 and lack expression of CD45, CD34, CD14 or CD11b, CD79a or CD19 and 
human leukocyte antigen (HLA)-DR surface molecules. However, the proposed panel of markers 
is not exclusively expressed on MSC (Haniffa et al., 2007; Jones et al., 2007). Hence, the surface 
phenotype should be used together with other functional criteria to characterise MSC. Thirdly, 
being multipotent, MSC must differentiate to default lineages of cartilage, bone and adipose 
tissue. In addition, they have also been demonstrated to differentiate to other lineages including 
neural precursors (Woodbury et al., 2000) and cardiomyocytes (Toma et al., 2002). As such, 
MSC are attractive candidates for application in regenerative medicine. 
1.4.2 Ontogeny and in vivo identity of MSC 
Pericytes have been suggested to be the native ancestor of the ex vivo MSC. Pericytes which are 
also known as Rouget cells or mural cells are predominantly located in the subendothelium of 
arteries, veins, arterioles, venules and capillaries, forming a continuous network in the vascular 
bed (Andreeva et al., 1998). Expression of surface markers NG2, a proteoglycan associated with 
pericytes during vascular morphogenesis, CD146, an endothelial cell antigen and platelet-derived 
growth factor-R could be used to identify pericytes in multiple human tissues such as skeletal 
muscle, pancreas, adipose tissue, skin, placenta, umbilical cord, bone marrow, heart, brain and 
dental pulp (Crisan et al., 2008). Crisan et al. (2008) also demonstrated that the pericytes 
expressed markers of MSC including CD44, CD73, CD90 and and CD105. At the same time, 
single-cell clones from pericytes exhibited the trilineage differentiation potential of MSC and 
could be differentiated to adipocytes, osteoblasts and chondrocytes (Crisan et al., 2008). 
If the in vivo identity of MSC is pericytes, then their functions in the body will involve the 
stabilisation of blood vessels and tissue homeostasis (da Silva Meirelles et al., 2008). The 
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proximity to vessels would allow the MSC pericytes to enter the bloodstream rapidly to protect 
and repair or regenerate the injured tissue. The implication of pericytes being the ancestors of 
MSC is that the perivascular zone in all tissue sites is the MSC niche (da Silva Meirelles et al., 
2008). The stem cell niche is made up of all elements immediately surrounding the stem cells 
when they are in their naïve state, including the non-stem cells, extracellular matrix and soluble 
molecules. All of these elements work synergistically to maintain the stem cells in the 
undifferentiated state until certain signals cue the stem cells to differentiate for regeneration or 
repopulation of a tissue (Schofield, 1978). 
1.4.3 Functions of MSC 
MSC play a major role in the bone marrow microenvironment. They secrete a number of 
extracellular matrix proteins, including fibronectin, laminin, collagen and proteoglycans (Devine 
and Hoffman, 2000), thus creating a tissue framework for the support of the haematopoietic cell 
system. In addition, MSC participate in the regulation of haematopoiesis by producing 
haematopoietic and non-haematopoietic growth factors, chemokines and cytokines. The secreted 
factors include various interleukins (IL): IL-1, IL-1, IL-6, IL-7, IL-8, IL-11, IL-14 and IL-15, 
macrophage colony-stimulating factor (M-CSF), granulocyte-macrophage colony-stimulating 
factor (GM-CSF), leukaemic inhibitory factor (LIF), stem cell factor (SCF), fetal liver tyrosine 
kinase-3, thrombopoietin and hepatocyte growth factor (HGF) (Dazzi et al., 2006; Haynesworth 
et al., 1996; Majumdar et al., 2000).  Through these secreted factors and direct cell-cell contact, 
MSC interact with HSC, influencing the ability of HSC to home, proliferate and differentiate. 
Haematopoietic progenitor cells with self-renewing capacity had a higher affinity to MSC and 
exhibited significant upregulations of adhesion molecules important for establishing cell-cell 
contact (Wagner et al., 2007b). The synergistic effect of HSC and MSC was demonstrated in 
studies that showed that cotransplantation of human MSC and HSC resulted in increased 
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chimerism and/or accelerated haematopoietic recovery in animal models and in humans (Fibbe 
and Noort, 2003; Koc et al., 2000). 
Besides their regenerative capacity, it is worthwhile to emphasise the immunomodulatory 
functions of MSC. Their immunomodulatory capacity can be due to the combination of growth 
factors, cytokines, chemokines and proteases produced. During solid organ transplantation, 
recipient T cell recognition of the donor alloantigen and non-specific inflammatory responses to 
the traumatised graft triggered by ischemic or reperfusion injury and surgery can lead to the 
rejection of the donor organ (de Sousa et al., 1991). Autologous MSC can be used to repair or 
replace damaged tissue. Under normal circumstances, allogeneic cells are recognised and deleted 
by host immune responses. Surprisingly, allogeneic MSC can be used as they do not appear to be 
subjected to allogeneic rejection due to their poor immunogenicity (Chamberlain et al., 2007; 
Ryan et al., 2005). When MSC were cocultured with allogeneic lymphocytes, MSC failed to 
elicit lymphocyte proliferation (Le Blanc et al., 2003a; Tse et al., 2003). Transplantation of 
allogeneic male fetal MSC to a femal fetus with osteogenesis imperfecta demonstrated that the 
allogeneic MSC could engraft and differentiate into bone (Le Blanc et al., 2005). 
1.4.4 Clinical applications of MSC 
The multipotent and immunomodulatory properties of MSC make them attractive candidates to 
be used in various clinical applications. A search on http://clinicaltrials.gov/ yielded 132 studies 
associated with MSC (National Institutes of Health, 2010). These trials included the use of MSC 
for the treatment of steroid refractory graft-versus-host disease (GVHD), Crohn’s disease, 
multiple sclerosis, osteoarthritis and distal tibial fractures. 
Prochymal® and Chondrogen® are examples of two commercial BM-MSC preparations 
produced by Osiris Therapeutics, Inc that are currently being evaluated in clinical trials.  
Prochymal® is being evaluated in Phase 3 clinical trials for several indications, including GVHD 
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and Crohn's disease, and in Phase 2 clinical trials for the repair of heart and lung tissue and the 
protection of pancreatic islet cells in patients with type 1 diabetes. Chondrogen® is being 
investigated in Phase 2 clinical trials for the treatment of arthritis in the knee. 
GVHD is a complication arising from HSC transplants. Previously, the depletion of alloreactive 
T cells from the donor graft was used to treat GVHD. However, patients tend to have a higher 
relapse rate than those who do not undergo alloreactive T cell depletion. This is due to a 
reduction in graft-versus-leukaemia effect by the mature donor T cells (Goldman et al., 1988). 
As MSC have an immunomodulatory effect on the recipients, cotransplantation of MSC has 
emerged as a treatment for the prevention of GVHD (Le Blanc and Ringden, 2005). At present, 
the exact mechanism by which MSC modulate the immune system is unknown although various 
mechanisms of action have been put forward and will be discussed in section 1.10.  
At the same time, cotransplanted MSC may exert a trophic effect on the microenvironment by 
locally producing growth factors, cytokines and chemokines, helping to recover damaged stroma 
and participating in the early developmental process of T lymphopoiesis (Le Blanc and Ringden, 
2007).  
1.5 hESC-derived MSC (hESC-MSC) 
Being similar to MSC, hESC-MSC can be used as an alternative source of MSC and offer 
several advantages. Firstly, as hESC can self-renew in culture for long periods of time, they can 
serve as an unlimited source of MSC through directed differentiation to hESC-MSC. In contrast, 
MSC, isolated from adult tissues such as bone marrow, adipose tissues and synovial fluid are 
limited in number and require invasive procedures for their isolation. As such, a second 
advantage of hESC-MSC is the elimination of potentially risky and invasive techniques. Thirdly, 
hESC-MSC can be stably propagated in culture for at least 80 population doublings as monitored 
by genome-wide gene expression profile and spectral karyotyping (Lian et al., 2007). In contrast, 
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the BM-MSC in our hands would start to senesce at passage 9. The stability of hESC-MSC 
ensures a consistent and renewable source of cells. Furthermore, it is possible to generate highly 
similar homogeneous MSC cultures from different hESC lines (Lian et al., 2007). As such, the 
use of hESC-MSC provides reproducible and consistent batch-to-batch preparation of MSC and 
their derivatives. 
1.5.1 Methods of derivation of hESC-MSC 
MSC or MSC-like cells have been generated from hESC by retroviral transduction, coculture 
with murine stromal cells, spontaneous differentiation or addition of growth factors (Table 1-1). 
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Table 1-1. Derivation of hESC-MSC. 
Reference Year hESC hESC-MSC Doubling Method Medium
line generated time (h) Osteogenesis Adipogenesis Chondrogenesis
Xu et al. 2004 H1 HEF1-hTERT 54 Transduction with retrovirus HEF1 differentiation medium   
EB formation KO-DMEM
Outgrowth transferred to HEF1 differentiation medium after 9 days 10% FBS
Generation of fibroblast-like cells after 3 passages 2 mM L-glutamine
Transduction with retrovirus expressing hTERT 1% NEAA
Barberi et al. 2005 H1 hESMPC H1.1 ND Coculture with murine stromal cells -MEM   
hESMPC H1.2 Sorted for CD73+ cells and replated after 40 days 20% FBS
hESMPC H1.3 Cultured for another 7-14 days 2 mM L-glutamine
hESMPC H1.4
H9 hESMPC H9.1
Olivier et al. 2006 H1 P37R 30 Spontaneous differentiation DMEM   ND
P51R 30 Raclures plated in DMEM for more than 4 wks 10% FBS
Weekly medium change 1% PS
Formation of thick, multilayer epithelium 1% NEAA
Dissociation of epithelium after 50-180 days
Trivedi and Hematti 2008 H1 H1-MSC ND Spontaneous differentiation -MEM   
H7 H7-MSC Increasing interval of medium change 10% FBS
H9 H9-MSC Appearance of fibroblastic cells
Lian et al. 2007 HuES9 huES9.E1 72 Addition of growth factors KO-DMEM  *  
huES9.E3 72 hESC trypsinised and grown in KO-DMEM 10% SR
H1 H1.E2 120 Fibroblast-looking cells formed within 2 wks 5 ng/ml FGF2
Sorting for CD105+CD24- cells 5 ng/ml PDGF-AB
Differentiation study
 
ND: No data *: Low efficiency FBS: Fetal bovine serum NEAA: Nonessential amino acids PS: Penicillin/streptomycin SR: serum replacement 
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1.5.1.1 Transduction with retrovirus expressing hTERT 
MSC-like cells were first derived by Xu et al. (2004). H1 hESC were induced to differentiate via 
embryoid bodies (EB) cultured in gelatin-coated plates. After 9 days, the outgrowth culture was 
dissociated and resuspended in human embryonic fibroblast-like cells (HEF1) differentiation 
medium. After three passages, a more homogeneous population exhibiting a fibroblast-like or 
mesenchymal-like morphology was formed. These cells were designated as HEF1. HEF1 cells 
were then stably transduced with a retrovirus expressing human telomerase reverse transcriptase 
(hTERT) to extend their replicative capacity, resulting in immortal human HEF1-hTERT cells. 
The HEF1-hTERT cells retained telomerase activity for at least 65 days.  
1.5.1.2 Coculture with murine stromal cells 
Barberi et al. (2005) used H1 and H9 hESC lines for the derivation of MSC. hESC were 
cocultured with murine OP9 stromal cells in -minimum essential medium (MEM). CD73 
positive cells were replated in the absence of OP9 cells and expanded in the same medium. The 
resulting MSC precursor cells were flat and spindle-like. 
1.5.1.3 Spontaneous differentiation 
Spontaneously differentiated cells are often found in the centre or at the edges of the hESC 
colonies. These cells are often scraped away in order to maintain only the undifferentiated 
population in the culture. The scraped cells, called “raclures” in French, remain multipotent and 
can differentiate into various cell types depending on the culture conditions (Olivier et al., 2006). 
To obtain MSC, the raclures were initially plated in Dulbecco’s Modified Eagle’s Medium 
(DMEM) with weekly medium change. Once a multilayer epithelium of cells was formed, the 
MSC were isolated by dissociation of the epithelium. The epithelium could be dissociated from 
50 to more than 180 days after the plating of the raclures. The resultant hESC-MSC could be 
passaged for at least 20 times. The cells could form a monolayer, bilayer or trilayer. This method 
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of generating hESC-MSC from H1 hESC was reproducible since 15 independent experiments 
yielded similar results.  
Trivedi and Hematti (2008) described another method of spontaneous differentiation by 
increasing the interval of medium change. hESC lines H1, H7 and H9, were initially maintained 
on murine embryonic fibroblast (MEF) cells before transferring to a feeder-free culture to ensure 
the absence of MEF cells in the cultures. Differentiation of hESC to MSC was induced by 
prolonging the interval of medium change. With the increase in the interval of medium change, a 
portion of the cells at the periphery of the hESC colonies became more fibroblastic. The 
undifferentiated hESC were removed and the remaining fibroblast-looking cells were transferred 
into new culture plates. When the majority of the cells were fibroblastic, they were transferred to 
gelatin-coated plates and cultured with -MEM. After the first passage, cells were almost 
completely CD73 (expressed on MSC) positive and stage-specific embryonic antigen (SSEA-4) 
negative. The authors were consistently able to derive MSC from the hESC lines in about 4 to 6 
weeks from the start of the differentiation protocol. H1 and H9 hESC-MSC could be grown up to 
a total of 18 to 21 passages. However, H7 hESC-MSC could not be passaged beyond passage 8 
to 10. 
1.5.1.4 Addition of growth factors 
HuES9 and H1 hESC were used for the derivation of MSC by the addition of growth factors 
(Lian et al., 2007). hESC were trypsinised and resuspended in KO-DMEM supplemented with 5 
ng/ml fibroblast growth factor (FGF) (FGF-2) and 5 ng/ml platelet derived growth factor 
(PDGF)-AB. A homogenous culture of fibroblast-looking cells was generated within 2 weeks. 
The hESC-MSC, huES9.E1 and huES9.E3, were generated from huES9 hESC while H1.E2 was 
generated from H1 hESC lines. 
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To enhance the reproducibility of the derivation protocol, genes which code for membrane 
proteins in hESC-MSC and hESC were identified. CD105 was among the top 20 highly 
expressed surface antigens in hESC-MSC compared to hESC. CD24 was found to be present on 
hESC but absent on hESC-MSC. Therefore, sorting for CD105 positive and CD24 negative 
(CD105+CD24-) cells was performed one week after trypsinisation of hESC to enhance the 
selection specificity for MSC and reduce the contamination with hESC. Gene expression 
analysis by microarray confirmed that different batches of sorted CD105+CD24- hESC-MSC 
had similar gene expression patterns. This suggests that sorting for CD105+CD24- cells will 
produce consistent batches of hESC-MSC cultures. 
1.5.2 Characteristics of hESC-MSC 
In the previously described methods of derivation, the hESC-MSC were fibroblast-looking and 
free from cells of mouse origin (Barberi et al., 2005; Lian et al., 2007; Trivedi and Hematti, 
2008). The average population doubling time differed among the cell lines (Table 1-1). This 
might be due to differences in the parental hESC used in the derivation. In addition, the 
population doubling time was closely related to the cell density and was most optimal when the 
cultures were between 30% and 80% confluent (Lian et al., 2007).  
Besides cell morphology and growth kinetics, the hESC-MSC were also evaluated based on 
surface antigen expression. The hESC-MSC were negative for haematopoietic markers, CD34 
and CD45  but positive for CD29, CD44, CD105, CD166 (Barberi et al., 2005; Lian et al., 2007; 
Trivedi and Hematti, 2008; Yen et al., 2009).  
In terms of differentiation capability, hESC-MSC were reported to differentiate to all three 
lineages of adipocytes, osteoblasts and chondroblasts by Trivedi and Hematti (2008) and Barberi 
et al. (2005) (Table 1-1). Olivier et al. (2006) showed that both adipogenesis and osteogenesis 
were efficient in their hESC-MSC, P37R and P51R. However, they did not perform any 
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chondrogenesis study. On the other hand, HuES9.E1 exhibited poor osteogenesis with only 1% 
of the cells positive for von Kossa staining despite a 2-3 fold upregulation of bone-specific 
alkaline phosphatase and bone sialoprotein (Lian et al., 2007). Although osteogenesis was poor, 
both adipogenesis and chondrogenesis were highly efficient in HuES9.E1. The HEF1-hTERT 
could only differentiate into osteoblasts and did not give rise to adipocytes or chondroblasts (Xu 
et al., 2004). 
1.5.3 Differences between hESC-MSC and BM-MSC 
Although hESC-MSC were similar to BM-MSC in their morphology, surface antigen expression 
and differentiation capability, there were differences in the gene expression patterns. Genes that 
were preferentially expressed in hESC-MSC were associated with embryonic processes such as 
proliferation and early developmental processes of embryogenesis and segmentation while those 
in BM-MSC were over-represented in biological processes linked with more mature cell types 
such as metabolic processes, cell structure and late developmental processes of skeletal 
development and muscle development (Lian et al., 2007). It has been observed that the age of the 
donor and the developmental stage of the tissue from which the MSC are derived, have an 
impact on the proliferation, differentiation potential and therapeutic efficacy of MSC. Generally, 
MSC isolated from young donors or developmentally less mature tissues are more proliferative, 
have a more robust differentiation potential and greater therapeutic efficacy than their adult 
counterparts (Le Blanc, 2003; Sethe et al., 2006). 
1.5.4 Potential clinical applications of hESC-MSC 
The hESC-MSC, HuES9.E1, were used to produce conditioned medium (CM) which could exert 
cardioprotective effects and preserve cardiac function in a pig model of myocardial ischemia and 
reperfusion injury (Lian et al., 2007; Timmers et al., 2007). There was a 60% reduction in infarct 
size and significant improvement of systolic and diastolic cardiac performance as assessed with 
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echocardiography and pressure volume loops (Timmers et al., 2007). The CM was prepared in a 
chemically defined, serum-free culture medium (Sze et al., 2007). Briefly, the CM was collected 
after three days, centrifuged, concentrated 25 times using 10-kDa molecular weight cutoff 
ultrafiltration membranes and finally sterilized by filtration through a 0.22-µm filter. Through 
fractionation studies, the cardioprotective factors were found to be in the fraction with a 
molecular weight of more than 1000 kDa and a size range of 100 to 220 nm (Timmers et al., 
2007). This cardioprotective effect of the fractionated CM could be due to reduced apoptosis 
arising from the attenuation of oxidative stress and altered transforming growth factor-beta 
(TGF-) signalling. The study suggests that the secretions from hESC-MSC could be used 
instead of cells themselves for clinical applications, thus reducing the need for tissue matching. 
1.6 Fibroblasts (Fb) 
1.6.1 Characteristics and functions of Fb 
Fb belong to the family of connective-tissue cells (Alberts et al., 2008). Other members include 
cartilage cells, bone cells, fat cells and smooth muscle cells. Connective-tissue cells play a part in 
the support and repair of almost all the tissues and organs. Fb, cartilage cells and bone cells 
secrete collagenous extracellular matrix and contribute to the framework of the body. Fb seem to 
be the least specialised cells in the connective-tissue family (Alberts et al., 2008) and exhibit 
specific functions in relation to their anatomical site (Chang et al., 2002).  
It is widely believed that Fb do not share the immunosuppressive effects of MSC (Horwitz et al., 
2005). However, it is difficult to distinguish MSC from Fb based on surface phenotype alone. 
The antigens used to characterise MSC are all expressed by Fb (Dominici et al., 2006; Horwitz et 
al., 2005). Both BM-MSC and Fb were positive for CD73, CD90, CD105 and HLA class I and 
negative for CD14, CD19, CD31, CD34, CD45 and HLA class II (Haniffa et al., 2007; Jones et 
al., 2007). Another key characteristic of MSC is the ability to differentiate into adipocytes, 
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osteoblasts and chondrocytes. Literature regarding the differentiation capability of Fb are mixed. 
Fb harvested from various sources differ in their differentiation potential. Synovial Fb showed 
slight osteogenic and adipogenic differentiation while chondrocytes had some adipogenic 
differentiation potential (Jones et al., 2007). Dermal Fb had been shown to differentiate to all the 
three lineages (Haniffa et al., 2007) as well as being unable to differentiate (Jones et al., 2007). 
Human foreskin Fb failed to generate adipocytes and osteoblasts when cultured under adipogenic 
or osteogenic medium (Wada et al., 2010). It has been suggested that mature Fb have lower 
capacity to differentiate while immature Fb (often called mesenchymal cells) can develop into a 
spectrum of cell types (Alberts et al., 2008). Therefore, differentiation is said to be a 
distinguishing characteristic of MSC (Dennis et al., 2002; Pittenger et al., 1999) and the 
immunosuppressive properties of MSC are thought to be a specialised function related to their 
primitive or multipotential state (Horwitz et al., 2005; Le Blanc, 2006; Potian et al., 2003).  
In addition to their role in the synthesis of extracellular matrix, Fb have previously been shown 
to interact with the immune system. When the fibrosarcoma cell line, MC57, was transfected 
with viral proteins and injected into the spleen of mice, the Fb were able to induce antiviral 
cytotoxic T lymphocyte (CTL) responses without involvement of the host antigen-presenting 
cells (APC) (Kundig et al., 1995). Therefore, Fb could act as alternative APC in cytokine-rich 
lymphoid organs. Fb could also mediate antiproliferative effects on lymphocytes through either 
direct cell-cell contact (Sarkhosh et al., 2003; Shimabukuro et al., 1992) or indirect production of 
soluble factors (Donnelly et al., 1993). Fb effect on lymphocytes will be discussed in greater 
detail in section 1.13. Production of IL-6 by skin Fb could also affect monocytes, skewing their 
differentiation towards macrophages instead of dendritic cells (DC) (Chomarat et al., 2003).  
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1.6.2 Clinical applications of Fb 
Fb can be used to enhance tissue repair including the treatment of burns and chronic venous 
ulcers (Wong et al., 2007). In patients suffering from burns, the exposure of bone occasionally 
leads to amputation.  Allogeneic Fb cultured on spongy sheet composed of hyaluronic acid and 
atelo-collagen were applied to the wound surface of a 82-year-old woman once weekly and 
complete healing was achieved with minimal scarring (Ohara et al., 2010). Chronic venous 
hypertension of the lower extremities may result in venous ulcers. Treatment of the ulcers with 
human skin equivalent consisting Fb and keratinocytes derived from neonatal foreskin, together 
with compression therapy, resulted in faster healing compared to compression therapy alone 
(Falanga et al., 1998). 
Fb have been manufactured into various tissue-engineered products. For example, Dermagraf® 
(Advanced Biohealing, La Jolla, CA, USA) is used in the treatment of diabetic foot ulcers 
(Marston et al., 2003). It is composed of human foreskin Fb, extracellular matrix and a 
bioabsorbable scaffold. Apligraf® (Novartis, Basel, Switzerland) is FDA-approved for use in 
venous ulcers and diabetic foot ulcers (Falanga and Sabolinski, 1999). It is a living skin 
substitute containing allogeneic Fb and keratinocytes. When the Fb and keratinocytes are 
cultured in vitro, the APC such as Langerhans cells, are lost with serial passaging and are no 
longer present in the tissue-engineered skin products (Phillips et al., 2002). This may be the 
reason why an acute rejection process is not evoked in patients. 
A patent describing the use of Fb or supernatants from Fb for the suppression of immune 
response in transplantation has been filed (Mc Intosh et al., 2009). The Fb were human dermal 
Fb, CCD-1087 Sk, from 18 years old female obtained from American Type Culture Collection 
(ATCC). They were able to suppress an ongoing mixed lymphocyte reaction (MLR) when added 
as third party cells. In addition, the supernatant could suppress MLR even at a 1:8192 dilution. 
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The supernatant was collected from confluent cultures of Fb after 3 days and added to the MLR 
for 7 days. 
1.7 Immunological hurdles for stem cell therapy 
The immunological barriers to successful transplantation of stem cells and derivatives are the 
same as those for conventional allografts obtained from donors. In general, the greater the 
number of genetic differences between the donor and the recipient, the faster the rejection 
response is elicited. The three classes of transplant antigens responsible for rejection are the 
ABO blood group antigens, major histocompatibility complex (MHC) and minor 
histocompatibility complex (mHC). 
1.7.1 ABO blood group antigens 
The ABO blood group antigens are mainly expressed on the surfaces of erythrocytes. At the 
same time, they are also expressed on cell types throughout the body (Clausen and Hakomori, 
1989; Ito and Hirota, 1992). The genes encoding the blood group antigens are polymorphic. The 
major blood group alleles, A and B, code for enzymes which make different sugars on proteins 
and lipids on the surface of erythrocytes and are codominantly expressed. Blood group O is a 
null allele and does not create sugars. As all individuals have antibodies (isohaemagglutinins) 
specific for the non-expressed antigens, after re-vascularisation of the graft, anti-A and/or anti-B 
antibodies which were pre-formed in the host circulation can bind to their respective antigens 
found on the donor vascular endothelium. This results in hyperacute graft rejection (Cooper, 
1990; Paul and Baldwin, 1987). Therefore, ABO incompatibility has to be avoided in 
vascularised organ transplantation.  
A few exceptions to the need for ABO matching are corneal and skin transplantations (Eastlund, 
1998). The cornea is considered to be an immune-privileged site as it is avascularised and 
separated from MHC and other antibodies in the blood  (Katami, 1991). Although the skin 
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expresses A and/or B antigens, it has been observed that ABO-incompatible skin grafts survived 
normally unless the recipients have been previously immunised by injections of A or B antigens 
(Eastlund, 1998). Hence, ABO compatibility is an important factor to consider before hESC-
derived cell products can be transplanted into certain sites. 
1.7.2 Major histocompatibility complex (MHC) 
The MHC molecules play a crucial role in the rejection and acceptance of a transplanted allograft 
as they are involved in antigen recognition by T cells. In humans, the MHC is called human 
leukocyte antigen (HLA) and in mice, H-2. There are two classes of MHC molecules: MHC 
class I molecules and MHC class II molecules. MHC class I molecules are expressed on all 
nucleated cells whereas MHC class II molecules are constitutively expressed on professional 
APC. Professional APC such as DC are haematopoietic in orgin (Sundstrom and Ansari, 1995). 
Non-professional APC do not constitutively express MHC class II molecules but the expression 
of MHC class II molecules can be induced by IFN- and tumour necrosis factor (TNF)- 
(Leeuwenberg et al., 1988). The MHC loci are highly polymorphic (Beck and Trowsdale, 2000). 
HLA class I molecules are encoded by three (A, B and C) genes while HLA class II molecules 
are encoded by six genes (DP, DQ and DR). Each gene can be coded by different alleles and the 
resultant HLA molecules can be recognised as foreign antigens. The combinations of the many 
different alleles which are codominantly expressed imply that the chances of two individuals 
who have a completely identical set of alleles are slim (1 in 35 million) (Lydyard et al., 2004). 
The importance of HLA-matching has been demonstrated in many types of tissue and organ 
transplants. In particular, HLA-matching enhances the survival rate of the graft in kidney and 
bone marrow transplantation (Chinen and Buckley, 2010). Since HLA molecules are expressed 
on all nucleated cells, HLA-matching has to be considered when hESC and their derivatives are 
transplanted. 
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1.7.3 Minor histocompatibility (mHC) antigens 
Despite being fully HLA-matched between the donor and the recipient, mismatches in mHC 
antigens can trigger GVHD in bone marrow transplantation (Goulmy, 1997; Korngold and 
Sprent, 1983) and kidney rejection (Dierselhuis and Goulmy, 2009). mHC antigens can be 
derived from any protein with polymorphism (Afzali et al., 2007). mHC antigens can be encoded 
by male-specific gene H-Y products, autosomes and mitochondrial DNA. Due to the absence of 
H-Y products in females, responses to the male antigens are elicited following a pregnancy 
(Piper et al., 2007). Non-Y-linked mHC antigens have also been identified to play a role in 
GVHD in MHC-matched individuals (Dierselhuis and Goulmy, 2009). In contrast, 
polymorphism in mitochondrial proteins did not affect the incidence of acute GVHD and the 
cumulative disease-free survival in a Japanese cohort (Ishikawa et al., 2001). Therefore, even if 
the stem cells are fully HLA-matched, mismatches in mHC antigens may lead to graft rejection. 
1.8 Allorecognition 
Since stem cells express MHC molecules, they have a potential to be recognised by T cells. 
Alloantigens can be recognised by the immune system by two distinct pathways: direct and 
indirect pathways of allorecognition (Lechler and Batchelor, 1982; Shoskes and Wood, 1994) 
(Figure 1-3).  
Donor APC Recipient APC
Donor MHC Donor peptide
Recipient MHC
Donor MHC
T cell T cell
A. B.

 Figure 1-3. Direct and 
indirect T cell 
allorecognition pathways. 
A. During direct 
allorecognition, donor APC 
in the graft present intact 
own MHC molecules bound 
with antigenic peptides to 
the T cell receptor (TCR) of 
the recipient T cell. 
B. During indirect 
allorecognition, recipient 
APC process and present 
donor antigenic peptides in 
association with recipient 
MHC. 
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For direct allorecognition of donor alloantigens, donor APC present the mismatched MHC 
molecules as intact molecules to recipient T cells. The presence of APC in donor tissues during 
transplantation contributes to the direct anti-donor response which attenuates with the death and 
removal of the APC (Afzali et al., 2007).  If the graft is devoid of APC, rejection occurs after a 
longer period of time (Bowen et al., 1980; Iwai et al., 1989; Lechler and Batchelor, 1982). In the 
absence of lymphatic drainage, there is also no response to the graft. Therefore, direct 
allorecognition is thought to be mainly responsible for acute graft rejection since MHC 
mismatches mean that the frequency of directly alloreactive recipient T cells is high. For indirect 
allorecognition of donor alloantigens, the donor molecules are processed into small peptides and 
presented by recipient’s APC to recipient T cells (Afzali et al., 2007). Activated effector T cells 
which bear the corresponding receptors are carried back to the graft, attacking the graft directly. 
Indirect allorecognition is more important in the development of an alloantibody response to a 
graft, leading to graft failure (Terasaki, 2003).  
1.8.1 T cell activation 
T cells are unable to respond to soluble antigens. They can only recognise antigens bound to 
MHC molecules. There are two broad categories of T cells based on their functions and 
expression of co-receptor molecules, CD4 or CD8. In general, CD4+ T cells recognise 
exogenous antigens bound to MHC class II molecules on APC. CD4+ T cells can be subdivided 
to T helper 1 (Th1) cells, T helper 2 (Th2) cells and other subsets such as T helper 17 (Th17) 
cells and regulatory T (Treg) cells. Th1 cells activate macrophages and secrete IFN- and IL-2, 
thus driving an inflammatory immune response (Mosmann et al., 1986). Th2 cells secrete IL-4, 
IL-5, IL-6 and IL-13 and activate B cells to produce antibody (Abbas et al., 1996). Th17 cells 
which secrete IL-17 can be induced by IL-23 or IL-1 (Wilson et al., 2007). They are 
proinflammatory and have been implicated in diseases such as inflammatory bowel disease and 
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arthritis (Wilson et al., 2007). On the other hand, Treg cells which express Foxhead box P3 
(FoxP3) play a role in maintaining self-tolerance (Jager and Kuchroo, 2010). CD8+ T cells 
recognise endogenous antigens in complex with MHC class I molecules which are displayed by a 
transformed or infected host cell. Activated CD8+ CTL are responsible for the direct killing of 
virus-infected or cancerous host cells, while sparing adjacent normal cells.  
The ligation of the T cell receptor (TCR) by the antigenic peptide:MHC complex presented by 
the APC provides the first signal for T cells activation. For T cells to become fully activated, a 
second costimulatory signal must be delivered to the T cell, triggering it to divide, proliferate and 
differentiate (Lafferty and Cunningham, 1975) (Figure 1-4). 
 
 APC
MHC
TCR
T cell
CD86
CD281
2

  
 
Figure 1-4. Activation of naïve T cells.  
The first signal is delivered to the T cell via the 
binding of the TCR to the MHC molecule bound 
with the antigenic peptide. A second 
costimulatory signal provided by CD80 or CD86 
is required to activate the T cell, causing it to 
divide and proliferate. In the absence of 
costimulation, T cells become anergic. 
 
For naïve CD4+ T cells, the costimulatory signal is delivered by costimulatory molecules, CD80 
and CD86, which bind to CD28, the receptor on T cells. CD80 and CD86 also provide 
costimulation to CD8+ T cells but clonal expansion of CD8+ T cells is further aided by CD4+ T 
cells interacting with the same APC (Janeway and Bottomly, 1994; Redmond and Sherman, 
2005). An absence of costimulatory signal will render the T cell anergic. The T cell becomes 
refractory to activation by the same antigen despite being presented with the antigen by APC. 
Costimulatory signals can be positive or negative in nature. Positive costimulatory molecules are 
pivotal in promoting activation, survival and/or differentiation of T effector cells or stimulate 
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generation or re-activation of memory T cells (Li et al., 2009). On the other hand, negative 
costimulatory molecules repress T cell activation. Figure 1-5 shows some of the different 
positive and negative costimulatory pathways.       
T cell APC
TCR MHC
CD80/CD86
CD80/CD86
PD-1
CTLA-4
CD28
PD-L1/PD-L2
CD40CD40L
ICOS ICOSL
Effect on T cell
+
+
+
-
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Figure 1-5.  Positive and negative costimulatory pathways.  
TCR binds MHC associated with an antigenic peptide but requires costimulation to modulate the T cell 
response. Positive costimulatory pathways (CD28/CD80/CD86, ICOS/ICOSL and CD40/CD40L) promote 
the activation of T cells. Negative costimulatory pathways (CTLA-4/CD80/CD86 and PD-1/PD-L1/PD-L2) 
inhibit T cell activation. 
1.8.1.1 Positive costimulatory pathways 
 
1.8.1.1.1 CD28/B7 pathway 
The CD28 molecule belongs to the immunoglobulin (IgG) superfamily and is the receptor for B7 
molecules (CD80 and CD86). Interaction of the receptor on T cells with B7.1 (CD80) and B7.2 
(CD86) molecules expressed on APC results in the full activation of naïve T cells. CD80 
expression is inducible and can be upregulated during allogeneic stimulation. It can be expressed 
by APC and other cell types including T cells. CD86 is constitutively expressed by APC and is 
upregulated by cell activation (Li et al., 2009). 
1.8.1.1.2 Inducible costimulatory molecule (ICOS)/ICOS ligand (ICOSL) 
pathway 
ICOS is a CD28 homolog. Unlike CD28, it is not constitutively expressed on naïve T cells. It is 
induced upon T cell activation and its expression persists in memory and effector T cells (Coyle 
et al., 2000). The ligand for ICOS is ICOSL. ICOSL is expressed on B cells and resting APC. 
ICOS signaling enhances T cell proliferation, cytokine production and survival (Li et al., 2009). 
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1.8.1.1.3 Tumour necrosis factor (TNF)/TNF-receptor (TNF-R) family 
The second costimulatory family consists TNF-R and their ligands, the TNF family.  CD40 and 
its ligand CD40L (CD154) were the first costimulatory molecules to be identified as members of 
the TNF/TNF-R family and will be discussed subsequently. Other members include the 
following receptor-ligand pairs: CD27/CD70, CD30/CD30L, TNFR superfamily member 4 
(OX40)/OX40 ligand (OX40L), TNFR superfamily member 9 (4-1 BB)/4-1 BB ligand, 
glucocorticoid-induced TNFR-related protiein (GITR)/GITR ligand, herpesvirus entry mediator 
A (HVEM)/ligand for herpesvirus entry mediator (LIGHT) (Adams et al., 2002). The members 
of this family are expressed only upon T cell activation, except for CD27 which is constitutively 
expressed on naïve T cells. 
CD40 is constitutively expressed on APC at low levels and is significantly upregulated upon 
activation. CD40 can also be induced on parenchymal cells during inflammation (Larsen and 
Pearson, 1997).  CD40L is expressed on activated CD4+ T cells and on a subset of CD8+ T cells 
and NK cells. CD40 stimulation activates DC and leads to the upregulation of costimulatory 
molecules and MHC molecules on DC. CD40 also triggers important signals for antibody 
producton by B cells. 
1.8.1.2 Negative costimulatory pathways 
 
1.8.1.2.1 Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)  
Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) belongs to the IgG superfamily. It also 
binds B7 molecules but with higher avidity compared with CD28 (Collins et al., 2002). CTLA-4 
is not constitutively expressed (except by FoxP3+ Treg cells) but is upregulated during T cell 
activation (Sakaguchi, 2004). Engagement of B7 molecules with CD28 provides a T cell 
activation signal while CTLA-4 inhibits T cell response (Linsley et al., 1991).  
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1.8.1.2.2 Programmed death-1/Programmed death ligands pathway 
The pathway consisting programmed death-1 (PD-1; also known as CD279) receptor and its 
ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2), is one of 
the most recently described pathways in the CD28/B7 family. PD-1 is approximately 23% 
homologous with CTLA-4 but it does not bind CD80 or CD86. Ligation of TCR or B cell 
receptor can upregulate PD-1 expression on lymphocytes (Agata et al., 1996). PD-1 is also 
expressed on activated T cells, B cells, natural killer (NK) T cells, activated monocytes and DC 
(Agata et al., 1996) (Table 1-2)  
Table 1-2. Comparison of PD-1, PD-L1 and PD-L2 expression on human and mouse cells. Adapted 
from (Keir et al., 2008) 
    Human       Mouse   
  PD-1 PD-L1 PD-L2   PD-1 PD-L1 PD-L2 
Naïve T cells  -  -  -   -  +  - 
Activated T cells    +  -   +  ++  - 
Exhausted CD8+ T cells  +  ND  ND   ++  ++  ND 
Naïve B cells  +  ND  ND   -  +  - 
Activated B cells  +  ND  ND   +  +  - 
Peritoneal macrophages      -  +  - 
Activated macrophages      -   ++  + 
Plasmacytoid DC  -  +  -   -  ++  - 
Myeloid DC  +  +  +   -  ++  + 
Monocytes  +  ++  +     
Mast cells  ND  ND  ND   -  ++  + 
Cornea  ND  ND  ND   -  +  - 
Lung  ND  ++  +   -  +  + 
Vascular endothelium  -  +  +   -  +  - 
Liver nonparenchymal cells  -  +  -   -  ++  - 
Mesenchymal stem cells  ND  ND  ND   +  ++  - 
Pancreatic islets  ND  ND  ND   -  +  - 
Placental synctiotrophoblasts  ND  ++  +   -  ++  - 
Keratinocytes  -  +  -    -  +  - 
ND: No data      -: No expression     +: Low expression     ++: High expression 
PD-L1 is constitutively expressed on mouse T and B cells, macrophages, DC, MSC and bone 
marrow-derived mast cells (Yamazaki et al., 2002). Exposure to lipopolysaccharides (LPS) and 
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IFN- can further upregulate the expression of PD-L1 on inflammatory macrophages (Loke and 
Allison, 2003). In addition, PD-L1 is found on a variety of parenchymal cells including heart, 
lung, kidney, pancreas and placenta and can be induced on endothelial cells (Keir et al., 2006; 
Liang et al., 2003). This suggests that parenchymal cells can regulate immune response through 
the PD-1/PD-L1 negative signaling pathway. PD-L2 expression is more restricted than that of 
PD-L1. PD-L2 is inducibly expressed on DC, macrophages and bone marrow-derived mast cells 
by GM-CSF, IL-4 and IFN- (Loke and Allison, 2003; Yamazaki et al., 2002). 
The binding of PD-L1 to PD-1 leads to the inhibition of TCR-mediated lymphocyte proliferation 
and cytokine secretion. The outcome of PD-1 engagement by PD-L1 is dependent on the strength 
of the TCR and CD28 signals (Freeman et al., 2000). When there was suboptimal engagement of 
TCR with the addition of 1 µg/ml anti-CD3 monoclonal antibody (mAb) to 1 × 105 T cells, T cell 
proliferation was suppressed in the presence of PD-L1. However, under saturating conditions of 
2 µg/ml anti-CD3 mAb, PD-L1 is unable to suppress T cell proliferation unless CD28 
costimulation was absent. Therefore, increasing TCR or CD28 signaling can circumvent the 
inhibitory effects of PD-1 ligation. CD28 signalling augments the production of IL-2 and the 
addition of exogenous IL-2 can overcome PD-L1-mediated inhibition (Carter et al., 2002).  
Similarly, PD-L2 binding of PD-1 inhibits TCR-mediated proliferation and cytokine production 
by CD4+ T cells (Latchman et al., 2001). However, PD-L2 appeared to be less potent than PD-
L1 at inhibiting T cell activation (Latchman et al., 2001). Engagement of PD-1 by PD-L1 
produced a greater amount of cell cycle arrest than PD-L2 (Latchman et al., 2001). In addition to 
the inhibition of T lymphocyte proliferation and cytokine production, PD-1 ligation also inhibits 
the induction of the pro-survival factor Bcl-xL (Chemnitz et al., 2004).  
Besides binding to PD-1, PD-L1 can also associate with CD80 (Butte et al., 2007). CD80 has the 
highest binding affinity for CTLA-4, followed by PD-L1 and then CD28 (CTLA-4 > PD-L1 > 
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CD28).  However, CD80 does not bind to PD-L2 (Butte et al., 2007). Another costimulatory 
molecule, CD86, on the other hand, is not a binding partner for either PD-L1 or PD-L2 (Butte et 
al., 2007). CD80 interaction with PD-L1 can induce an inhibitory signal into T cells. When T 
cells lacking two of the receptors for CD80, CD28 and CTLA-4 receptors, were stimulated with 
anti-CD3 mAb and CD80-coated beads, proliferation and cytokine production was reduced 
(Butte et al., 2007). When all the receptors for CD80 (CD28, CTLA-4 and PD-L1) were absent, 
T cell proliferation and cytokine production was no longer inhibited. This shows that the ligation 
of PD-L1 by CD80 leads to T cell inhibition. Therefore, PD-L1 can exert an inhibitory effect on 
T cells through both CD80 and PD-1. 
1.9 Immunology of hESC and their derivatives 
Before hESC and their derivatives can be used clinically, their immunological profiles have to be 
determined to ensure that the cells do not elicit an immune response by the recipient. Non-self 
antigens which are present on the transplanted hESC and their derivatives may be recognised by 
the recipient, leading to the destruction of the transplanted cells.  
1.9.1 Expression of HLA and other immune molecules 
HLA mismatch is a major cause of graft rejection. Therefore, studies which focussed on the 
expression of HLA molecules on hESC and their derivatives will be discussed. The expression of 
HLA class I molecules on hESC and their differentiated derivatives (in vitro EB and in vivo 
teratomas) was determined and found to be at low levels and more than 10 times less than that on 
the adult cells (HeLa cells and monocytes) (Drukker et al., 2002).  hESC and their derivatives 
did not express HLA class II (Drukker et al., 2002; Grinnemo et al., 2006; Li et al., 2004).  
During inflammation, IFN will be released. IFN can upregulate the expression of HLA class I 
and HLA class II molecules. Since hESC and their derivatives expressed minimal levels of HLA 
molecules, it would be interesting to know if their expression would be altered during 
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inflammation. When IFN- or – were added to hESC and teratomas for 48 h, there was no 
significant change in HLA class I expression on hESC (Drukker et al., 2002). However, the 
addition of IFN- led to a dramatic upregulation of HLA class I expression on hESC. In contrast, 
all the different types of IFN, IFN-, - and –, led to a significant upregulation of HLA class I 
expression on teratomas. HLA class II molecules, on the other hand, remained absent on 
teratomas, even with the addition of all types of IFN. Similar results with respect to the effects of 
IFN- on hESC were reported by Grinnemo et al. (2006). When hESC were stimulated with  
IFN- for a longer period of 7 days, there was a 10-fold upregulation of HLA class I expression 
on hESC but HLA class II expression remained absent (Grinnemo et al., 2006). 25 ng/ml of IFN-
 was sufficient in the maximal upregulation of HLA class I expression and this upregulation 
occurred within the first 48 h (Drukker et al., 2002). In agreement with the results on IFN- 
effect on HLA expression, DNA microarrays showed that the receptor for IFN- was expressed 
on hESC but the receptors for IFN- and – were not (Drukker et al., 2006).  
The expression of HLA molecules is important because T cells are able to recognise antigenic 
peptides bound with the HLA molecules. For T cells to be fully activated, an additional 
costimulatory signal has to be delivered. The expression of costimulatory molecules at the 
transcript (Grinnemo et al., 2006) and protein level (Drukker et al., 2006; Li et al., 2004) on 
hESC and its derivatives was low or absent. CD80 and CD86 were not expressed on hESC and a 
differentiated primary cell line derived from a hESC-induced teratoma in the presence or absence 
of IFN- (Drukker et al., 2006). Therefore, hESC could not function as APC due to the absence 
of HLA class II and costimulatory molecules.  
Since hESC and EB expressed low levels of HLA class I molecules, it was possible for them to 
be lysed by NK cells which kill cells that do not express HLA class I molecules (Ljunggren and 
Karre, 1990). However, both hESC and EB were minimally lysed by NK cells in the presence 
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and absence of IFN- (Drukker et al., 2002). The authors also explained that this lack of 
recognition by NK cells was due to the minimal expression of ligands on hESC and EB that NK 
cell lysis receptors bind to. 
1.9.2 Immunogenicity of hESC transplants 
To determine if hESC could be rejected when transplanted, hESC were transplanted under the 
kidney capsule of immunocompetent and immunodeficient mice. Teratomas failed to develop in 
the immunocompetent mice after one month, suggesting that the hESC were rejected (Drukker et 
al., 2006). The rejection was T cell-mediated and not due to NK cells or B cells as only T cell-
deficient mice did not reject hESC-derived grafts. Similarly, following the transplantation of 
hESC into the myocardium of immunocompetent mice, there was an increase in the number of 
macrophages and T cells on day 5 which lasted till day 7 (Grinnemo et al., 2006). The absence of 
hESC at the site of injection in imuunocompetent mice was confirmed by fluorescence in-situ 
hybridisation (FISH) which was specific for human cells, suggesting that hESC were rejected. In 
contrast, FISH-positive hESC persisted in mice which were immunodeficient. 
When CD4+ T cells from the mice were cultured with the same hESC in a MLR, with or without 
DC syngeneic to the T cells, the proliferation of CD4+ T cells in the culture with hESC was 
similar to that with Fb (Grinnemo et al., 2006). Hence, the authors concluded that hESC did not 
inhibit immune responses and were rejected in a xenogenic setting. However, it is possible that 
hESC were minimally immunogenic since the degree of proliferation was 4-fold lower than the 
proliferation obtained when CD4+ T cells were cultured with allogeneic DC alone.  
However, Li et al. (2004) showed that hESC were not rejected. In their study, hESC were stably 
transduced with the transgene green fluorescent protein (GFP) and injected into the quadriceps of 
immunocompromised mice. There was no infiltration of granulocytes, suggesting that it was 
possible for hESC not to elicit an inflammatory response in patients on immunosuppressants. 
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When hESC were injected together with endotoxin-containing PBS vehicle into 
immunocompetent mice, hESC abrogated leukocyte infiltration compared to the use of the 
vehicle alone. This meant that hESC were not inflammatory. 
In order to determine that the inability to evoke a reaction in mice was not xenospecific, hESC 
were incubated with human immune cells (Li et al., 2004). Addition of hESC to cultures of 
human T cells with allogeneic DC inhibited T cell proliferation. However, the addition of hESC 
or EB CM alone did not inhibit T cell proliferation, suggesting that the immunomodulatory 
effect was mediated by direct membrane interactions between hESC and T cells. Subsequently, 
fixed hESC continued to inhibit T cell proliferation. Primary T cells failed to proliferate in the 
presence of hESC in a secondary MLR. But the T cells could proliferate in the presence of PHA 
and ionomycin. Thus, T cells exposed to hESC were not induced to become tolerant. The 
inhibition was due to direct contact with hESC. 
To evaluate the in vivo response by the human immune system towards hESC and their 
derivatives, Drukker et al. (2006) made use of a human peripheral blood mononuclear cells 
(PBMC)-reconstituted Trimera mouse model. CB6F1 mice were irradiated and then 
radioprotected with bone marrow cells from NOD/SCID mice. One to three days later, human 
PBMC were injected peritoneally to reconstitute human T, B and NK cell populations. When 
hESC and their derivatives were transplanted under the kidney capsule of the Trimera mice, 
there was tumour formation. This indicated that hESC and their derivatives failed to activate a 
direct allospecific response by HLA mismatched human lymphocytes. However, the failure to 
elicit an immune response was not due to the induction of T cell apoptosis by FasL as hESC and 
its derivatives did not express FasL (Drukker et al., 2006). It was possible that other mechanisms 
triggering T cell death might be responsible. In an attempt to uncover possible differences, the 
transcription pattern of 306 genes known to be involved in immune responses was compared 
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among three groups: 1) undifferentiated hESC, EB and teratomas; 2) leukocytes and 3) seven 
organs. Genes which were important for T cell activation were highly expressed in the organ 
group but were almost undetectable in hESC and their derivatives. This supported the notion that 
hESC and their derivatives do not have the capacity to stimulate T cell immune responses.  
1.9.3 Ways to overcome rejection of hESC and their derivatives 
The immune system may elicit a response to hESC and their derivatives following 
transplantation into the human body. To reduce the possibility of rejection, various approaches 
can be undertaken. Transplantation into immune-privileged sites may protect the transplants and 
reduce the risk of immunogenicity. Another way is to minimise the genetic differences between 
the donor and the recipient. This includes the generation of isogenic hESC lines, cell line 
matching, induction of immune tolerance by haematopoietic chimerism and creation of a 
universal donor cell line.  
1.9.3.1 Transplantation into immune-privileged sites 
Immune-privileged sites exist in the body. These areas such as the brain, testis and the anterior 
part of the eye (Ferguson et al., 2002), have restricted immune responses to tissue grafts and the 
grafts can survive for extended periods of time. For example, non-matched corneal transplants 
can be performed without supplementary immunosupressants (Green and Ferguson, 2001). These 
immune-privileged sites have at least three characteristics contributing to the reduced 
immunogenicity. Firstly, they have atypical lymphatic drainage and are separated from the rest 
of the body by a physical barrier such as the blood-brain barrier. Secondly, there is the presence 
of immunosuppressive factors like TGF-, IDO. Thirdly, FasL is expressed and this induces 
apoptosis in Fas-bearing lymphocytes (Green and Ferguson, 2001). Transplantation of HLA-
mismatched hESC-derived tissues into immune-privileged sites may protect the transplants from 
rejection.  
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1.9.3.2 Generation of isogenic hESC lines 
Somatic nuclear transfer to an enucleated oocyte can give rise to cell lines which are genetically 
identical to the nucleus. Almost all the histocompatibility antigens expressed by the cell line are 
the same as the donor’s since only the mitochondrial DNA is inherited from the oocyte. 
Transplantation of tissues from cloned animals to their nuclear donors did not lead to rejection 
(Cibelli et al., 2002). 
hESC lines can also be generated from human parthenotes (Brevini and Gandolfi, 2008; Lee and 
Teixeira, 2009). Parthenogenesis is the process by which an unfertilised oocyte gets activated 
and starts to divide. With the use of calcium ionophore ionomycin followed by the protein kinase 
inhibitor 6-dimethylamino purine, parthenotes have been successfully cultured in vitro to the 
blastocyst stage (Brevini and Gandolfi, 2008).  
1.9.3.3 Cell line matching 
For organ transplantation, the most important HLA molecules are the HLA-A and HLA-B class I 
molecules and the HLA-DR class II molecules (Flomenberg et al., 2004; Petersdorf and Malkki, 
2005). The highly polymorphic glycoproteins encoded by these three loci are typed to determine 
the degree of compatibility between donor and recipient. HLA matching can improve the 
transplant outcome for kidney allografts (Terasaki et al., 1996). The same rationale of isotype 
matching can be extended to the patient and the hESC cell line. 
1.9.3.4 Induction of immune tolerance by haematopoietic chimerism 
Acute immune response towards a graft can be avoided with the induction of haematopoietic 
chimerism where the recipient is conditioned to carry donor-derived cells in the peripheral blood 
(Sykes, 2001). This is achieved by the injection of donor-derived bone marrow cells to the 
recipient which leads to haematopoietic coexistence. Therefore, thymic deletion of potentially 
donor-specific alloreactive T cells (Tomita et al., 1994) along with the blocking of costimulatory 
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T cell activation may facilitate engraftment (Sykes et al., 1997; Wekerle et al., 2000; Wekerle et 
al., 1999). 
1.9.3.5 Creating a universal donor cell line 
Genetic modification can create a hESC line which will not be recognised by recipient 
lymphocytes. The main strategy is to reduce or eliminate the expression of histocompatibility 
antigens in the cell. Therefore, genes which encode and control the cell surface expression of 
HLA class I and HLA class II molecules will be the targets of modification. For example, genes 
that encode 2-microglobulin (essential for the formation and translocation of the HLA class I 
molecule to the cell surface) and genes that encode the invariant chain (CD74) and class II 
transactivator (CIITA) proteins (essential for the regulation of HLA class II expression) are 
possible targets. However, when tissues from MHC class I and MHC class II knockout mice 
were transplanted into immunocompetent mice, they were still rejected (Dierich et al., 1993; 
Grusby et al., 1993). The residual MHC and mHC expression was still sufficient to induce 
alloreactive T cell proliferation. Another point to note is that these universal donor cells might be 
susceptible to NK cell lysis due to the absence of MHC class I (Ruggeri et al., 2001). 
Genetic modification can also enhance the survival of hESC by conferring on them an “immune-
privileged” phenotype through the transduction of genes encoding FasL and cytokines. FasL can 
trigger the apoptosis of CD95-expressing immune cells while cytokines such as IL-10 can 
contribute to immunosuppression. 
1.10  BM-MSC and immunomodulation 
As mentioned in section 1.4, MSC are being evaluated in various clinical trials. This section will 
discuss in detail how the immunomodulatory properties of MSC, in particular BM-MSC, make 
them attractive as candidates for clinical applications. 
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1.10.1 BM-MSC are not immunogenic and avoid allogeneic rejection 
BM-MSC constitutively express HLA class I and minimally HLA class II (Klyushnenkova et al., 
2005; Le Blanc et al., 2003a; Potian et al., 2003). The expression of HLA class I by BM-MSC is 
important because it protects BM-MSC from being lysed by NK cells. A major function of NK 
cells is to kill tumour cells that have downregulated HLA class I (Ruggeri et al., 2001). HLA-G 
is a HLA-like protein that is known to protect the fetal allograft against NK-mediated rejection 
(McMaster et al., 1995; Rouas-Freiss et al., 1997). It binds to the inhibitory NK receptor, KIR2, 
and inhibits NK cell killing (LeMaoult et al., 2005). HLA-G can be expressed in seven different 
isoforms, including 4 membrane-bound (HLA-G1 to –G4) and 3 soluble (HLA-G5 to –G7) 
proteins (Carosella et al., 2003). BM-MSC secrete the soluble isoform HLA-G5 which is 
upregulated by the key cytokine, IL-10 (Selmani et al., 2008). Blocking experiments using 
neutralising anti-HLA-G antibody demonstrated that HLA-G5 contributes first to the suppression 
of allogeneic T cell proliferation, and then, to the expansion of CD4+CD25highFoxP3+ Treg cells 
(Selmani et al., 2008).  
The absence of HLA class II gives BM-MSC the potential to escape recognition by alloreactive 
CD4+ T cells. Even with HLA class II upregulated following an exposure to IFN- (Potian et al., 
2003), BM-MSC could still immune suppress (Le Blanc et al., 2003a). Since BM-MSC do not 
express the costimulatory molecules CD40, CD40L, CD80, or CD86 required for effector T cell 
induction (Klyushnenkova et al., 2005; Tse et al., 2003), any residual engagement of the TCR on 
T cells  after upregulation of HLA class II would result in anergy and contribute to tolerance 
rather than allogeneic responses. 
The possibility that BM-MSC could be tolerated in vivo was demonstrated by donor-recipient 
chimerism after allogeneic BM-MSC infusions. When allogeneic BM-MSC were infused into an 
elderly woman patient with end stage severe aplastic anaemia, analysis of the BM demonstrated 
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partial recovery of stroma. At the same time, allogeneic BM-MSC were detected in the recipient 
BM, suggesting engraftment (Fouillard et al., 2003). 
1.10.2 BM-MSC and T cells 
The immunosuppressive effects of BM-MSC on T cells have been widely reported (Le Blanc and 
Ringden, 2007; Petrie Aronin and Tuan, 2010) (Figure 1-6). Generally, BM-MSC can inhibit the 
proliferation and cytokine production of T cells as discussed in the subsequent sections. 
 
Figure 1-6. Immunomodulatory effects of BM-MSC.  
BM-MSC have inhibitory effects on activated T cells, Th1 cells and DC. BM-MSC can increase the 
number of Treg cells and enhance IL-4 production by Th2 cells. Under the influence of IFN-, BM-MSC 
can produce suppressive factors. 
1.10.2.1 BM-MSC suppress T cell proliferation 
When adult rodent, baboon or human BM-MSC were present in a MLR or were added to 
lymphocytes stimulated to proliferate by mitogens, T cell proliferation was suppressed in a dose-
dependant fashion (Bartholomew et al., 2002; Krampera et al., 2003; Le Blanc et al., 2003b; Tse 
et al., 2003). However, at low concentrations (1:100-1:10000 MSC:lymphocyte ratio), BM-MSC 
sometimes enhanced proliferation in MLR (Le Blanc et al., 2003b). The suppression was MHC-
independent and was most dramatic if BM-MSC were added on the first day of a six-day culture 
(Le Blanc et al., 2003b). The failure of human allogeneic lymphocytes to proliferate in the 
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presence of BM-MSC was not a result of MSC-induced T cell anergy as the lymphocytes 
responded if they were restimulated after the BM-MSC had been removed (Maccario et al., 
2005). In contrast, if rodent BM-MSC had been present in the primary cultures of splenocytes 
with peptide-pulsed APC for more than 24 h, T cells were arrested in G1 phase of cell division 
and failed to proliferate despite retaining their ability to produce IFN- when restimulated 
(Glennie et al., 2005). Literature regarding the suppressive effect of BM-MSC through the 
induction of apoptosis are mixed. The presence of BM-MSC reduced the number of T cells 
stimulated with anti-CD3 antibody recovered after one day (Plumas et al., 2005). Furthermore, 
annexin V staining showed that there was an increase in the population of apoptotic T cells. 
However, BM-MSC inhibited the apoptosis of Jurkat cells when Jurkat cells were induced to 
undergo apoptosis using anti-Fas antibody (Benvenuto et al., 2007). Similarly, BM-MSC rescued 
T cells from apoptosis induced by serum deprivation (Jones et al., 2007). 
1.10.2.2 BM-MSC function through suppressive T cells 
There is evidence that BM-MSC may direct CD4+ T cells to a suppressive or regulatory 
phenotype (Aggarwal and Pittenger, 2005; Maccario et al., 2005). In the presence of BM-MSC, 
Th1 secretion of IFN- was reduced by 50% compared to cultures without BM-MSC. At the 
same time, there was enhanced IL-4 production when effector T cells undergoing Th2 
differentiation were cocultured with BM-MSC (Aggarwal and Pittenger, 2005). 
BM-MSC may also exert their suppressive effect by inducing an upregulation of the number of 
CD4+CD25+ Treg cells in the target population (Batten et al., 2006; Maccario et al., 2005; 
Selmani et al., 2008). This increase in Treg cell population could be due to LIF secretion by BM-
MSC as neutralising antibody against LIF downregulated the expression of FoxP3 in a MLR 
(Nasef et al., 2008). However, another group found that CD25 and CTLA-4 surface expression 
and FoxP3 mRNA levels were not dependent upon the presence of BM-MSC in CD4+ T cell 
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cultures (Krampera et al., 2006a).  Low levels of FoxP3 mRNA were expressed in CD4+ T cell 
cultures both in the presence and absence of MSC. More importantly, no significant differences 
were observed in the suppressive activity of BM-MSC on the proliferation induced by allogeneic 
stimulation of either total CD4+ T cells or CD25-depleted CD4+ T cells. 
1.10.3 BM-MSC and other immune cells 
BM-MSC could also modulate DC functions, generating tolerogenic APC which did not induce 
T cell proliferation in a secondary proliferation assay. BM-MSC interfered with DC maturation 
and downregulated the surface expression of CD11c, CD83, MHC class II and costimulatory 
molecules (Zhang et al., 2004). Similarly, Beyth et al. (2005) suggested that BM-MSC converted 
APC into an inhibitory or suppressor phenotype via cell-cell contact, thereby locking DC into a 
semi-mature state and inducing peripheral tolerance. Thus, the inhibition of T cell proliferation is 
a synergistic result of direct suppressive effect on T cells and inhibitory effect on DC maturation, 
activation and antigen presentation. 
1.10.4 Mechanism of suppression 
1.10.4.1 Immunoprivileged status of BM-MSC is not absolute 
The immunoprivileged status of BM-MSC is not absolute, depending on cell-cell interactions 
and the ‘licensing’ provided by the inflammatory environment. At low BM-MSC cell 
concentrations (1:100 MSC:T cell ratio), lymphocyte proliferation was enhanced (Fang et al., 
2006; Le Blanc et al., 2003b). IL-2 production was also upregulated at low BM-MSC doses 
(Fang et al., 2006). Therefore, the BM-MSC dose to be administered in clinical settings is 
important to avoid unwanted T cell stimulation and bystander activation of other immune cells 
by elevated IL-2 concentrations (Fang et al., 2006). 
Time course studies using CFSE-labelled T cells revealed that the proliferation of T cells was 
suppressed only after 3 days (Krampera et al., 2006a). The delay in suppression suggested that 
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crosstalk between BM-MSC and T cells was needed during the initial phase of culture for the 
‘licensing’ of the suppressive activity of BM-MSC. The importance of the presence of target 
immune cells in the induction of the suppressive activity of BM-MSC was demonstrated when 
supernatants collected from cultures of BM-MSC and PBMC reduced the proliferation of 
activated PBMC (Jones et al., 2007; Maitra et al., 2004). In contrast, supernatants collected from 
cultures of BM-MSC alone did not inhibit PBMC proliferation.  
IFN- is a key cytokine produced by activated T cells and plays a role in the suppressive activity 
of BM-MSC. The addition of a neutralising anti-IFN- receptor monoclonal antibody 
consistently inhibited the suppressive activity of BM-MSC on both CD4+ and CD8+ T cells as 
well as NK cells (Krampera et al., 2006a). The substantial role of IFN- in BM-MSC-driven 
suppression was further supported by the finding that BM-MSC had no inhibitory effect on the 
proliferation of a purified population of Th2 cells producing IL-4 but not IFN- (Krampera et al., 
2006a). IFN- can enhance the expression of IDO and PGE2 (discussed in the next section). 
Pretreatment of BM-MSC with TNF-, another pro-inflammatory cytokine, has also been shown 
to enhance the immunosuppressive effect of BM-MSC (Prasanna et al., 2010; Ren et al., 2009). 
Therefore, the presence of inflammatory cytokines in the microenvironment influences the 
immunoprivileged status of BM-MSC.  
The concentration of the inflammatory cytokines may affect the behaviour of BM-MSC and 
favour either an immunoprivileged or allostimulatory state. In the presence of low IFN- 
concentration of 10 U/ml (approximately 25 pg/ml), BM-MSC has been shown to act as APC 
and can stimulate antigen-specific CD4+ T cells following pulsing or incubation with recall 
antigens (Chan et al., 2006). However, at higher IFN- concentration of 100 U/ml 
(approximately 300 pg/ml), the allogeneic potential was diminished (Chan et al., 2006). Another 
study on the effect of IFN- concentration yielded conflicting results. When BM-MSC pretreated 
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with 500 U/ml (approximately 25 ng/ml) of IFN- was incubated with CD3+ T cells, 
proliferation of CD3+ T cells was induced (Chan et al., 2008). The difference in results could be 
due to different cell types and experimental conditions used in the two studies. In the first study 
by Chan et al. (2006), the BM-MSC were already expressing HLA class II molecules and IFN- 
basally. On the other hand, in the latter study by Chan et al. (2008), the BM-MSC did not express 
HLA class II molecules and IFN-. 
The exact mechanism by which BM-MSC modulate the immune response remains to be 
clarified. Thus far, data suggest that soluble factors as well as cell-cell contact mediated 
mechanisms are involved (Aggarwal and Pittenger, 2005; Krampera et al., 2006a; Meisel et al., 
2004; Nasef et al., 2009; Ren et al., 2009; Selmani et al., 2008). 
1.10.4.2 BM-MSC mediate suppression via soluble factors 
By using a transwell system in which BM-MSC and target cells are separated by a semi-
permeable membrane that allows the diffusion of molecules without cell contact, it has been 
shown that BM-MSC do not depend on cell-cell contact for the suppressive activity (Krampera et 
al., 2006a; Tse et al., 2003). 
Several factors have been proposed to mediate this suppressive effect, including TGF-, HGF, 
prostaglandin E2 (PGE2) and indoleamine-2,3-deoxygenase (IDO)-mediated tryptophan depletion 
(Aggarwal and Pittenger, 2005; Di Nicola et al., 2002; Meisel et al., 2004).  However, other 
investigators, who used slightly different experimental conditions, have not been able to 
corroborate these data (Le Blanc et al., 2004; Rasmusson et al., 2005).  
1.10.4.2.1 Indoleamine-2,3-dioxygenase (IDO) 
IDO is an enzyme that catabolises L-Tryptophan, thereby depleting an essential amino acid from 
the local environment (Muller and Scherle, 2006; Munn et al., 1998). The downsteam products 
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of tryptophan catabolism include kynurenine and kynurenine-derived metabolites (collectively 
grouped as kynurenines) (Figure 1-7). The biological effects of IDO can be due to the depletion 
of tryptophan, the accumulation of kynurenines or a combination of both.   
                               
Tryptophan
IDO
Kynurenine Kynurenic acid
3-HydroxykynurenineAnthranilic acid
3-Hydroxyanthranilic acid
Quinolinic acid
Nicotinamide
1-MT
 
Figure 1-7. The kynurenine pathway of tryptophan metabolism. 
Tryptophan is catabolised by IDO, giving rise to kynurenine and kynurenine-derived metabolites. The 
activity of IDO can be inhibited by 1-MT. 
IDO is widely expressed throughout the immune system and IDO-expressing cells can be found 
or induced under inflammatory states at immune-privileged sites such as thymus, epididymis, 
mucosa of the gut, placenta and the anterior chamber of the eye (Malina and Martin, 1996; Munn 
et al., 1998; Yoshida et al., 1980). The expression of IDO by the placenta is exploited by the 
mammalian fetal allograft to suppress T cell activity and prevent rejection (Munn et al., 1998). 
The authors identified the depletion of tryptophan as the main mechanism of suppressive 
activity. They did not observe any evidence of any immunosuppressive metabolite since CM 
collected from cocultures of macrophages and mitogen-stimulated T cells did not support a 
second round of T cell proliferation until tryptophan was replenished. If there were 
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immunosuppressive metabolites present in the CM, T cell proliferation would still have been 
suppressed. On the other hand, metabolites of tryptophan - kynurenine, picolinic acid and 
quinolinic acid, were shown to inhibit T cell proliferation in the absence of tryptophan 
(Frumento et al., 2002). Kynurenine-dependent inhibition of T cell proliferation was specific to 
cells which were previously activated (Frumento et al., 2002). Upon exposure to the same 
stimulating donor in the secondary MLR, the proliferation of T cells was reduced. The degree of 
inhibition was lower when the T cells were exposed to a new stimulating donor. 
An isomeric form of IDO has been recently identified and termed IDO2 (Ball et al., 2007). IDO1 
which was first identified is expressed in the intestines, kidney and reproductive system, 
including the epididymis, and can be induced in inflammatory states in the presence of IFN- 
(Takikawa et al., 1999). IDO2 can also be found in similar tissues but the different cellular 
localisation of the enzymes suggests a distinct role for each enzyme. For example, murine IDO1 
was found to be localised to the kidney vasculature while IDO2 was localised to the kidney 
tubules (Ball et al., 2007). 
Murine IDO2 can catabolise a similar range of substrates (L-tryptophan, D-tryptophan, 5-
hydroxy-tryptamine, tryptamine and serotonin) as IDO1 but with a lower efficiency (Ball et al., 
2009). When genes coding for IDO2-like enzymes from lower vertebrates were transfected into 
mammalian cells, the translated proteins retained significant enzymatic activity, suggesting that 
the protein produced in lower vertebrates is subjected to post-translational modifications in 
mammals for optimal activity (Ball et al., 2009). 
The activity of IDO can be inhibited with the use of 1-methyltryptophan (1-MT) which acts as a 
competitive inhibitor. There are different potencies for the D and L isomers of 1-MT. L-1-MT is 
more potent than D-1-MT in blocking the activity of IDO. L-1-MT inhibits IDO activity by 63% 
while D-1-MT produces an inhibition of 12% (Peterson et al., 1994). In addition, D-1-MT has 
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been reported to be selective for the inhibition of IDO2 whilst L-1-MT blocks IDO1 (Metz et al., 
2007). D-1-MT has been broadly used in clinical studies to enhance the efficacy of 
chemotherapy in order to prove the concept that inhibition of IDO activity of human tumour cells 
reduces tumour growth by reversing the block on the activation of effector T cells (Hou et al., 
2007; Muller and Scherle, 2006). Interestingly, D-1-MT was more effective than the L-isomer 
for treating tumour-bearing mice in two different breast cancer models (Muller and Scherle, 
2006). It has been hypothesised that the clinical efficacy of D-1-MT may be due to the better 
pharmacokinetic profile and the racemisation that occurs in vivo resulting in the formation of the 
active L-1-MT isomer or the modulation of an unknown anti-tumour target (Prendergast, 2008). 
Similar to the tumour cells, MSC-mediated immunosuppression involves IDO. IDO is not 
constitutively expressed by BM-MSC but can be induced by IFN- (Meisel et al., 2004; Plumas 
et al., 2005). In the BM-MSC culture without IFN-, tryptophan concentration was high (25 µM) 
while kynurenines concentration was low (0.5 µM) (Plumas et al., 2005). This suggested an 
absence of IDO activity. Similarly, in a MLR, there was an absence of kynurenines. In contrast, 
when BM-MSC were present in the MLR, there was no tryptophan but a high level of 
kynurenine (10 µM), implying the induction of IDO activity by BM-MSC. Accordingly, 
neutralisation of IDO activity by using competitive inhibitors or the addition of exogenous 
tryptophan, partially but substantially inhibited the suppressive activity of BM-MSC on T cell 
proliferation (Krampera et al., 2006a; Meisel et al., 2004; Ren et al., 2009). On the other hand, 
studies have also demonstrated that IDO expression is not essential to the maintenance of 
tolerance (Tse et al., 2003). Addition of exogenous tryptophan and 1 mM 1-MT did not reverse 
the suppressive effect of BM-MSC on anti-CD3/CD28-activated PBMC significantly. 
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1.10.4.2.2 Prostaglandin E2 (PGE2) 
Another factor, PGE2, which is constitutively expressed by BM-MSC (Arikawa et al., 2004) can 
also be induced by IFN- (Aggarwal and Pittenger, 2005). PGE2 influences a number of immune 
functions including suppression of B cell activation (Roper et al., 1994) and induction of Treg 
cells  (Akasaki et al., 2004). However, there is controversy surrounding the role of PGE2 as a 
mediator for suppression of alloresponses in MLR. Blocking PGE2 production did not restore 
allogeneic MLR responses but did influence mitogen-driven proliferation (Rasmusson et al., 
2005). 
1.10.4.2.3 Hepatocyte growth factor (HGF) 
HGF is secreted by BM-MSC (Barry et al., 2005; Sze et al., 2007). HGF induces a mitogenic and 
anti-apoptotic activity in different systems and has a role in wound repair (Xin et al., 2001). 
Although Di Nicola et al. (2002) reported that addition of neutralising anti-HGF reversed the 
suppressive effect of BM-MSC, most groups did not report a role of HGF in BM-MSC-mediated 
suppression of T cell proliferation (Le Blanc et al., 2004; Plumas et al., 2005; Rasmusson et al., 
2005).  
1.10.4.2.4 Transforming growth factor (TGF)- 
TGF- plays a role in T cell suppression (Ruegemer et al., 1990) and affects APC as well 
(Gollnick et al., 1995). However, there is no difference in TGF- concentration in cocultures 
with or without BM-MSC (Le Blanc et al., 2004). Similarly, Beyth et al. (2005) showed that 
although TGF- was secreted in cocultures of BM-MSC and immune cells, the concentration of 
TGF- was not augmented in cocultures. The neutralisation of TGF- did not reverse the 
suppressive activity of MSC (Aggarwal and Pittenger, 2005; Krampera et al., 2006a). It has been 
suggested that HGF works together with TGF- to promote the immunosuppressive activity. 
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Neutralising antibodies to HGF and TGF- restored the proliferative response in MLR (Di 
Nicola et al., 2002).  
1.10.4.2.5 Interleukin (IL)-10 
IL-10 is a recognised growth factor for Treg cells, thus promoting a “regulatory” or suppressor 
phenotype (Asseman and Powrie, 1998).  IL-10 can antagonize IL-12 during induction of 
inflammatory immune responses (Asseman and Powrie, 1998; McGuirk et al., 2000). This is 
supported by studies showing that BM-MSC partially mediate suppression through IL-10 
secretion in MLR cultures (Beyth et al., 2005; Rasmusson et al., 2005). IL-10 also works 
synergistically with HLA-G5, and is the key cytokine upregulating both the expression and 
secretion of HLA-G5 by BM-MSC (Selmani et al., 2008). HLA-G2 mediated the expansion of 
CD4+CD25highFoxP3+ Treg cells but is dependent on a preliminary direct cell-cell contact 
between T cells and BM-MSC. 
1.11  Immune characteristics of hESC-MSC 
Like hESC, hESC-MSC expressed HLA class I but not HLA class II (Trivedi and Hematti, 2008; 
Yen et al., 2009). They were negative for the costimulatory molecules CD40 (Trivedi and 
Hematti, 2008), CD80 (Trivedi and Hematti, 2008; Yen et al., 2009) and CD86 (Yen et al., 
2009). In addition, the mesenchymal progenitors derived from HSF-6 hESC using the protocol 
from Olivier et al. (2006) expressed HLA-G, a non-classical HLA class I molecule (Yen et al., 
2009). The presence of IFN- could alter the surface expression of the immune molecules. 
hESC-MSC were 49-58% HLA class II positive while BM-MSC were 94-99% HLA class II 
positive after 5 days of IFN- treatment (Trivedi and Hematti, 2008). The expression of HLA-G 
on the hESC-MSC was slightly upregulated after stimulation with IFN- for 2 days (Yen et al., 
2009). However, HLA-G remained absent on BM-MSC. There were no significant changes in 
the expression of costimulatory molecules even after treatment with IFN- (Trivedi and Hematti, 
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2008). When T lymphocytes were cocultured with IFN--treated hESC-MSC, there was no 
proliferation of T lymphocytes (Trivedi and Hematti, 2008). Suppression of T lymphocyte 
proliferation in a MLR by hESC-MSC was comparable to that of BM-MSC in both the contact 
and transwell settings (Trivedi and Hematti, 2008). Suppression of proliferation was slightly 
more in the direct contact setting. When anti-CD3/CD28 stimulated CD4+ T cells or CD8+ T 
cells were incubated with hESC-MSC for 2 days, the degree of suppression of proliferation was 
similar in both the contact and transwell settings (Yen et al., 2009). The CM collected from 
hESC-MSC was more suppressive than that from BM-MSC in MLR (Trivedi and Hematti, 
2008). In addition, hESC-MSC were more resistant to the cytotoxic effects of IL-2 and IL-15 
activated NK cells compared to BM-MSC (Yen et al., 2009). 
1.12  Immune characteristics of MSC derived from other sources 
MSC derived from other sources have been shown to display immunomodulatory properties. In 
this section, an example of adult MSC, adipose tissue-derived MSC (AD-MSC), and an example 
of fetal MSC, umbilical cord blood-derived MSC (UCB-MSC) will be discussed. AD-MSC 
produced comparable suppressive effect on PBMC proliferation as BM-MSC (Yanez et al., 
2006). AD-MSC could inhibit proliferation by 80% when added to PHA-stimulated PBMC at a 
1:10 AD-MSC:PBMC ratio (Cui et al., 2007; Yanez et al., 2006). AD-MSC could also suppress 
the proliferation of PBMC in a 5-day MLR (Cui et al., 2007; Puissant et al., 2005). Although 
Yanez et al. (2006) found that the inhibitive effect of AD-MSC was reduced in a transwell, Cui 
et al. (2007) showed that there was no difference between the inhibition produced by AD-MSC 
in contact and transwell systems. When supernatants were collected from cultures of AD-MSC 
alone and cultures of AD-MSC exposed to allogeneic PBMC, the latter could suppress the 
proliferation of PBMC significantly (Yanez et al., 2006).  However, the degree of suppression 
was still lower than that produced by the cells themselves when they were cultured with PBMC. 
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Besides inhibiting cell proliferation, cytokine production was reduced. There was inhibition of 
TNF-, IFN- and IL-12 secretion by PHA-stimulated PBMC when AD-MSC were present 
(Yanez et al., 2006). To identify the suppressive factors involved in the anti-proliferative effect, 
supernatants were analysed. In the presence of AD-MSC, HGF (Puissant et al., 2005) but not IL-
10 and TGF- (Cui et al., 2007; Puissant et al., 2005) was produced in the MLR. Addition of 
neutralising antibodies against TGF- and HGF failed to restore lymphocyte proliferation while 
proliferation was enhanced when PGE2 inhibitor, indomethacin, was added (Cui et al., 2007). 
This suggested that PGE2 was involved in AD-MSC-mediated suppression of lymphocytes 
proliferation. 
UCB-MSC could inhibit the proliferation of PBMC in a MLR and in cultures stimulated with 
PHA (Chen et al., 2010; Wang et al., 2009). UCB-MSC could also reduce the proliferation of T 
cells incubated with allogeneic DC (Tipnis et al., 2010). In addition to its anti-proliferative 
effect, the presence of UCB-MSC led to a downregulation of IFN- production by stimulated 
PBMC (Chen et al., 2010). Pretreatment with IFN- for 2 days, which upregulated the expression 
of HLA class II molecules on UCB-MSC, did not affect the suppressive effect on PBMC (Wang 
et al., 2009). Although UCB-MSC could exert their suppressive effect in a transwell, the degree 
of suppression was slightly lower than that in a contact system (Chen et al., 2010; Wang et al., 
2009). This shows that both cell-cell contact and soluble factors produced are important in 
mediating the suppressive effect. In order to determine the importance of possible suppressive 
factors, the factors were neutralised using antibodies. Neutralisation of TGF-, IDO and NO did 
not affect the immunosuppressive activity of UCB-MSC (Chen et al., 2010). However, addition 
of indomethacin reversed the suppressive effect of UCB-MSC, suggesting that PGE2 is the major 
mediator of suppression. The concentration of PGE2 was significantly increased only when 
UCB-MSC and stimulated PBMC were incubated together (Chen et al., 2010). Very low levels 
  
62
of PGE2 were detected in cultures of either UCB-MSC or stimulated PBMC alone. This 
suggested that activated PBMC delivered inducing signals to UCB-MSC, leading to the 
upregulation of PGE2. Subsequently, IFN- and IL-1 but not TNF- and IL-6 were shown to be 
the inflammatory cytokines which stimulated the production of PGE2.  
1.13 Immune characteristics of Fb 
Since the environment where immune reactions occur in vivo is rich in Fb and other connective 
tissue, it is possible for Fb to influence immune cell functions (Korn, 1981). Human foreskin Fb 
were able to suppress the proliferation of PBMC cultured in the presence of PHA by 35% when 
Fb and PBMC were cocultured at a Fb:PBMC ratio of 1:10 (Korn, 1981). However, Fb had to be 
added at the onset of PHA stimulation and the inhibition was PGE2-dependent (Korn, 1981). On 
the other hand, the addition of indomethacin, a PGE2 inhibitor, did not completely restore the 
suppressive effect on PHA-stimulated T cells induced by IFN--treated gingival Fb in a contact 
system (Shimabukuro et al., 1992). When T cells were cultured in a separate chamber from 
gingival Fb, addition of indomethacin completely abrogated the suppressive effect (Shimabukuro 
et al., 1992). Therefore, the authors concluded that IFN--dependent immunosuppressive effects 
of gingival Fb were not solely due to PGE2 when the Fb were in direct contact with T cells.  
The involvement of IFN- in the suppressive effect was also reported in corneal Fb (Donnelly et 
al., 1993) and fetal dermal Fb (Sarkhosh et al., 2003). Corneal Fb were cultured for 4 days in the 
presence of IFN- and then added to a MLR for 7 days. IFN- enhanced the suppressive effect of 
corneal Fb and IFN--pretreated Fb suppressed the proliferation of PBMC by 99% while 
untreated Fb produced an inhibition of 92% (Donnelly et al., 1993). The suppressive effect 
persisted in transwells and TGF- was thought to be the soluble factor responsible for the 
inhibition (Donnelly et al., 1993). However, the addition of neutralising antibody against TGF- 
did not reverse the suppressive effect. Similary, IDO expression was induced in fetal dermal Fb 
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upon incubation with IFN- for 48 h (Sarkhosh et al., 2003). IDO-expressing Fb did not 
stimulate allogeneic PBMC to proliferate after a 5-day incubation. On the other hand, non-IDO-
expressing Fb led to enhanced proliferation by allogeneic PBMC. In the presence of neutralising 
antibodies against IFN-, Fb-mediated suppression was abrogated (Haniffa et al., 2007). IFN- 
induced IDO in Fb, and accelerated tryptophan metabolism was partly responsible for 
suppression of T cell proliferation. However, Wada et al. (2009) showed that gene expression of 
IDO was absent in human foreskin Fb after incubation with Concanavalin A-stimulated PBMC 
for 3 days. Instead, the authors identified IFN- as the major immunosuppressive mediator as the 
addition of a neutralising antibody against IFN- (5 µg/ml) partly restored PBMC proliferation. 
Recently, it was demonstrated that the immunosuppressive properties of MSC could be shared by 
Fb of different tissues of origin and differentiation states when Fb (from the skin, joints and 
synovial membrane) were compared with BM-MSC concurrently (Jones et al., 2007).  Both BM-
MSC and Fb arrested PHA-stimulated PBMC in the G0/G1 phase of the cell cycle and rescued 
them from apoptosis. At the same time, IFN- and TNF- production was reduced. This 
inhibitory effect is ultimately mediated by soluble factors but requires initial cell-cell contact 
activation in an inflammatory environment since Fb did not inhibit the proliferation of PBMC in 
a transwell system (Jones et al., 2007). Fb appear to require induction by activated T cells to 
mediate their  suppressive effect (Haniffa et al., 2007). Supernatants collected from cultures of 
Fb with PBMC could suppress the proliferation of PBMC stimulated with anti-CD3/CD28 beads 
while supernatants from cultures of Fb alone had no effect (Jones et al., 2007).  
The suppression of T cells by Fb was reversible and the T cells were able to proliferate normally 
upon restimulation (Haniffa et al., 2007). However, transient exposure to Fb had reprogrammed 
T cells, resulting in an upregulation of Th2 cytokines, IL-4 and IL-10, secretion upon 
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restimulation (Haniffa et al., 2007). BM-MSC was even more potent than Fb, producing more 
than twice the levels of Th2 cytokines than Fb. 
In conclusion, MSC and Fb from different sources could mediate the suppression of T cell 
proliferation. The suppressive effect was enhanced by cell-cell contact and mediated by 
suppressive factors such as IDO and PGE2. 
2 Aims 
Previous studies have demonstrated the ability of BM-MSC in immunomodulation 
(Klyushnenkova et al., 2005; Le Blanc and Ringden, 2007). There are on-going clinical trials 
involving the use of BM-MSC in the prevention and treatment of GVHD, multiple sclerosis and 
Crohn’s Disease. However, a huge number of BM-MSC (1-8 million cells per kg body weight) is 
required for therapeutic applications and there is a limit to the ex vivo expansion of BM-MSC. 
Two hESC-MSC lines, hESC-MSC1 and hESC-MSC2, were derived from hESC, HuES9 and 
ESI035 respectively. hESC can serve as an unlimited source of MSC through directed 
differentiation to hESC-MSC.  
The CM from hESC-MSC1 has been shown to be cardioprotective and preserve cardiac function 
in a pig model of myocardial ischemia and reperfusion injury (Timmers et al., 2007). Before 
hESC-MSC themselves can be used clinically, their effect on T cells has to be determined. 
hESC-MSC derived by other groups were capable of suppressing the proliferation of T cells and 
avoided NK cell lysis (Trivedi and Hematti, 2008; Yen et al., 2009). Similarly, we hypothesised 
that the hESC-MSC in our study could suppress T cell proliferation. Additionally, the hESC-
MSC could use similar mechanisms of suppression as BM-MSC. The first aim of the project was 
to investigate if the hESC-MSC derived here were as effective as BM-MSC at suppressing T cell 
proliferation. Fb was included in the study as literature had demonstrated the ability of Fb to 
immunesuppress (Haniffa et al., 2007; Jones et al., 2007). The ability of MSC (hESC-MSC1, 
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hESC-MSC2 and BM-MSC) and Fb to suppress CD4+ T cell proliferation when they were 
cocultured with CD4+ T cells in a contact or transwell system was determined. The second aim 
was to uncover similarities and differences in the mechanisms of T cell immunomodulation, in 
particular, the factors secreted by the MSC and Fb. Firstly, the population of T cells undergoing 
apoptosis in the presence of MSC or Fb was determined. Secondly, the expression of PD-L1 and 
PD-L2 on MSC and Fb was compared and T cell inhibition via PD-1/PD-L1/PD-L2 was 
investigated. Thirdly, the role of IDO in mediating T cell suppression was determined. Finally, 
the supernatants produced by MSC or Fb alone and transwells of MSC or Fb with stimulated 
CD4+ T cells were tested to determine if the factors present in the supernatant might be 
sufficient to achieve T cell inhibition.  Concurrently, the supernatants were compared using 
antibody arrays in an attempt to uncover novel suppressive candidates. 
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3 Materials and methods 
3.1 Cell culture 
3.1.1 Adult bone marrow-derived mesenchymal stem cells (BM-MSC) 
BM-MSC (PT-2501) were purchased from Lonza, MD, USA. The lots used were 6F3502, 
7F3753, 7F3914 and 8F3543. The lot numbers 6F3502 and 7F3914 were donated by 21-year-old 
Black males. The lot numbers 7F3753 and 8F3543 were obtained from Chinese males, aged 43 
and 20 respectively. Cells were cultured in MSC growth medium (MSCGM; MSC basal medium 
with MSC growth supplement, glutamine, penicillin, and streptomycin added; Lonza), as 
described by the manufacturer. Briefly, cells were seeded at a density of 6000 cells/cm2. 3-4 days 
after seeding, the medium was completely removed and replaced with an equal volume of 
MSCGM. Cultures were near confluent by day 7 and were subcultured. Passage 5-8 BM-MSC 
were used for the experiments. 
3.1.2 Human embryonic stem cell-derived mesenchymal stem cells (hESC-
MSC) 
Two cell lines, HuES9.E1 and ESI035, were used. The first hESC-MSC, HuES9.E1, was derived 
from the human embryonic stem cell line HuES9 (HUES Facility, MA, USA) (Lian et al., 2007). 
The derived HuES9.E1 (hESC-MSC1) were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Invitrogen-Gibco, CA, USA) supplemented with 2 mM glutamine, 1% nonessential 
amino acids (NEAA) and 10% Fetal bovine serum (FBS) (Hyclone, UT, USA). Supplements 
used were from Invitrogen-Gibco unless otherwise stated. Cells were split 1:3 every 3-4 days. 
Passage P15-22 hESC-MSC1 were used for the experiments. 
The second hESC-MSC, hESC-MSC2, was derived from ESI035 (Crook et al., 2007) using the 
same protocol by Lian et al. (2007) and maintained in the same medium as hESC-MSC1. 
Passage 4-13 hESC-MSC2 were used. 
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3.1.3 Fibroblasts (Fb) 
Human foreskin Fb, BJ-10, were obtained commercially from ATCC, VA, USA. Cells were 
grown in DMEM (Invitrogen-Gibco) supplemented with 10% FBS (Hyclone), 2 mM L-
glutamine, 50 U/mL penicillin and 50 g/mL streptomycin. Supplements used were from 
Invitrogen-Gibco unless otherwise stated. Cells were split 1:3 every 3-4 days. Passage 9-22 BJ-
10 were used for the experiments.  
3.1.4 Peripheral blood mononuclear cells (PBMC) 
Frozen PBMC were purchased from Allcells, CA, USA. All isolated T cell cultures were 
maintained in Roswell Park Memorial Institute (RPMI) 1640 (Invitrogen-Gibco) supplemented 
with 10% FBS (Hyclone), 2 mM L-glutamine, 50 U/mL penicillin and 50 g/mL streptomycin. 
All supplements were from Invitrogen-Gibco unless otherwise stated. 
3.2 Differentiation 
The differentiation protocols were adapted from (Liu et al., 2007).  
3.2.1 Adipogenesis 
Cells were plated and induced to differentiate into adipocytes once they were confluent. They 
were left in adipogenic medium for 2-4 weeks. Adipogenic medium contained 0.5 mM isobutyl 
methylxanthine (Sigma-Aldrich, MO, USA), 1 µM dexamethasone (Sigma-Aldrich), 10 µM 
insulin (Sigma-Aldrich), 200 µM indomethacin (Sigma-Aldrich), 10% FBS (Hyclone), 1 mM 
(Mimimum Essential Medium) MEM sodium pyruvate, 2 mM L-glutamine, 50 U/mL penicillin 
and 50 g/mL streptomycin in DMEM low glucose basal medium. All the medium components 
were obtained from Invitrogen-Gibco unless otherwise stated. Control wells were cultured in 
parallel. The induced cells were fed every 3 days for 2-4 weeks by completely replacing the 
medium with fresh induction medium. The non-induced control cells were fed with their 
respective maintenance medium on the same schedule. 
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3.2.2 Osteogenesis 
Cells were plated and induced to differentiate into osteoblasts once they were confluent. They 
were left in osteogenic medium for 2-4 weeks. Osteogenic medium contained 0.1 µM 
dexamethasone (Sigma-Aldrich), 50 µM ascorbate-2-phosphate (Sigma-Aldrich), 10 mM -
glycerophosphate (Sigma-Aldrich), 10% FBS (Hyclone), 1 mM MEM sodium pyruvate, 2 mM 
L-glutamine, 50 U/mL penicillin and 50 g/mL streptomycin in DMEM low glucose basal 
medium. All the medium components were obtained from Invitrogen-Gibco unless otherwise 
stated. Control wells were cultured in parallel. The induced cells were fed every 3 days for 2-4 
weeks by completely replacing the medium with fresh induction medium. The non-induced 
control cells were fed with their respective maintenance medium on the same schedule. 
3.2.3 Chondrogenesis 
2 × 105 cells were cultured in 0.5 ml of basic control or differentiation medium in a 15-ml 
polypropylene tube for 4 weeks. Cells were pelleted at 200 g for 5 min. The caps of the 
polypropylene tubes were loosened and the tubes incubated in a 37oC incubator. The medium 
was changed every 2-3 days. After each medium change, the tube was flicked to ensure that the 
pellet was free-floating. Chondrogenic basic control medium contained 10 µM dexamethasone 
(Sigma-Aldrich), 50 µM ascorbate-2-phosphate (Sigma-Aldrich), 1% insulin, human transferrin, 
selenous acid (ITS)+Premix (BD Biosciences, NJ, USA), 4 mM proline (Sigma-Aldrich), 1mM 
MEM sodium pyruvate, 2 mM L-glutamine, 50 U/mL penicillin and 50 g/mL streptomycin in 
DMEM high glucose basal medium. For chondrogenic differentiation, 10 ng/ml TGF-3 (R&D 
Systems, MN, USA) was added. All the medium components were obtained from Invitrogen-
Gibco unless otherwise stated. 
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3.3 Staining 
3.3.1 Alizarin red staining 
The medium was aspirated from each well.  Cells were washed with distilled water and dried 
completely. They were then fixed with a 1:10 solution of 37% formaldehyde and phosphate 
buffer saline (PBS), pH 7.4, for 10-15 min at room temperature (RT). The fixative was removed 
and the cells were rinsed three times (5-10 min each) with an excess of distilled water. 1% w/v 
Alizarin Red S (Sigma-Aldrich) and 0.1% w/v ammonium hydroxide was added. The fixed cells 
were incubated at RT with gentle rocking for 30-45 min. Excess dye was removed and the well 
was washed four times with distilled water. The wells were air dried completely. Differentiated 
cells containing mineral deposits were stained bright red by the Alizarin Red Solution. 
3.3.2 Oil red O (ORO) 
The medium was aspirated from each well.  Cells were washed with distilled water and dried 
completely. They were then fixed with 4% formaldehyde diluted in PBS, pH 7.4, for 10-15 min 
at RT. The fixative was removed and the cells were rinsed three times (5-10 min each) with an 
excess of distilled water. ORO working solution was prepared by dissolving 300 mg of ORO 
powder (Sigma-Aldrich) in 100 ml of 99% isopropanol. For ORO staining, fixed cells were 
rinsed twice with water, and 60% isopropanol was briefly added to the flasks. This stock solution 
was then mixed at a 6:5 ratio with water, filtered, and added to fixed cells for 10-20 min. Excess 
dye was removed and the well was washed four times with distilled water. The wells were air 
dried completely. The lipid vacuoles were stained red. 
3.3.3 Alcian blue staining 
Deparaffinisation was performed on the pellet sections mounted on glass slides. The slides were 
dipped in two changes of xylene (BDH Prolabo Chemicals, London, UK) for 2 min each. To 
remove the excess xylene, the slides were dipped in two changes of absolute ethanol for 1 min 
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each, followed by 95% ethanol for 1 min and then 70% ethanol for 1 min. Finally, the slides 
were washed in distilled water for 5 min. The alcian blue solution, pH 2.5, was prepared by 
dissolving 1 g alcian blue (Sigma-Aldrich) in 100 ml of 3% acetic acid. The sections were 
stained with alcian blue solution for 30 min. The slides were then rinsed in distilled water and 
counterstained with nuclear fast red solution (Sigma-Aldrich) for 5 min. Acidic sulphated 
mucosubstances and acetic mucins on the cartilage were stained blue and nuclei were stained 
pink. 
3.4 Flow cytometry 
1 × 105 MSC or Fb were stained with primary unconjugated mouse anti-human CD29, CD34, 
CD44, CD45, CD73, CD80, CD90, CD105 (Lab Vision Corporation, CA, USA) HLA-A,B,C, 
HLA-DP,DQ,DR, ICOSL (Biolegend, CA, USA) and FasL (Biolegend) antibodies and the 
following conjugated antibodies: fluorescein isothiocyanate (FITC)-conjugated mouse anti-
human CD40 and PD-L1 antibodies, phycoerythrin (PE)-conjugated mouse anti-human CTLA-4 
and PD-L2 antibodies and allophycocyanin (APC)-conjugated mouse anti-human CD86 antibody 
(Table 3-1) for 30 min at 4oC. Cells were also stained with the corresponding isotype controls 
(Biolgend) (Table 3-2). All the antibodies were purchased from BD Biosciences, CA, USA 
unless otherwise stated (Biolegend). The concentration of antibody used was 0.5 µg/ml except 
for mouse anti-human CD105 which was added at 0.25 µg/ml. The concentrations of antibodies 
used were determined by titration of 1 × 105 cells with 0.25-1 µg/ml of antibodies. Cells were 
washed with 500 µL 1% bovine serum albumin (BSA)/PBS after 30 min-incubation. Cells were 
then centrifuged at 16 100 g for 1 min and the supernatant was removed. For cells stained with 
primary unconjugated mouse anti-human antibodies, they were further resuspended in 100 µL of 
secondary rabbit anti-mouse-FITC antibody (Dako, Glostrup, Denmark) at a ratio of 1:500 anti-
mouse-FITC: 1% BSA/PBS and incubated at 4oC for 15 min. 500 µL 1% BSA/PBS was added to 
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each tube and mixed thoroughly. Cells were centrifuged at 16 100 g for 1 min and the 
supernatant was removed. Before flow cytometry analysis, cells were resuspended in 200 µL of 
propidium iodide (PI)/1% BSA/PBS (resultant PI concentration of 1.25 µg/ml). Flow cytometry 
was performed using FACSCalibur (BD Biosciences) and analysed with Cellquest (BD 
Biosciences) and FlowJo software (TreeStar, CA, USA). 
Table 3-1. Antibodies used to stain cells for flow cytometry. 
Antibody Conjugate Concentration (µg/ml) Source 
MSC phenotyping 
   
Mouse anti-Human CD29 Unconjugated 0.5 BD Biosciences 
Mouse anti-Human CD34 Unconjugated 0.5 BD Biosciences 
Mouse anti-Human CD44 Unconjugated 0.5 BD Biosciences 
Mouse anti-Human CD45 Unconjugated 0.5 BD Biosciences 
Mouse anti-Human CD73 Unconjugated 0.5 BD Biosciences 
Mouse anti-Human CD90 Unconjugated 0.5 BD Biosciences 
Mouse anti-Human CD105 Unconjugated 0.25 BD Biosciences 
    
Immunophenotyping 
   
Mouse anti-Human CD80 Unconjugated 0.5 BD Biosciences 
Mouse anti-Human CD86 APC 0.5 BD Biosciences 
Mouse anti-Human CD40 FITC 0.5 BD Biosciences 
Mouse anti-Human CTLA-4 R-PE 0.5 BD Biosciences 
Mouse anti-Human FasL Unconjugated 0.5 Biolegend 
Mouse anti-Human HLA-A,B,C Unconjugated 0.5 BD Biosciences 
Mouse anti-Human HLA-DP,DQ,DR Unconjugated 0.5 BD Biosciences 
Mouse anti-Human ICOSL Unconjugated 0.5 Biolegend 
Mouse anti-Human PD-L1 FITC 0.5 BD Biosciences 
Mouse anti-Human PD-L2 R-PE 0.5 BD Biosciences 
 
Table 3-2. Isotype control antibodies used for flow cytometry. 
Isotype Conjugate Source 
Mouse IgG1 Unconjugated Biolegend 
Mouse IgG2b Unconjugated Biolegend 
Mouse IgG1 FITC Biolegend 
Mouse IgG2a R-PE Biolegend 
Mouse IgG1 APC Biolegend 
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3.5 Mitomycin C-treatment of cells 
Cells were mitomycin C-treated (10 g/ml) for 2.5 h. After which, cells were washed once with 
the respective culture media and another three times with PBS. Cells were trypsinised and 
counted. The appropriate number of cells was cryopreserved in 90% FBS and 10% dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich). 
3.5.1 Cell proliferation enzyme-linked immunosorbent assay (ELISA) (5-
bromo-2’-deoxyuridine) (BrdU) 
Cell proliferation ELISA (BrdU) (Roche Diagnostics GmbH, Mannheim, Germany) was used to 
determine the proliferation of MSC and Fb after mitomycin-C treatment. 5 × 103 MSC or Fb 
which had or had not been subjected to mitomycin-C treatment were plated in a 96-well plate 
(black opaque) and incubated for 5 days. The ELISA was performed according to manufacturer’s 
recommendations. Briefly, 20 µl of BrdU labelling solution (final concentration of 10 µM) was 
added to each well in the last 18 h before harvest. The supernatant was removed and the cells 
were fixed with 200 µl of FixDenat solution per well for 30 min at RT. The FixDenat solution 
was removed and the fixed cells were incubated with 100 µl of anti-BrdU-POD (anti-BrdU 
antibody conjugated with peroxidase) working solution for 2 h at RT. Anti-BrdU-POD working 
solution was removed and the wells were washed three times with 300 µl of 1× PBS Washing 
buffer each time. The clear bottom of the 96-well plate was sealed with black adhesive tape 
before 100 µl of Substrate solution (buffered solution containing luminol, 4-iodophenol and 
hydrogen peroxide) was added to each well. The light emission of the cells was measured using 
Tecan Infinite M200 plate reader (Tecan Group Ltd, Zurich, Switzerland). As shown in Table 
3-3, the cells exhibited lower values of light emission after mitomycin-C treatment, indicating 
that the cells had been rendered non-proliferative. 
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Table 3-3. Proliferation of MSC and Fb with or without mitomycin-C treatment. 
 Light emission (rlu/s) 
Cells No mitomycin-C treatment With mitomycin-C treatment 
hESC-MSC1 110000 ± 9800 2800 ± 430 
hESC-MSC2 620000 ± 41000 2200 ± 120 
BM-MSC 24000 ± 7500 2400 ± 610 
Fb 120000 ± 9100 3400 ± 40 
5 × 103 MSC or Fb (with or without mitomycin-C treatment) were plated in a 96-well plate and incubated 
for 5 days. The cells were labelled with BrdU during the last 18 h. Mean ± SEM of triplicate cultures in one 
experiment is shown. 
 
3.6 Purification of CD4+ T cells 
Frozen PBMC (Allcells) were thawed and transferred to pre-warmed RPMI 1640. Cells were 
centrifuged at 300 g for 10 min at RT. The cell pellet was resuspended in 500 l of RPMI 1640. 
30 uL of anti-human CD14 microbeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) 
was added to the cell suspension and incubated for 30 min at 4oC on a rotator.  The cells were 
then washed with PBS and centrifuged at 300 g for 10 min. Cells were resuspended in 1 mL of 
PBS and passed through the magnetic column. The CD14 positive fraction was flushed out and 
frozen. The CD14 negative (CD14-) fraction was collected, washed and centrifuged at 300 g for 
10 min. The CD14- fraction (approximately 5 × 107 cells) was resuspended in 1 ug/ml of mouse 
anti-human CD8 antibody (BD Biosciences) and 0.5 ug/ml of mouse anti-human CD16 (BD 
Biosciences), CD14, CD19, CD33 and CD56 antibodies (all from Millipore-Chemicon 
International, MA, USA) in RPMI 1640 and left on a rotator for 30 min at 4oC. The cells were 
washed with PBS and centrifuged at 300 g for 10 min. 2 ml of biomag goat anti-mouse IgG 
beads (Qiagen, Duesseldorf, Germany) were added to the cells and incubated for 30 min at 4oC 
on a rotator. The concentrations of antibodies and the volume of biomag goat anti-mouse IgG 
beads used were determined in titration studies. The magnetically-labelled cells were removed 
by applying a magnetic field. Cells which were not labelled (mainly CD4 positive (CD4+) T 
cells) were collected and used for T cell proliferation assays. Isolated cells were 80-95% CD4+ 
and CD8 negative. 
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3.7 Labelling of CD4+ T cells 
3.7.1 Thymidine pulsing 
CD4+ T cell proliferation was analysed by tritiated thymidine incorporation. 5 × 104 CD4+ T 
cells were stimulated with 0.2 µl of anti-CD3/CD28-coated beads (Dynal Biotech, Oslo, 
Norway) in the presence or absence of MSC or Fb for 3, 4 or 5 days. The cells were incubated in 
a total volume of 200 µl per well. 1 µCi of [3H]-thymidine was added to each well in the 96-well 
plate 18 h prior to harvesting. Incorporation of tritiated thymidine was assessed by harvesting the 
T cells (Harvester 96 MACH III M, TOM TEC (Receptor Technologies, Adderbury, UK), and 
counting radioactive incorporation using a Wallac Trilux 1450 Microbeta liquid scintillation and 
luminescence counter (PerkinElmer, Beaconsfield, UK) at stipulated timepoints.  
3.7.2 Carboxyfluorescein diacetate succinimidyl ester (CFSE) labelling and 
analysis 
CD4+ T cells were resuspended at 1 × 106 cells/ml in warm PBS. CFSE (CellTrace CFSE cell 
proliferation kit, Invitrogen) was added at a final concentration of 0.5 µM. Cells were incubated 
at 37°C for 5 min. Staining was then quenched by the addition of ice-cold culture medium. Cells 
were washed once with RPMI 1640 and twice more with PBS. The CFSE-labelled T cells were 
subsequently added to the pre-plated MSC or Fb. Proliferation of the CFSE-labelled T cells was 
determined using flow cytometry (FACSCalibur (BD Biosciences)). CFSE proliferation analysis 
was performed using FlowJo software (TreeStar) and will be discussed in section 4.2. 
3.8 In vitro CD4+ T cell proliferation assay with anti-CD3/CD28-coated 
beads 
3.8.1 Contact experiments 
The proliferation of CD4+ T cells in the presence of MSC or Fb was performed in a 96-well or 
24-well clear microtitre plate with flat bottom (Corning, NY, USA). In the 96-well plate, 
mitomycin C-treated MSC or Fb were seeded at dilutions of 0.05, 0.5 or 5 × 104 per well and 
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allowed to attach overnight before the addition of CD4+ T cells. CD4+ T cells (5 × 104 per well) 
in RPMI 1640 were added with or without 0.2 µl/well anti-CD3/CD28-coated beads (Dynal 
Biotech). In the 24-well plate, 2.8 × 105 mitomycin C-treated MSC or Fb were seeded and left 
overnight for cells to adhere. An equal number of CD4+ T cells was added per well the next day 
with or without 1.12 µl/well anti-CD3/CD28-coated beads. The plates were incubated at 37oC for 
up to 5 days. Cell proliferation was determined using tritiated thymidine or CFSE.  
3.8.1.1 Anti-PD-1 blocking antibody experiments 
2.8 × 105 mitomycin C-treated MSC or Fb were seeded in a 24-well plate and left overnight for 
cells to adhere. An equal number of CFSE-labelled CD4+ T cells was added per well the next 
day and stimulated with 1.12 µl of anti-CD3/CD28-coated beads. Anti-PD-1 blocking antibody 
(R&D Systems) was added at a concentration of 10 µg/ml. The plates were incubated at 37oC for 
5 days. Cell proliferation was determined using flow cytometric analysis.  
3.8.2 Transwell experiments 
2.8 × 105 mitomycin C-treated MSC or Fb were preseeded in the bottom chamber of a 24-well 
plate transwell (Corning). 2.8 × 105 CFSE-labelled CD4+ T cells were added to the top chamber 
(a 6.5-mm diameter, 0.4 µM pore-size transwell insert) the next day in the presence or absence of 
1.12 µl of anti-CD3/CD28-coated beads. After 5 days, CFSE-labelled cells were harvested and 
flow cytometry was performed using FACSCalibur. Cell proliferation was analysed using 
FlowJo software.  
3.8.3 Supernatant experiments 
3.8.3.1 Preparation of supernatants 
Supernatants were collected from cultures of MSC or Fb or anti-CD3/CD28-stimulated CD4+ T 
cells only and transwell cultures of MSC or Fb with stimulated CD4+ T cells. 2.8 × 105 
mitomycin-C treated-MSC or -Fb were plated and cultured in the presence or absence of an 
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equal number of stimulated CD4+ T cells in 700 µl of RPMI 1640 for 5 days. At the end of 5 
days, the freshly-collected supernatants were filtered before use.  
3.8.3.2 Secondary T cell proliferation assay 
The supernatants collected were added at 0.5× or 0.75× to anti-CD3/CD28-stimulated CD4+ T 
cell cultures suspended in fresh RPMI 1640 to a total of 200 µl. 50 µl of 5 × 104 CFSE-labelled 
CD4+ T cells were pipetted into each well in a 96-well plate. Appropriate volumes of the 
supernatants were added and the stimulated CD4+ T cells (0.2 µl of anti-CD3/CD28-coated 
beads) were incubated for 5 days. CFSE-labelled cells were harvested and flow cytometry was 
performed using FACSCalibur. Cell proliferation was analysed using FlowJo software. 
3.9 Apoptosis 
For the quantification of apoptotic cells, CD4+ T cells were stimulated with anti-CD3/CD28-
coated beads for 5 days in the presence or absence of MSC or Fb in the transwell system. Seven 
hours prior to harvesting, one of the wells containing stimulated CD4+ T cells was subjected to 
ultraviolet (UV) treatment using Stratalinker UV Crosslinker 1800 (Stratagene, CA, USA) to 
induce apoptosis at 200 millijoules. This served as the positive control. After harvesting the T 
cells from the wells, they were washed twice in cold PBS and resuspended at 1 × 106 cells/ml in 
annexin V-binding buffer (BD Biosciences). FITC-conjugated mouse anti-human annexin V was 
then added at a concentration of 5 µl/105 cells along with 0.5 µg/ml PI and incubated for 15 min 
at RT in the dark. Cells were analysed immediately by flow cytometry. 
3.10  Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) and western blotting 
3.10.1 Cell lysis 
Cells were harvested and washed with ice-cold PBS to remove FBS. The cells were then 
centrifuged at 16 100 g for 5 min at RT. The washing and centrifugation steps were repeated 
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twice. The cell pellets were resuspended in 40 µl of lysis buffer (1% Igepal NP40 (Sigma-
Aldrich), 150 mM NaCl (Merck, Hesse, Germany) 50 mM Tris HCl (Bio-Rad Laboratories, CA, 
USA) containing freshly added Protease Inhibitor Cocktail tablet (1 tablet for every 50 ml, 
proprietary mixture of several protease inhibitors with broad inhibitory specificity-inhibits 
serine, cysteine, metalloproteases and calpains; Roche).  Cells were sonicated on ice to ensure 
complete cells lysis using Misonix Sonicator 3000 (Qsonica LLC, CT, USA).  Cell debris was 
then pelleted at 16 100 g for 1 min at 4˚C. The supernatants were transferred to a clean tube 
before being stored at -80˚C for future use. 
3.10.2 Protein quantification 
The protein concentration in the cell lysate was determined using Pierce 660 nm protein assay 
(Themo Scientific, MA, USA). A range of BSA standards (0-2000 µg/ml) was prepared. 10 µl of 
each replicate of standard, unknown sample and appropriate blank sample (lysis buffer) was 
pipetted into a microplate well. 150 µl of Protein Assay Reagent (Proprietary dye-metal 
complex) was added to each well. The contents were mixed on a plate shaker at medium speed 
for 1 min and then incubated at RT for 5 min. The absorbance of the standards and samples was 
measured at 660 nm on Tecan Infinite M200 plate reader (Tecan Group Ltd). The protein 
concentration of the unknown sample was determined by using the standard curve (0-2000 
µg/ml) generated with the albumin standards. 
3.10.3 SDS-PAGE 
1 µg of protein was reduced using 15% v/v -mercaptoethanol (Sigma-Aldrich) in Lithium 
Dodecyl Sulphate (LDS) buffer (Invitrogen) by heating the sample at 95oC for 5 min. SDS-
Polyacrylamide gels (Precast NuPAGE Novex 4-12% Bis-Tris Gels; Invitrogen) were submerged 
in NuPAGE 2-(N-morpholino)ethanesulfonic acid (MES) SDS Running Buffer (Invitrogen) for 
electrophoresis in the XCell SureLock™ Mini-Cell (Invitrogen).  An appropriate volume of 
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Seeblue Plus 2 Prestained standard (Invitrogen) was loaded onto gels for comparison with 
proteins detected. Samples (1 µg) were loaded onto the gels and separated by electrophoresis at 
100 V for 1.5 h.  
3.10.4 Western blotting 
Proteins were transferred from SDS-Polyacrylamide gels to polyvinylidene fluoride (PVDF) 
membranes (Bio-Rad) by wet electroblotting in Transfer Buffer (12.5 mM Tris Base, 142 mM 
Glycine, 20% v/v methanol) at 100 V for 1.5 h in an ice-cooled blotting system (Mini Trans-Blot 
Cell; Bio-rad).  Membranes were removed from the blotting apparatus and incubated for 1 h at 
RT in Blocking Solution (5% w/v milk powder and 0.1% v/v Tween 20 in PBS). The membranes 
were then incubated with the appropriate primary antibodies (mouse anti-human IDO antibody 
1:500 dilution (Millipore) or rabbit anti-human -actin antibody 1:2000 dilution (Abcam, 
Cambridge, UK)) diluted in Blocking Buffer (LI-COR Biotechnology, NE, USA) for 1 h at RT 
or overnight at 4˚C.  Membranes were washed three times for 5 min during each wash, in 
Washing Buffer (0.1% v/v Tween 20 in PBS) before incubation with the appropriate secondary 
antibodies (goat anti-mouse horseradish peroxidase (HRP) or goat anti-rabbit HRP) (Dako, 
Glostrup, Denmark) diluted (1:10 000) in blocking solution (2.5% w/v milk powder and 0.1% 
v/v Tween 20 in PBS) for 1 hr at RT.  Membranes were washed three times for 5 min during 
each wash, in Washing Buffer before chemiluminescent detection using Immobilon Western 
Chemiluminescent HRP Substrate (Millipore) or Amersham ECL plus Western Blotting 
Detection Reagents (GE Healthcare, Uppsala, Sweden) and Lumi-Film Chemiluminescent 
Detection Film (Roche) to visualise proteins. -actin was used as the loading control. 
3.10.5 Detection of IDO activity 
IDO activity was indirectly determined by measuring the concentration of kynurenines in the 
supernatants. IDO converts tryptophan to kynurenines. A series of L-kynurenine (Sigma-
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Aldrich) standards (0-200 µM) were made. 100 µl of the supernatant or the standard was pipetted 
into each well of a v-bottom microplate. 100 µl of 30% w/v trichloroacetic acid (Sigma-Aldrich) 
was added to each well. The plate was incubated at 50oC for 30 min. The plate was centrifuged at 
3200 g for 5 min. The supernatants were collected and 100 µl was added to a new flat-bottom 
clear microplate. 100 µl of freshly prepared Ehrlich’s reagent (6.2 ml 1-propanol, 1.2 ml distilled 
water, 2.6 ml of 70% perchloric acid and 1.5 g of 4-dimethylbenzinamide (Sigma-Aldrich)) was 
added to each well and the plate was incubated at 65oC for 15 min. The plate was cooled at RT 
before the absorbance at 492 nm was measured using the Tecan Infinite M200 plate reader 
(Tecan Group Ltd). The concentration of the unknown sample was determined by comparing 
with the standard curve generated by known concentrations of L-kynurenine. 
3.11  Metabolite analysis 
Supernatants collected were analysed for glucose, glutamine, lactate and ammonia. 
Concentrations of the metabolites were determined electrochemically using BioProfile 100 Plus 
(Nova Biomedical Corporation, MA, USA). Enzymes are immobilised on the oxygen-permeable 
membrane covering the electrode and a current proportional to the concentration of the substrate 
(glutamine, glucose and lactate) develops. For the measurement of ammonium concentration, the 
electrode measures the amount of charged NH4+ ions and a voltage proportional to the 
concentration of the ions develops. 
3.12  Antibody array 
The RayBio Biotin Labelled-based Human Antibody Array L series kit (RayBiotech, GA, USA) 
was used to obtain a broad spectrum of cytokine expression. 250 µl of supernatant from each 
condition (refer to section 3.8.3.1) was dialysed twice with at least 500 ml 1 × PBS buffer (pH 8) 
at 4oC for a minimum of 3 h each time. An appropriate amount of proprietary Labelling Reagent 
(36 µl of 1 × Labelling Reagent for labelling 1 mg total protein in supernatant) was added into 
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the dialysed sample and the mixture incubated at RT with gentle shaking for 30 min. 3 µl of 
proprietary Stop Solution was added into the reaction solution and dialysed as above mentioned. 
The samples were then centrifuged at 10 000 g for 5 min at 4oC. 400 µl of proprietary Blocking 
Buffer was added into each well in the array chip (Figure 3-1) and incubated at RT for 30 min to 
block the slides. 400 µl of the biotin-labelled supernatant with appropriate dilution was added 
into the wells after the blocking step.  The arrays were incubated with the diluted supernatants at 
RT for 2 h with gentle shaking or 4oC overnight. The samples were decanted from all the wells 
and washed three times with 800 µl of proprietary 1 × Wash Buffer I at RT with gentle shaking 
for 5 min per wash. The array chip with frame was covered with 1 × Wash Buffer I and washed 
twice at RT with gentle shaking for 10 min per wash.  The array chip with frame was washed 
twice again with proprietary Wash Buffer II at RT with gentle shaking for 5 min. Wash Buffer II 
was removed and 400 µl of 1 × Fluorescent dye-Conjugated Streptavidin (Cy3 equivalent) was 
added into each well and incubated at RT for 2 h or 4oC overnight. Incubation was done in the 
dark from this step onwards. The array chip was washed in 1 × Wash Buffer I three times for 10 
min each time. The array chip was subsequently washed in 1 × Wash Buffer II twice for 5 min 
each time. Finally, the chip was washed in distilled water for 5 min and dried with compressed 
nitrogen. The signals on the chip were visualized with the Axon GenePix 4000B laser scanner 
(Molecular Devices, CA, USA). Analysis was performed with the Raybio Analysis Tool. 
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Figure 3-1. Layout of array glass chip. 
A. The chip consists two subarrays for two samples to be loaded at one time. B. Array chip assembled in 
the incubation frame and chamber. 
 
3.13 Statistical analysis 
Statistical analysis was performed with GraphPad Prism 4 software (GraphPad Software, 
CA,USA). Results are expressed as mean ± SEM. The ANOVA test was used to test the 
probability of significant differences among samples. Results were considered significant if the p 
value was less than 0.05. 
 
A. B. 
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4 Results 
4.1 Characterisation of MSC and Fb 
MSC can be isolated from a variety of tissues using different methods. Differences in tissue 
sources and methods of isolation, expansion and characterisation make it difficult to compare 
and contrast studies from different research groups. Therefore, the MTSCC-ISCT proposed a set 
of standards to define human MSC so that valid comparisons can be made among MSC which 
display similar characteristics (Dominici et al., 2006). Firstly, MSC must be plastic-adherent 
when maintained in standard culture conditions. Secondly, MSC must express CD105, CD73 and 
CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR 
surface molecules. Thirdly, MSC must be able to differentiate into osteoblasts, adipocytes and 
chondroblasts in vitro. To determine if the MSC (hESC-MSC1, hESC-MSC2 and BM-MSC) 
used in our study fulfilled the MSC criteria proposed, they were subjected to a phenotypic 
characterisation. Fb were also subjected to the same tests to determine how similar they are to 
MSC. 
4.1.1 Morphology 
When the MSC and Fb used in this study were cultured in plastic tissue culture flasks, all the 
cells could adhere well to the surface. Therefore, MSC fulfilled the first MSC criterion of being 
plastic-adherent under standard culture conditions. As expected, Fb were plastic-adherent too. 
Figure 4-1 shows the morphology of confluent cells. hESC-MSC (Figure 4-1A-B) appeared 
smaller in size and more rounded compared to BM-MSC (Figure 4-1C). BM-MSC had small cell 
bodies with a few membrane extensions which were long and thin and appeared more similar to 
Fb (Figure 4-1D).  
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Figure 4-1. Morphology of MSC and Fb. 
Phase contrast micrographs of A. hESC-MSC1, B. hESC-MSC2, C. BM-MSC and D. Fb. Scale bars 
represent 200 µm. 
4.1.2 Surface antigen expression 
Surface antigen expression is a rapid way to identify a cell population. Therefore, flow cytometry 
was performed to determine the surface antigen expression on the MSC and Fb based on 
published literature (Bobis et al., 2006; Chamberlain et al., 2007; Dominici et al., 2006; 
Krampera et al., 2006b). A panel of positive markers, CD29, CD44, CD73, CD90 and CD105, as 
well as two negative markers, CD34 and CD45, were used. A typical profile of the cells, as 
represented by hESC-MSC1, is shown in Figure 4-2. All the MSC (except hESC-MSC2) and Fb 
lacked the haematopoietic markers, CD34 and CD45 (Figure 4-3). Although hESC-MSC2 was 
negative for CD45, it was positive for CD34. All the cell types were positive for CD29, CD44, 
CD73, CD90 and CD105. However, hESC-MSC2 and Fb expressed higher levels of CD29, 
CD44 and CD90 than BM-MSC (Figure 4-4). All the MSC evaluated, except hESC-MSC2, 
expressed the set of surface antigens stipulated by the MTSCC-ISCT (Dominici et al., 2006). 
Likewise, Fb also expressed the same set of antigens. As such, it was difficult to differentiate 
MSC from Fb based on surface antigen expression. 
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Figure 4-2. hESC-MSC1 is negative for CD34 and CD45 but positive for CD29, CD44, CD73, CD90 
and CD105. 
Flow cytometry was performed to determine the surface antigen expression on hESC-MSC1. Cells were 
stained with the respective primary antibodies or isotype control antibodies, followed by secondary anti-
mouse-FITC antibodies. The results are expressed as percentage positive staining. Profiles are 
representative of five experiments.  
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Figure 4-3. MSC and Fb are positive for CD29, CD44, CD73, CD90 and CD105. 
Flow cytometry was performed to determine the surface antigen expression on MSC and Fb. All the MSC 
(except hESC-MSC2) and Fb are negative for both CD34 and CD45. Cells were stained with the 
respective primary antibodies or isotype control antibodies, followed by secondary anti-mouse-FITC 
antibodies. The results are expressed as percentage positive staining. Mean ± SEM of at least four 
independent experiments is shown. 
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Figure 4-4. hESC-MSC2 and Fb express higher levels of CD29, CD44 and CD90 compared to BM-
MSC.  
Flow cytometry was performed to determine the surface antigen expression on MSC and Fb. Cells were 
stained with the respective primary antibodies or isotype control antibodies, followed by secondary anti-
mouse-FITC antibodies. The results are expressed as relative mean fluorescence intensity (MFI) which is 
the ratio of the MFI of the cells stained with the antibody to that of the isotype control. *, p<0.05 where the 
relative MFI was significantly higher than that of BM-MSC. Mean ± SEM of at least four independent 
experiments is shown. 
4.1.3 Differentiation 
To determine the multipotential capability of the MSC and Fb, the cells were induced to 
differentiate into osteoblasts, adipocytes and chondrocytes using lineage specific induction 
factors (Figure 4-5). The cells were left in the induction media for up to 4 weeks. A control set of 
cells grown in normal media was maintained in parallel (data not shown). The cells were fixed 
and stained for osteoblasts, adipocytes and chondrocytes using alizarin red, ORO and alcian blue 
respectively. Only BM-MSC could successfully be induced to differentiate to all three lineages. 
hESC-MSC displayed minimal adipogenic differentiation and negligible differentiation to 
osteoblasts and chondrocytes. On the other hand, Fb failed to differentiate to any of the three 
lineages. Hence, only BM-MSC were multipotent while hESC-MSC demonstrated limited 
differentiation capability. Since hESC-MSC1 were previously reported to undergo both 
adipogenesis and chondrogenesis efficiently (Lian et al., 2007), it was possible that the ability to 
differentiate had been reduced with prolonged culture. It was not surprising that Fb failed to 
differentiate as Fb was terminally differentiated.  
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Figure 4-5. Differentiation capability of MSC and Fb.  
Only BM-MSC could differentiate to all three lineages, namely, osteoblasts, adipocytes and chondrocytes. Osteogenic and adipogenic differentiation 
media was added to subconfluent monolayers of cells for at least two weeks. Chondrogenic differentiation medium was added to cell pellets for four 
weeks. Control cultures in normal growth medium were also maintained in parallel (data not shown). Alizarin red stained for calcium in osteoblasts (top 
panel). ORO stained for lipid in adipocytes (middle panel). Alcian blue stained for sulphated proteoglycans in chondrocytes (bottom panel). Scale bars 
represent 200 µm (osteogenic, adipogenic, magnification 4 × 10) and 100 µm (chondrogenic, magnification 10 × 10). Inset: Same micrographs at 
magnification 20 × 10. 
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4.1.4 Immune phenotype 
In addition to the surface antigen chracterisation of MSC markers, the immune phenotype of 
MSC and Fb was also determined by flow cytometry (Figure 4-6). They were analysed for their 
expression of cell surface molecules known to be crucial for eliciting an immune response to 
determine if they were capable of stimulating or inhibiting T cell activation. All the MSC and Fb 
were positive for HLA class I and negative for HLA class II. hESC-MSC2 and Fb expressed 
higher levels of HLA class I. Cells which do not express HLA class I may be subjected to NK 
cell lysis. The higher expression of HLA class I on hESC-MSC2 and Fb might enhance the 
recognition of HLA class I by CTL and stimulate the killing of the HLA class I presenting cells. 
HLA class II, on the other hand, is expressed primarily on APC. The absence of HLA class II on 
MSC and Fb implies that MSC and Fb will not be able to present antigenic peptides to helper T 
cells, decreasing the risk in direct allorecognition. 
               
Figure 4-6. Immune phenotype of MSC and Fb. 
The immune phenotype of MSC and Fb was determined by flow cytometry. The panel of markers used 
included HLA class I, HLA class II, CD80, CD86, CD40, ICOSL, PD-L1, PD-L2, CTLA-4 and FasL. Each 
bar represents the relative mean fluorescence intensity compared to the respective isotype control. Mean 
± SEM of at least three independent experiments is shown. 
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In terms of costimulatory molecules, BM-MSC were negative for both CD80 and CD86. hESC-
MSC1 and hESC-MSC2 expressed negligible amounts of CD80 and CD86 whilst Fb expressed 
low levels of CD80 and CD86. This suggests that Fb could deliver the costimulatory signal 
required for the full activation of T cells. It is unclear if this low expression of costimulatory 
molecules could possibly activate T cells. All the cells except Fb were negative for CD40. Fb 
expressed low levels of CD40. CD40 stimulation can lead to the upregulation of costimulatory 
molecules and MHC molecules on DC. If DC were present together with T cells, Fb could 
enhance the antigen-presenting property of DC. All the cells were negative for ICOSL. ICOSL is 
expressed on B cells and resting APC and enhances T cell proliferation (Li et al., 2009). All the 
MSC and Fb except BM-MSC expressed PD-L1 and PD-L2. The expression of PD-L2 by BM-
MSC was minimal. Binding of PD-L1 and PD-L2 to the receptor PD-1 downregulates the T cell 
response as there is a reduction in pro-inflammatory cytokines produced (Keir et al., 2008). All 
the MSC and Fb had low expression of CTLA-4. CTLA-4 plays a role in tolerance during 
pregnancy as it is expressed on placenta Fb (Kaufman et al., 1999). All the MSC and Fb were 
negative for FasL and thus, could not induce apoptosis via the Fas/FasL pathway. 
After establishing the characteristics of the MSC and Fb used in this study, the 
immunosuppressive effect of these cells would be assessed and compared in the next section. 
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4.2 Effect of MSC and Fb on T cell proliferation 
4.2.1 Establishment of T cell proliferation assay 
A commonly used assay of cell proliferation involves the pulsing of cultures with [3H]-
thymidine, a radioactive-labelled DNA precursor, and the subsequent determination of the 
incorporation of [3H]-thymidine into the DNA. A higher radioactive signal measured by the 
scintillation counter indirectly indicates a higher cell proliferative response. However, this assay 
does not reveal information on the proliferation of individual cells as the use of [3H]-thymidine 
only provides an estimate of DNA synthesis and cell proliferation in an entire cell population. 
Furthermore, the use of [3H]-thymidine is limited to laboratories with facilities approved for 
radioactive work and proper waste management.  
An alternative non-radioactive assay is the CFSE proliferation assay. CFSE is a dye that can 
diffuse across the cell membrane and bind to free amines in the cell cytoplasm. After diffusion 
into the intracellular environment, endogenous esterases cleave off the acetate groups, leaving 
the molecule highly fluorescent and impermeable to the cell membrane. As such, cells labelled 
with CFSE can be analysed by flow cytometry upon excitation by the 488 nm argon laser.  
When the parent cell divides, the amount of CFSE is divided between the two daughter cells. 
Therefore, the amount of CFSE fluorescence is approximately halved with each cellular division. 
As the cells divide, the division peaks shift left, corresponding with the reduction in fluorescence 
(Figure 4-7A). CFSE allows 8 to 10 cell divisions to be resolved on the flow cytometer. The cells 
which were originally stained with CFSE at the start of the experiment are called the cohort cells. 
The cohort cells appear in the extreme right peak with the brightest fluorescence and are said to 
be in division number 0 since they have not divided. Cells which have divided once are in 
division number 1. In short, cells which have divided i times are in division number i. After i 
divisions, each cohort cell has given rise to 2i daughter cells (termed as responder cells). If there 
  
90
were no cell death, the number of cohort cells which would have generated the daughter cell 
population in division number i can be determined by 
i
iNidivisionincellscohortofNo
2
)(
. =  
where i is the division number (undivided=0) and N(i) is the number of events in division i 
Cohort cells giving rise to daughter cells in division number 1 onwards are termed as responder 
cohort cells. The total number of responder cohort cells is calculated as follows: 
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In an experiment, only a proportion of the cohort cells will have divided (Figure 4-7B, (D)). 
Some cells may have died before dividing (K) while some cells do not divide and remain in 
division number 0 (N). The non-dividing cells may not be sufficiently stimulated and have not 
started cell division. 
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Figure 4-7. Tracking division of T 
cells in vitro. 
A. CD4+ T cells were labelled with 
CFSE and stimulated with anti-
CD3/CD28-coated beads for 4 days. 
Cells were harvested and analysed by 
flow cytometry. Division can be 
visualised by the sequential halving of 
CFSE fluorescence, producing equally 
spaced peaks on a logarithmic scale. 
Cells in division number 0 (cohort cells) 
were the cells which were originally 
stained with CFSE. Cells in subsequent 
peaks have divided i times where 
i=division number i. B. At any time, cells 
can do nothing (N), die (K) or divide 
(D). 
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The use of CFSE labelling allows us to calculate various indices. In all the equations, i is the 
division number (undivided=0) and N(i) is the number of events in division i. The percentage of 
cells divided is the percentage of cells found in division number 1 onwards. It can be determined 
on the flow cytometry profile as the percentage of cells gated from division number 1 onwards 
(Figure 4-8). 
% cells divided
95.6%
 
 
 
Figure 4-8. Determination of percentage of cells 
divided from flow cytometry profile. 
CD4+ T cells were labelled with CFSE and stimulated 
with anti-CD3/CD28-coated beads for 5 days. Cells were 
harvested and analysed by flow cytometry. The 
percentage of cells divided is the percentage of cells 
gated. In this case, 95.6% of the cells have divided. 
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However, if one is more interested in the fate of the cohort cells, the percentage of cohort 
divided, division index and proliferation index can be calculated. The percentage of cohort 
divided is the percentage of cohort cells found in division number 1 onwards. It gives an 
indication of the percentage of cells (added at the beginning of the experiment) which have 
divided. 
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The division index (Tree Star Inc., 2010) is the average number of cell divisions undergone by 
the cohort cells (includes non-dividing cells in division number 0) and is calculated as follows: 
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The proliferation index is the average number of cell divisions undergone by the responder 
cohort cells (ignores cells in division number 0).  To calculate proliferation index, start the sum 
with i=1 instead, in the equation used to calculate division index. 
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Therefore, the proliferation index reflects how the responding system is behaving while the 
division index reflects what the entire system (including cells which have not divided) is doing. 
In comparing two systems, a lower proliferation index means that the rate of division by dividing 
cells is lower. 
4.2.1.1 Comparison of [3H]-thymidine and CFSE proliferation assays 
The non-radioactive CFSE proliferation assay was compared with the “gold standard” [3H]-
thymidine incorporation assay to determine if they displayed similar trends in proliferation. The 
proliferation of CD4+ T cells in response to anti-CD3/CD28 stimulation was determined using 
both the [3H]-thymidine and CFSE proliferation assays simultaneously. 5 × 104 CD4+ T cells 
were plated in each well of the 96-well plate and stimulated with 0.2 µl of anti-CD3/CD28-
coated beads over a period of 5 days. This volume of anti-CD3/CD28-coated beads was 
previously used by Jones et al. (2007). The T cells were harvested and analysed after 3, 4 and 5 
days of stimulation. For the [3H]-thymidine proliferation assay, T cells were pulsed with [3H]-
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thymidine in the final 18 h before harvest. For the CFSE proliferation assay, CFSE-labelled T 
cells were used in the experiment. Three sets of experiments were performed with different T 
cell donors and the counts per minute (cpm) measured in the [3H]-thymidine proliferation assay 
was compared with the proliferation index calculated in the CFSE proliferation assay. The 
proliferation index was chosen as comparison since it gives an indication of the number of cell 
divisions by responder cohort cells which have divided. Similarly, [3H]-thymidine proliferation 
measures the amount of [3H]-thymidine incorporation into actively dividing cells.  
Both the [3H]-thymidine and CFSE proliferation assays displayed similar proliferation trends in 
the three sets of experiments performed (Figure 4-9). The extent of proliferation measured 
increased with the number of days of stimulation with anti-CD3/CD28-coated beads. As shown 
in Figure 4-9, the maximum proliferation of CD4+ T cells occurred after 5 days of stimulation 
with anti-CD3/CD28-coated beads. The increase in proliferation between day 3 and day 4 was 
greater than that between day 4 and day 5.          
              
Figure 4-9. CD4+ T cells exhibit similar proliferation trends as determined by CFSE and [3H]-
thymidine proliferation assays.  
5 × 104 CD4+ T cells were stimulated with 0.2 µl of anti-CD3/CD28-coated beads and harvested on day 3, 
4 and 5 for analysis. A. For the [3H]-thymidine incorporation assay, [3H]-thymidine was added to the wells 
in the final 18 h of culture before harvest. Mean ± SEM of at least duplicate cultures at each time point is 
shown. B. CFSE-labelled CD4+ T cells were used in the CFSE proliferation assay. The proliferation index 
was calculated based on a single culture. Three sets of experiments were done with different T cell 
donors. 
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4.2.2 Effect on T cell proliferation via direct contact with MSC or Fb 
It was previously shown that BM-MSC had immunomodulatory properties and they could inhibit 
the proliferation of T cells (Klyushnenkova et al., 2005; Le Blanc and Ringden, 2007).  
However, this immunosuppressive effect did not seem to be confined to MSC. Fb could suppress 
the proliferation of T cells as well (Haniffa et al., 2007; Jones et al., 2007). If hESC-MSC are to 
be used in patients, they should ideally be immunologically inert or suppressive so that they will 
not be rejected by T cells. Therefore, hESC-MSC were compared with BM-MSC and Fb in their 
ability to suppress T cell proliferation. As results from the previous section indicated that 
maximum proliferation of CD4+T cells was achieved after 5 days of stimulation, a similar 
incubation period was used. 
Mitomycin C-treated MSC or Fb were cocultured with anti-CD3/CD28 stimulated CD4+ T cells 
in a 96-well plate at increasing cell numbers for 5 days. MSC or Fb were plated at MSC/Fb: T 
cell ratios of 1:100, 1:10 and 1:1. The four CFSE indices (percentage of cells divided, percentage 
of cohort divided, proliferation and division indices) were calculated and normalised to the 
values of the positive control which was with stimulated CD4+ T cells. The CFSE indices of the 
positive control were taken to be 100% and the normalised indices expressed as a percentage of 
the positive control.  
%100/ ×=
onlycellsTstimulatedwithindexCFSE
FbMSCofpresencetheinindexCFSEindexCFSENormalised  
In general, there was dose-dependent suppression of T cell proliferation with increasing numbers 
of MSC or Fb added, with the exception of the hESC-MSC2 line (Figure 4-10). The extent of 
suppression was the greatest at a MSC/Fb:T cell ratio of 1:1, as indicated by the smallest 
normalised values of percentage of cells divided, percentage of cohort divided, proliferation and 
division indices. The normalised percentages of cells divided were significantly reduced 
(p<0.001) when T cells were cocultured with BM-MSC or Fb (Figure 4-10A) at a MSC/Fb: T 
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cell ratio of 1:1. The cohort T cells which were added at the beginning of the experiment were 
also prevented from dividing when BM-MSC (p<0.05) or Fb (p<0.001) were 
 
Figure 4-10. BM-MSC and Fb suppress the proliferation of CD4+ T cells (CFSE analysis).  
5  × 102, 5  × 103 and 5  × 104 mitomycin C-treated MSC or Fb were plated and left to adhere overnight. 5 
× 104 CD4+ T cells were stained with CFSE and added to the MSC or Fb the next day. The resulting 
MSC/Fb: T cell ratios were 1:100, 1:10 and 1:1. CD4+ T cells were stimulated with anti-CD3/CD28-coated 
beads in the cocultures for 5 days. A. The percentage of cells divided at each cell concentration was 
normalised to that of CD4+ T cells without MSC or Fb (91.17±2.09%) in each experiment. B. The 
percentage of cohort divided at each cell concentration was normalised to that of CD4+ T cells without 
MSC or Fb (55.20±6.31%) in each experiment. C. The proliferation index at each cell concentration was 
normalised to the proliferation index of CD4+ T cells without MSC or Fb (2.64±0.06 cell divisions) in each 
experiment. D. The division index at each cell concentration was normalised to the division index of CD4+ 
T cells without MSC or Fb (1.46±0.18 cell divisions) in each experiment. Each bar represents the 
normalised CFSE index of 5  × 104 CD4+ T cells in the presence of increasing numbers of mitomycin C-
treated MSC or Fb. Mean ± SEM of at least four independent experiments is shown. *, p<0.05; **, p<0.01; 
***, p<0.001 when compared to CD4+ T cells without MSC or Fb.  
 
added (Figure 4-10B). Fb inhibited the division of cohort T cells more than BM-MSC (18±5% vs 
39±17% at MSC/Fb:T cell ratio of 1:1). When only the responder cohort T cells were taken into 
consideration, BM-MSC and Fb slowed down the rate of cell division significantly (p<0.01 and 
p<0.05 respectively) at a MSC/Fb:T cell ratio of 1:1 (Figure 4-10C). In addition, Fb could slow 
down the rate of division at a lower cell concentration of 1:10 (p<0.05). The extent of inhibition 
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by MSC and Fb on T cell proliferation was even more apparent when the division index was 
compared as it combines two factors (Figure 4-10D). A lower division index can be due to either 
fewer number of cell divisions by the responding cells or a greater population of cohort cells not 
dividing.  
When hESC-MSC were compared with BM-MSC and Fb, they were not as suppressive as BM-
MSC or Fb. The normalised percentage of T cells divided and the normalised percentage of 
cohort T cells divided in the presence of hESC-MSC1 at a 1:1 MSC/Fb:T cell ratio were twice 
the values of those in the presence of BM-MSC (Figure 4-10A-B). The second hESC-MSC line, 
hESC-MSC2, failed to reduce the normalised percentage of T cells divided and the normalised 
percentage of cohort T cells divided (Figure 4-10A-B). However, based on the fact that the 
number of cell divisions by the responder cohort T cells was lower than that of the positive 
control, it is possible that both the hESC-MSC lines could slow down the division of dividing 
cells (Figure 4-10C). In summary, all the MSC and Fb slowed down the rate of cell division by 
cohort responder cells, as indicated by the lower normalised proliferation indices. Only hESC-
MSC1, BM-MSC and Fb prevented cohort cells from dividing, as shown by the lower 
normalised percentage cohort divided. 
When [3H]-thymidine proliferation assay was used to determine the effect of MSC or Fb on 
CD4+ T cell proliferation, there were slight differences compared to the results obtained from 
the CFSE proliferation assay. As described previously, mitomycin C-treated MSC or Fb were 
preplated at increasing numbers in a 96-well plate. 5 × 104 CD4+ T cells were added to the wells 
the next day and the resultant MSC/Fb:T cell ratios were 1:100, 1:10 and 1:1. The cells were 
cocultured in direct contact for 5 days and stimulated with anti-CD3/CD28-coated beads. The 
cpm measured was normalised to that of the positive control with stimulated CD4+ T cells only 
in each experiment and expressed as a percentage of the positive control.  
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In agreement with the CFSE proliferation assay, MSC and Fb inhibited the proliferation of CD4+ 
T cells in a dose-dependent manner (Figure 4-11). Both assays also showed that hESC-MSC2 
were the least suppressive. However, the degree of inhibition of T cell proliferation by MSC and 
Fb at a MSC/Fb:T cell ratio of 1:1 was greater when the [3H]-thymidine proliferation assay was 
used. The degree of inhibition by hESC-MSC1 was comparable to that by BM-MSC and Fb. The 
marginal differences in the extent of inhibition could be attributed to the differences in the 
parameters measured. [3H]-thymidine shows a snapshot of the proliferation of T cells at a 
stipulated time while CFSE gives an overview of the extent of proliferation from the beginning 
of the experiment up to the time of harvest. 
                                   
Figure 4-11. The suppressive effects of hESC-MSC1, BM-MSC and Fb on CD4+ T cell proliferation 
are comparable ([3H]-thymidine assay). 
5 × 102, 5  × 103 and 5  × 104 mitomycin C-treated MSC or Fb were plated and left to adhere overnight. 5 
× 104 CD4+ T cells were added to the MSC or Fb the next day. The resulting MSC/Fb: T cell ratios were 
1:100, 1:10 and 1:1. CD4+ T cells were stimulated with 0.2 µl of anti-CD3/CD28-coated beads in the 
cocultures for 5 days. The cpm of stimulated T cells measured in the presence of MSC or Fb was 
normalised to that of CD4+ T cells without MSC or Fb (32.4±4.5 ×104 cpm) in each experiment. Each bar 
represents the normalised percentage proliferation of 5 × 104 CD4+ T cells in the presence of increasing 
numbers of mitomycin C-treated MSC or Fb. Mean ± SEM of four independent experiments is shown.  
Since both assays gave comparable readouts of cell proliferation, the CFSE proliferation assay 
was chosen over the [3H]-thymidine proliferation assay because it gave greater clarity about the 
behaviour of the cells in the system. [3H]-thymidine proliferation assay gives only information 
regarding the overall proliferative responses but CFSE allows the tracing of the fate of the 
original set of cells which can be presented as the percentage of cohort divided, proliferation 
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index and division index. It is possible that the high proliferation measured in the [3H]-thymidine 
proliferation assay is due to a small subset of cohort cells. A higher percentage of cohort cells 
divided means that cells which were originally added were actively dividing. A higher 
proliferation index implies that the rate of cell division is higher in cells which have started 
dividing. The division index is similar to the proliferation index but includes the non-dividing 
cell population. Two systems can have the same proliferation indices but different division 
indices if one system has more non-dividing cells. The system with more non-dividing cells will 
have a lower division index. The combined use of the proliferation index and percentage of 
cohort divided gives more information than just the division index alone. The division index is 
unable to provide information about the actual proportion of responder cohort cells. Therefore, in 
future analysis, percentage of cells divided, percentage of cohort divided and proliferation index 
will be compared to give a more thorough understanding of the entire cell system.  
A time course of the extent of T cell proliferation was performed at the MSC/Fb:T cell ratio of 
1:1 to determine when suppression was more evident. 5 × 104 mitomycin C-treated MSC or Fb 
were cocultured with an equal number of anti-CD3/CD28 stimulated CD4+ T cells in a 96-well 
plate over a period of 5 days. The CFSE-labelled T cells were harvested after 3, 4 or 5 days of 
incubation and analysed by flow cytometry. In the control culture without MSC or Fb added, the 
proliferation of CD4+ T cells was negligible on day 3 (Figure 4-12). The extent of inhibition by 
MSC and Fb was most evident on day 5. 
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Figure 4-12. Suppression of T cell proliferation is most evident after 5 days. 
5 × 104 mitomycin C-treated MSC or Fb were plated and left to adhere overnight. An equal number of 
CD4+ T cells were stained with CFSE and added to the MSC or Fb the next day. CD4+ T cells were 
stimulated with anti-CD3/CD28-coated beads in the cocultures and harvested after 3, 4 or 5 days of 
incubation. The extent of T cell proliferation was determined by flow cytometry. Proliferation profiles are 
representative of four independent experiments. 
The contact coculture experiment in the 96-well plate was scaled up to a 24-well plate format for 
valid comparison to be made with the 24-well plate transwell system which would be used in the 
next section 4.2.3.  Since the greatest extent of suppression of T cell proliferation was observed 
at a MSC/Fb:T cell ratio of 1:1, this 1:1 ratio was used in the scale-up. The number of MSC or 
Fb plated in the 24-well plate was determined based on the 5.6-fold increase in the surface area, 
from 96-well plate of 0.35 cm2 to 24-well plate of 1.96 cm2. 
2.8 × 105 mitomycin C-treated MSC or Fb were cocultured with an equal number of CD4+ T 
cells in a 24-well plate. The volume of stimulating beads was also scaled up linearly and 1.12 µl 
of anti-CD3/CD28-coated beads per well was used to activate the T cells for 5 days. All the MSC 
and Fb could inhibit the proliferation of T cells (Figure 4-13A), prevent cohort cells from 
dividing (Figure 4-13B) and slow down the proliferation of dividing cells (Figure 4-13C). 
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Similar to the 96-well plate, the extent of inhibition on the percentages of cells and cohort cells 
divided in the 24-well plate was the greatest by BM-MSC and Fb. Even though incubation with 
hESC-MSC2 had a significantly lower inhibition on the normalised percentages of both cells and 
cohort cells divided when compared with hESC-MSC1, BM-MSC and Fb (Figure 4-13A,B), it 
was as effective at slowing down the rate of cell division of dividing cells (Figure 4-13C).  
                          
Figure 4-13. MSC and Fb suppress the proliferation of CD4+ T cells in a 24-well plate contact 
system. 
2.8  × 105 mitomycin C-treated MSC or Fb were plated and left to adhere overnight. An equal number of 
CD4+ T cells were stained with CFSE and added to the MSC or Fb the next day. CD4+ T cells were 
stimulated with anti-CD3/CD28-coated beads in the cocultures for 5 days. A. The percentage of cells 
divided was normalised to that of CD4+ T cells without MSC or Fb (88.07±1.28%) in each experiment. B. 
The percentage of cohort divided was normalised to that of CD4+ T cells without MSC or Fb 
(38.25±3.46%) in each experiment. C. The proliferation index was normalised to the proliferation index of 
CD4+ T cells without MSC or Fb (1.05±0.08) in each experiment. Each bar represents the normalised 
CFSE index of 2.8 × 105 CD4+ T cells in the presence of an equal number of mitomycin C-treated MSC or 
Fb. Mean ± SEM of at least 11 independent experiments is shown. *, p<0.05; **, p<0.01; ***, p<0.001 
when the different CFSE indices were compared among cultures with or without MSC or Fb. 
 
Unlike what was observed in the 96-well plate contact system, hESC-MSC could suppress T cell 
proliferation in the 24-well plate. Although the number of MSC or Fb added was scaled up 
linearly from the 96-well plate, the volume added into the 24-well plate was not. A total volume 
of 700 µl was added, based on the recommendation in the transwell protocol. This corresponded 
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to a 3.5-fold increase in volume instead of the 5.6-fold increase in number of MSC or Fb plated. 
Hence, suppressive factors secreted by the MSC or Fb could be more concentrated (1.6-fold the 
concentration in the 96-well plate) and may account for the enhanced suppression of the T cells 
in a 24-well plate. 
4.2.3 Effect on T cell proliferation in a transwell 
To determine if cell-cell contact is required for the suppressive effect, MSC or Fb were cultured 
in a separate chamber from CD4+ T cells in a transwell system. 2.8 × 105 mitomycin C-treated 
MSC or Fb were preplated in the bottom chamber and an equal number of CFSE-labelled CD4+ 
T cells activated with 1.12 µl of anti-CD3/CD28-coated beads was added to the top chamber the 
next day. The two types of cells were separated using a 0.4 µm semi-permeable membrane which 
did not allow the cells to pass through. CFSE analysis of the T cells was done after 5 days of 
incubation.  
The results show that all the MSC and Fb were able to suppress T cell proliferation (p<0.05)  
(Figure 4-14). They could inhibit the overall proliferation of T cells (p<0.05) (Figure 4-14A), 
prevent cohort cells from dividing (p<0.001) (Figure 4-14B) and inhibit proliferating cells 
(p<0.001) (Figure 4-14C). However, both hESC-MSC were not as suppressive as BM-MSC and 
Fb when percentages of cells and cohort divided were compared (p<0.01). There were no 
statistical differences in the ability of hESC-MSC1 to limit the proliferation of T cells which had 
started dividing when compared to BM-MSC and Fb (Figure 4-14C). When the CFSE indices 
were compared between transwell (Figure 4-14) and contact (Figure 4-13) systems, there were 
no significant differences in the CFSE indices between transwell and contact systems except for 
the percentage of cohort divided being lower in the contact system when incubated with BM-
MSC (p<0.05). These results indicate that MSC and Fb could mediate their suppressive effect on 
T cells via soluble factors without direct contact with T cells. 
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Figure 4-14. MSC and Fb suppress T cell proliferation via soluble factors without direct contact. 
2.8 × 105 mitomycin C-treated MSC or Fb were plated in the bottom chamber of the transwell and left to 
adhere overnight. An equal number of CD4+ T cells were stained with CFSE and added to the MSC or Fb 
the next day. The T cells were separated from the MSC or Fb by a 0.4-µm semi-permeable membrane. 
CD4+ T cells were stimulated with 1.12 µl of anti-CD3/CD28-coated beads for 5 days. A. The percentage 
of cells divided was normalised to that of CD4+ T cells without MSC or Fb (92.80±1.04%) in each 
experiment. B. The percentage of cohort divided was normalised to that of CD4+ T cells without MSC or 
Fb (56.11±3.63%) in each experiment. C. The proliferation index was normalised to the proliferation index 
of CD4+ T cells without MSC or Fb (2.59±0.09) in each experiment. Each bar represents the normalized 
CFSE index of 2.8 × 105 CD4+ T cells in the presence of an equal number of mitomycin C-treated MSC or 
Fb. Mean ± SEM of at least eight experiments is shown. *, p<0.05; **, p<0.01; ***, p<0.001 when the 
different CFSE indices were compared among transwells in the presence or absence of MSC or Fb. 
4.2.4 Determination of IC50 
4.2.4.1 Calculation of IC50 in transwell 
It was postulated that the variability in the extent of suppression among different MSC and Fb 
could be due to the different numbers of adherent cells because not all the mitomycin C-treated 
MSC or Fb adhered to the bottom of the well after plating. Assuming that only live cells could 
secrete soluble factors necessary for the suppression of T cell proliferation, then the number of 
adherent MSC or Fb would affect their suppressive effect. Therefore, 2.8 × 105 mitomycin C-
treated MSC and Fb were preplated in the bottom chamber of the transwell and the number of 
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adherent cells determined the next day. MSC and Fb were trypsinised, harvested from one well 
and the number of live adherent cells determined by trypan blue exclusion assay. The number of 
live cells per well was counted at least three times.  
The percentage of adherent cells which is the number of adherent cells expressed as a percentage 
of the initial number of cells seeded was calculated. The percentages of adherent cells of MSC 
and Fb varied among the three sets of experiments (Figure 4-15). In the first and second sets, the  
                               
Figure 4-15. Variability in the number of adherent MSC or Fb. 
2.8 × 105 mitomycin-C treated MSC or Fb were preplated in the bottom chamber of the transwell and the 
number of adherent cells determined the next day.  MSC and Fb were trypsinised and harvested from 
each well. Using trypan blue, the number of live cells per well was counted. Each bar represents the 
percentage of adherent cells. Mean ± SEM of triplicate counts per well of three independent experiment is 
shown.  
percentage of adherent hESC-MSC2 was the least. However, hESC-MSC2 was as equally 
adherent as the other cell lines in the third set. Therefore, it can be concluded that cell adherence 
was variable and not cell type dependent. In addition, it is possible that the variation in the 
suppressive effect of each cell line was due to the difference in the number of adherent cells from 
one experiment to another. 
In order to minimise variation in the suppressive effect among MSC and Fb due to differing 
numbers of adherent cells, the inhibitory concentration, IC50, in a transwell system was 
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determined. IC50 is defined as the number of adherent MSC or Fb required per 100 CD4+ T cells 
to inhibit the proliferation of CD4+ T cells by 50%. A titration of increasing numbers of 
mitomycin C-treated MSC or Fb plated with T cells was performed to determine the inhibitory 
concentration. Between 1.75 × 104 and 2.8 × 105 MSC or Fb were preplated in the bottom 
chamber of the transwell and the number of adherent cells determined the next day (as described 
in the previous paragraph). 2.8 × 105 CFSE-labelled CD4+ T cells were added to the top 
chamber of the remaining wells and stimulated with 1.12 µl of anti-CD3/CD28-coated beads for 
5 days. A plot of normalised proliferation index against the number of adherent MSC or Fb 
allows the determination of IC50 to be made by fitting the best curve through the data points 
(Figure 4-16). 
 
 
 
Figure 4-16. Curve fitting of plot of 
normalised proliferation index against 
number of adherent cells. 
Between 1.75 × 104 and 2.8 × 105 
mitomycin C-treated MSC or Fb were 
preplated in the bottom chamber of the 
transwell and the number of adherent cells 
was determined the next day using trypan 
blue exclusion assay. 2.8 × 105 CFSE-
labelled CD4+ T cells were added to the 
top chamber of the remaining wells and 
stimulated with 1.12 µl of anti-CD3/CD28-
coated beads for 5 days. The normalised 
proliferation index was plotted against the 
number of adherent MSC or Fb. Results 
are representative of three experiments. 
 
The IC50 could not be determined directly from the fitted curves for all the MSC and Fb as 
hESC-MSC did not reduce the extent of CD4+ T cell proliferation by 50%. Based on 
extrapolation, the IC50 of hESC-MSC1, hESC-MSC2, BM-MSC and Fb in the transwell system 
were 72.6±4.3, 245.1±86.5, 38.1±3.8 and 48.7±22.3 cells per 100 CD4+ T cells respectively 
(BM-MSC<Fb<hESC-MSC1<hESC-MSC2) (Figure 4-17). The IC50 of hESC-MSC2 was 
significantly higher than BM-MSC, implying that more hESC-MSC2 was required to produce 
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the same extent of suppression as BM-MSC. There was a huge variation in the extrapolated IC50 
of hESC-MSC2 among the three sets of experiments. The extrapolation from the fitted curves 
was inaccurate since the extent of T cell proliferation was far from 50%. Therefore, IC25 was 
determined from the best-fitted curve through the data points instead. 
 
Figure 4-17. BM-MSC has a significantly lower IC50 than hESC-MSC2.  
Mitomycin C-treated MSC and Fb were preplated in 24-well plates at various cell concentrations. The 
number of adherent cells at each cell concentration was determined using the trypan blue exclusion 
assay. 2.8 × 105 CFSE-labelled CD4+ T cells were added to the upper chamber of the transwell the next 
day and stimulated with anti-CD3/CD28-coated beads for 5 days. IC50 can be calculated from the plot of 
normalised proliferation index against the number of adherent MSC or Fb. Each bar represents the 
number of mitomycin C-treated MSC or Fb per 100 CD4+ T cells required to reduce the proliferation by 
50%. Results from three independent experiments are shown. *, p<0.05 when IC50 was compared among 
MSC and Fb. 
The IC25 of hESC-MSC1, hESC-MSC2, BM-MSC and Fb in the transwell system were 
40.5±0.3, 57.2±7.7, 10.9±1.0 and 4.7±1.3 cells per 100 CD4+ T cells respectively (Fb<BM-
MSC<hESC-MSC1, hESC-MSC2) (Figure 4-18).  The IC25 of hESC-MSC1 was significantly 
higher than that of BM-MSC (p<0.01) and Fb (p<0.001). The IC25 of hESC-MSC2 was also 
significantly higher than that of BM-MSC and Fb (p<0.001). Fb was the most potent at 
suppressing T cell proliferation on a per cell basis. After taking into account the number of 
adherent cells, hESC-MSC were still less potent than BM-MSC and Fb at suppressing T cell 
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proliferation. This result was congruent with the transwell result obtained in 4.2.3 where Fb was 
the most suppressive, followed by BM-MSC, hESC-MSC1 and then hESC-MSC2. 
 
Figure 4-18. The IC25 of hESC-MSC is significantly higher than BM-MSC and Fb.  
Mitomycin C-treated MSC and Fb were preplated in 24-well plates at various cell concentrations. The 
number of adherent cells at each cell concentration was determined using the trypan blue exclusion 
assay. 2.8 × 105 CFSE-labelled CD4+ T cells were added to the upper chamber of the transwell the next 
day and stimulated with anti-CD3/CD28-coated beads for 5 days. IC25 can be calculated from the plot of 
normalised proliferation index against the number of adherent MSC or Fb. Each bar represents the 
number of mitomycin C-treated MSC or Fb per 100 CD4+ T cells required to reduce the proliferation by 
25%. Results from three independent experiments are shown. **, p<0.01; ***, p<0.001 when IC25 was 
compared among MSC and Fb. 
 
4.2.4.2 Comparison of IC25 in contact and transwell system 
To investigate if the IC25 in contact and transwell system differed, the IC25 in contact system was 
determined, in a similar manner as the transwell IC25. The IC25 of hESC-MSC1, hESC-MSC2, 
BM-MSC and Fb in the contact system were 13.1, 10.2, 8.0 and 0.6 respectively (Fb<BM-
MSC<hESC-MSC2<hESC-MSC1). Compared to the IC25 in the contact system, the IC25 in the 
transwell system was higher (Figure 4-19). This meant that more MSC and Fb were required to 
bring about the same degree of suppression of T cell proliferation in a transwell than contact 
system. Therefore, it its likely that cell-cell contact could enhance the suppressive effect of MSC 
and Fb, in addition to suppressive factors being produced. 
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Figure 4-19. The IC25 of all the MSC and Fb are higher in transwell than in the contact system.  
The IC25 in the contact system was determined and compared with the corresponding IC25 in the 
transwell. Mitomycin C-treated MSC and Fb were preplated in 24-well plates at various cell 
concentrations. The number of adherent cells at each cell concentration was determined using the trypan 
blue exclusion assay. 2.8 × 105 CFSE-labelled CD4+ T cells were added directly to the preplated MSC or 
Fb the next day and stimulated with anti-CD3/CD28-coated beads for 5 days. IC25 can be calculated from 
the plot of normalised proliferation index against number of MSC. Each bar represents the number of 
mitomycin C-treated MSC or Fb per 100 CD4+ T cells required to reduce the proliferation by 25%. Mean 
± SEM of three independent experiments is shown for the transwell IC25. Mean of two independent 
experiments is shown for the contact IC25. 
4.2.5 Effect of supernatants on T cell proliferation 
Since MSC and Fb were able to inhibit T cell proliferation in the transwell system in the absence 
of cell-cell contact, we speculated that soluble factors secreted by the cells were important in 
mediating the suppressive effect. Therefore, supernatants collected from cultures of MSC, Fb or 
stimulated CD4+ T cells only and transwells of MSC or Fb incubated with stimulated CD4+ T 
cells were tested to determine if the secreted factors alone were sufficient in suppressing T cell 
proliferation. 2.8 × 105 mitomycin C-treated MSC or Fb were preplated in a 24-well plate. Fresh 
RPMI medium was replenished the next day. In transwell cultures, an equal number of 
stimulated CD4+ T cells was added to the top chamber and stimulated with anti-CD3/CD28-
coated beads. RPMI medium without any cells added was also concurrently incubated and served 
as a negative control to evaluate if the degradation of medium components at 37oC for 5 days 
would affect T cell proliferation. The supernatants were collected after 5 days and added to 
  
108
secondary T cell cultures stimulated with anti-CD3/CD28-coated beads for another 5 days. 150 
µl of supernatant was added to the stimulated T cells suspended in 50 µl of fresh RPMI medium. 
Therefore, the supernatants were added at 0.75× to the secondary T cell cultures.  
The proliferation index was normalised to that of the positive control T cells grown in 
completely fresh RPMI medium in the absence of MSC or Fb. Anti-CD3/CD28-stimulated 
CD4+ T cells incubated in 5-day-old RPMI medium had a normalised proliferation index close 
to 100% (Figure 4-20). Since the 5 day-old RPMI medium could still support T cell proliferation 
as well as the fresh RPMI medium, there should be minimal degradation of medium components. 
Therefore, any effect on the T cells should be due mainly to factors secreted by MSC or Fb.  
Supernatants collected from transwells of MSC or Fb with stimulated CD4+ T cells were more 
suppressive than those collected from cultures of MSC, Fb or T cells only (Figure 4-20).                          
                   
Figure 4-20. Supernatants collected from transwells are more suppressive. 
2.8 × 105 mitomycin C-treated MSC or Fb were incubated for 5 days in the absence or presence of an 
equal number of anti-CD3/CD28 stimulated T cells in a transwell. After 5 days, the supernatants were 
collected, filtered and added at 0.75× of the total volume to a secondary T cell culture. 5 × 104 CD4+ T 
cells were stimulated with 0.2 µl of anti-CD3/CD28-coated beads for 5 days. The proliferation index was 
normalised to that of the positive control with stimulated T cells in completely fresh RPMI medium 
(2.23±0.09 cell divisions). Each bar represents the normalised proliferation index of 5 × 104 CD4+ T cells 
in the various supernatants collected. Mean ± SEM of four independent experiments is shown. 
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Supernatants collected from transwells of BM-MSC or Fb with stimulated CD4+ T cells were 
the most suppressive and T cell proliferation was about 75% of the positive control. Supernatants 
were not as effective as the MSC or Fb themselves at suppressing T cell proliferation. It was 
possible that the suppressive factors have to be replenished by MSC and Fb throughout the 
incubation period. To test if the more suppressive supernatants from transwells of BM-MSC or 
Fb with stimulated CD4+ T cells could inhibit T cell proliferation at a lower concentration, the 
normalised proliferation index when supernatants were added at 0.75× to secondary T cell 
cultures was compared to that when supernatants were added at 0.5×. There was no suppression 
of T cells when the suppressive supernatants were dosed at 0.5× (Figure 4-21). Hence, the 
concentration of the suppressive factors was important in mediating the suppressive effect. 
                
Figure 4-21. The concentration of suppressive factors is important in mediating the suppressive 
effect.  
2.8 × 105 mitomycin C-treated BM-MSC or Fb were incubated for 5 days in the presence of an equal 
number of anti-CD3/CD28 stimulated T cells in a transwell. After 5 days, the supernatants were collected, 
filtered and added at 0.5× or 0.75× of the total volume to a secondary T cell culture. 5 × 104 CD4+ T cells 
were incubated with the supernatants and stimulated with 0.2 µl of anti-CD3/CD28-coated beads for 5 
days. The proliferation index was normalised to that of the positive control with stimulated T cells in 
completely fresh RPMI medium (2.47 cell divisions). Each bar represents the normalised proliferation 
index of 5 × 104 CD4+ T cells in the supernatants collected. Results are representative of two 
independent experiments. 
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4.2.6 Metabolism of nutrients by MSC and Fb 
To determine if nutrients were depleted or if there was an accumulation of toxic metabolites, the 
supernatants collected from transwells of MSC or Fb with stimulated CD4+ T cells and cultures 
of MSC, Fb or T cells only were analysed for glutamine, glucose, ammonium and lactate 
concentrations electrochemically. Enzymes are immobilised on the oxygen-permeable membrane 
covering the electrode and a current proportional to the concentration of the substrate (glutamine, 
glucose and lactate) develops. For the measurement of ammonium concentration, the electrode 
measures the amount of charged NH4+ ions and a voltage proportional to the concentration of 
the ions develops.  
hESC-MSC consumed more glutamine than BM-MSC and Fb (Figure 4-22). However, the 
production of waste ammonium was similar in all the culture conditions of MSC or Fb in the 
presence or absence of stimulated CD4+ T cells. Supernatants collected from transwells had 
lower concentrations of glucose than those collected from MSC or Fb alone. However, the 
amount of waste lactate production was similar in all the culture conditions. The supernatants 
collected were not nutrient limiting since hESC-MSC cultures which had lower concentrations of 
glutamine and glucose could support the proliferation of T cells in the secondary cultures. The 
amount of waste metabolites was not growth-inhibitory as well since all the cultures had similar 
amounts of ammonium and lactate. The suppressive or stimulatory effect of the supernatants was 
likely due to factors produced by MSC and Fb. 
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Figure 4-22. Suppression of T cell proliferation is not due to nutrient limitation or growth-
inhibitory metabolite accumulation.  
Supernatants collected from hESC-MSC which consumed the most amount of glutamine and high 
amount of glucose could still support T cell proliferation. Supernatants were collected from cultures of 2.8 
× 105 mitomycin C- treated MSC or Fb in the presence or absence of an equal number of stimulated 
CD4+ T cells in transwells after a 5-day incubation. Supernatants were analysed for glutamine, 
ammonium, glucose and lactate electrochemically.  
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4.3 Mechanism 
4.3.1 Cell death and apoptosis 
CFSE data showed that there was an inhibition of T cell proliferation by MSC and Fb in the 
transwell system (Figure 4-14). This inhibition was also reflected by a reduction in the absolute 
cell number of viable CD4+ T cells after incubation with MSC and Fb (Figure 4-23). At the 
beginning of the experiment, 2.8 × 105 CD4+ T cells were incubated in the top chamber of a 
transwell with the same number of mitomycin C-treated MSC or Fb in the bottom chamber and 
stimulated with anti-CD3/CD28-coated beads. The number of viable T cells was determined 
using trypan blue at the end of 5 days. In the culture without MSC or Fb, there was an increase in 
the number of T cells (7.8 × 105) due to T cell proliferation. In contrast, in the cultures with MSC 
or Fb, there was a reduction in the number of T cells recovered (<1.5 × 105), suggesting cell 
death. 
 
Figure 4-23.  MSC and Fb induce cell death of stimulated CD4+ T cells.  
2.8 × 105 mitomycin C-treated MSC or Fb were preplated overnight in the bottom chamber of the 
transwell. An equal number of CD4+ T cells was added the next day into the top chamber of the transwell 
and stimulated with 1.12 µl of anti-CD3/CD28-coated beads. The number of viable CD4+ T cells was 
determined using trypan blue exclusion assay after 5 days. Results are representative of two sets of 
experiments. 
 
  
113
Annexin V-staining of CD4+ T cells was performed to determine if apoptosis could contribute to 
the enhanced cell death observed in the presence of MSC and Fb. 2.8 × 105 mitomycin C-treated 
MSC or Fb were preplated in the bottom chamber of the transwell and an equal number of CD4+ 
T cells added the next day. CD4+ T cells were stimulated with anti-CD3/CD28-coated beads for 
5 days. Seven hours before harvesting, one well of stimulated CD4+ T cells (positive control) 
was induced to undergo apoptosis by subjecting the cells to UV treatment.   
Annexin V-staining did not reveal any significant increase in the percentage of apoptotic cells 
(annexin V positive and PI negative (annexin V+PI-)) and dead cells (PI+) (Figure 4-24) after 5 
days of incubation with MSC or Fb. 45% of the cells in the positive were annexin V+PI- (Figure 
4-24A, positive control). In the absence of MSC or Fb in the transwell, there was a small 
population of apoptotic T cells (3.18%±0.89) in cultures of stimulated T cells (Figure 4-24B). In 
the presence of MSC or Fb, there was no significant increase in the population of apoptotic T 
cells. However, apoptosis could have occurred prior to day 5. Although MSC and Fb did not 
induce an increase in the population of apoptotic T cells after 5 days, there was slightly more T 
cell death in the presence of MSC or Fb (Figure 4-24C). 
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Figure 4-24. MSC and Fb enhance death of CD4+ T cells but do not induce apoptosis.  
2.8  × 105 mitomycin C-treated MSC or Fb were preplated in the bottom chamber of the transwell. An 
equal number of CD4+ T cells were stained with CFSE and added to the top chamber of the transwell the 
next day. CD4+ T cells were stimulated with 1.12 µl of anti-CD3/CD28-coated beads for 5 days. The 
proportion of apoptotic cells was determined using a flow cytometric annexin V-FITC kit. A. 
Representative plots showing induction of apoptosis of CD4+ T cells with UV (positive control) and the 
relative proportion of T cells undergoing apoptosis in the presence or absence of MSC or Fb in a 
transwell. The bottom right quadrant shows apoptotic cells (annexin V+PI-) and the top half dead cells 
(PI+). B-C. Each bar represents the percentage of apoptotic or dead CD4+ T cells in the presence or 
absence of 2.8  × 105 mitomycin C-treated MSC or Fb. Mean ± SEM of at least three independent 
experiments is shown. 
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Calculation of the normalised percentage of cohort divided showed that there was a lower 
number of cohort T cells in division number 1 onwards when CD4+ T cells were incubated with 
MSC or Fb in a transwell (Figure 4-14B). This meant that the cohort T cells which were initially 
stained with CFSE did not divide. However, we were also interested in determining if the cohort 
cells were dead or remained in the culture without dividing. Flow cytometry allows the number 
of cohort cells that remained in the culture to be determined during data analysis if counting 
beads are added to the sample. The number of cohort cells sampled, Cs, by the flow cytometer 
can be determined using the sum of the number of cohort cells in each division peak: 

∞
=
=
0 2
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i
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iNC  
where N(i)= Number of events in division peak i 
          i=division number 
The total number of cohort cells that remained in the culture, C, can then be calculated: 
sC
countedbeadsofNo
addedbeadsofNoC ×=
.
.
 
The percentage of live cohort cells that remained in the culture, L, can subsequently be 
calculated: 
%100
.
×=
starttheataddedcellsTofNo
CL  
The percentage of live cohort T cells was determined after incubation with MSC or Fb in the 
transwell for 5 days. In the presence of MSC or Fb, there were more live cohort CD4+ T cells 
compared to the control (Figure 4-25). However, this greater number of live cohort cells was not 
statistically significant. Therefore, MSC and Fb did not kill more cohort T cells compared to the 
control. They merely prevented the division of the cohort cells (Figure 4-14B). 
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Figure 4-25. MSC and Fb do not kill cohort CD4+ T cells and merely prevent their division. 
2.8  × 105 mitomycin C-treated MSC or Fb were preplated in the lower chamber of the transwell. An equal 
number of CD4+ T cells were stained with CFSE and added to the top chamber the next day. CD4+ T 
cells were stimulated with 1.12 µl of anti-CD3/CD28 beads for 5 days. Each bar represents the 
percentage of live cohort CD4+ T cells in the absence or presence of an equal number of mitomycin C-
treated MSC or Fb in a transwell. Mean ± SEM of eight independent experiments is shown.  
4.3.2 Programmed death-ligands 
Flow cytometry demonstrated the expression of programmed death ligands on MSC and Fb. The 
B7 homolog and costimulatory molecule programmed death-1 (PD-1) and its ligands, PD-L1 and 
PD-L2, constitute an inhibitory regulatory network.  Activation of the PD-1 pathway leads to the 
inhibition of TCR-mediated lymphocyte proliferation and cytokine secretion (refer to 1.8.1.2.2). 
It has been shown that murine BM-MSC upregulated the expression of PD-L1 and PD-L2 when 
incubated with PHA-stimulated splenocytes and mediated the inhibition of splenocytes, T cells 
and B cells (Augello et al., 2005). Therefore, the expression of programmed death ligands in the 
presence of stimulated CD4+ T cells was determined to evaluate if there was any further 
upregulation of these inhibitory ligands. 2.8 × 105 MSC or Fb were preplated in the bottom 
chamber of the transwell. An equal number of CD4+ T cells was added to the top chamber the 
next day. CD4+ T cells were stimulated with anti-CD3/CD28-coated beads for 5 days. The MSC 
and Fb incubated with stimulated T cells were harvested and the surface expression of PD-L1 
and PD-L2 was compared to those incubated in the absence of stimulated T cells. Upregulation 
of PD-L1 expression (Figure 4-26A-B) and a slight reduction in the expression of PD-L2 was 
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observed (Figure 4-26A, C). hESC-MSC expressed elevated levels of PD-L1 in the presence of 
stimulated T cells. Expression of PD-L1 on BM-MSC was only induced in the presence of 
stimulated T cells. The upregulation of PD-L1 expression could play a role in the inhibition of T 
cell proliferation. 
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Figure 4-26.  PD-L1 but not PD-L2 expression is upregulated in the presence of stimulated CD4+ T 
cells. 
2.8 × 105 MSC or Fb were preplated in the bottom chamber of the transwell. An equal number of CD4+ T 
cells was added to the top chamber the next day and stimulated with 1.12 µl of anti-CD3/CD28-coated 
beads for 5 days. The surface expression of PD-L1 and PD-L2 on MSC and Fb incubated with or without 
stimulated T cells was determined using flow cytometry. A. Representative plots of the expression profiles 
of PD-L1 and PD-L2 by MSC and Fb. B. The relative median fluorescence intensities of PD-L1 
expression by MSC and Fb. C. The relative median fluorescence intensities of PD-L2 expression by MSC 
and Fb. Mean ± SEM of at least two independent experiments is shown.  
A. 
B. C. 
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To investigate the role of PD-L1 and PD-L2 on T cell suppression, the receptor, PD-1, was 
blocked using anti-PD-1 antibody. 2.8 × 105 MSC or Fb were preplated in a 24-well plate. An 
equal number of CD4+ T cells was added to the MSC or Fb the next day. Either 10 µg/ml of 
anti-PD-1 antibody or an equivalent volume of vehicle was added to the wells at the start of the 
experiment. CD4+ T cells were stimulated with anti-CD3/CD28-coated beads for 5 days and 
harvested for flow cytometry to determine the extent of proliferation. Preliminary results showed 
that there was no difference in the proliferation of T cells in the presence or absence of anti-PD-1 
antibody (Figure 4-27). This meant that blocking of the PD-1 receptor which prevented the 
binding of its ligands, PD-L1 and PD-L2, did not affect the immunosuppressive potential of 
MSC and Fb. Therefore, the PD-1/PD-L1/PD-L2 pathway might not be important in mediating 
the immunosuppressive effect of MSC and Fb. 
 
Figure 4-27. The PD-1/PD-L1/PD-L2 pathway may not be significant in the immunosuppressive 
effect of MSC and Fb. 
2.8 × 105 MSC or Fb were preplated in the 24-well plate. An equal number of CD4+ T cells was added to 
the MSC or Fb the next day and stimulated with 1.12 µl of anti-CD3/CD28-coated beads for 5 days. 10 
µg/ml of anti-PD-1 antibody was added to one set of cells while an equivalent volume of vehicle was 
added to another. The proliferation index was normalised to the proliferation index of CD4+ T cells in the 
absence of MSC or Fb with vehicle added (3.18 cell divisions). Each bar represents the normalised 
proliferation index of 2.8 × 105 CD4+ T cells. Only one set of experiment was performed. 
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4.3.3 IDO 
Since there was no enhanced apoptosis of CD4+ T cells incubated with MSC or Fb, other 
possible factors responsible for T cell suppression were investigated. Although T cells were 
separated from MSC and Fb by a semi-permeable membrane in a transwell, MSC and Fb could 
still suppress T cell proliferation. This suggested that soluble factors may be responsible for 
mediating the suppressive effect. During inflammation, IFN- is produced by activated T cells. 
IFN-, in turn, induces the production of IDO in BM-MSC. IDO has been shown to partially 
contribute to the immunosuppressive property of BM-MSC (Haniffa et al., 2007; Meisel et al., 
2004).  IDO is an enzyme that catabolises L-Tryptophan, thereby depleting an essential amino 
acid from the local environment (Mellor and Munn, 2001). The catabolism of tryptophan 
produces kynurenine and kynurenine-derived metabolites (kynurenines) (Figure 1-7). The 
depletion of tryptophan could starve cells and prevent cell proliferation while the accumulation 
of kynurenines could be toxic for the cells. The IDO activity is exploited by the mammalian fetal 
allograft to suppress T cell and prevent rejection (Munn et al., 1998). Hence, we wanted to 
determine if IDO was also expressed by hESC-MSC. 
MSC, Fb and CD4+ T cells were collected from transwell cultures (set up in the same manner as 
4.2.3) after 5 days of incubation. MSC and Fb were trypsinised from the bottom chamber of the 
transwell while stimulated T cells were collected from the top chamber. The harvested cells were 
lysed and the proteins in the cell lysates separated by SDS-PAGE. The proteins were then 
transferred to a PVDF membrane where they were detected using anti-IDO and anti--actin 
antibodies. 
MSC and Fb did not express IDO basally as evidenced from the absence of bands when probed 
with the anti-IDO antibody (Figure 4-28, Lanes 1-4). However, in the presence of stimulated T 
cells, all the MSC and Fb expressed IDO (Figure 4-28, Lanes 5-8). In contrast, stimulated T cells 
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did not express IDO in the presence or absence of MSC or Fb (Figure 4-28, Lanes 9-13). This 
shows that IDO expression by MSC and Fb was induced by factors produced by stimulated 
CD4+ T cells. 
 
Figure 4-28. MSC and Fb express IDO in the presence of stimulated CD4+ T cells.  
Cell lysates were prepared from cultures of MSC, Fb and stimulated CD4+ T cells harvested from the 
transwell system after 5 days of incubation. Western blotting was performed using anti-IDO and anti--
actin antibodies. Lanes 1-4. Cultures of MSC or Fb only did not express IDO. Lanes 5-8. MSC and Fb 
expressed IDO in the presence of stimulated CD4+ T cells. Lanes 9-13. T cells did not express IDO even 
in the presence of MSC or Fb. Results are representative of three experiments. 
 
The amount of IDO activity can be indirectly measured by quantitating the concentration of 
kynurenines in the cultures. Kynurenines (kynurenine, kynurenic acid, 3-hydroxykynurenine) are 
downstream products of tryptophan metabolism by IDO. A higher concentration of kynurenines 
implies that there is enhanced IDO activity. Supernatants were collected from cultures of MSC, 
Fb or stimulated CD4+ T cells only and transwells of MSC or Fb with stimulated CD4+ T cells 
after 5 days. The concentration of kynurenines in each supernatant was determined by comparing 
the absorbance measured at 492 nm with the absorbances of known concentrations of L-
kynurenine standards. The concentrations of kynurenines were negligible in cultures of MSC, Fb 
or T cells only (Figure 4-29). Kynurenines were produced in cultures with MSC or Fb incubated 
with stimulated T cells (p<0.001). The concentration of kynurenines was higher in transwells of 
BM-MSC or Fb than in transwells of hESC-MSC (p<0.01). Hence, the concentration of 
kynurenines could correlate with the amount of IDO activity and provide a plausible explanation 
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for the enhanced suppressive effect of BM-MSC and Fb compared to hESC-MSC on T cell 
proliferation. 
 
Figure 4-29.  Transwells have higher concentrations of kynurenines compared to cultures with 
MSC, Fb or T cells alone.  
2.8 × 105 MSC or Fb were preplated in the lower chamber. For transwell cultures, an equal number of 
CFSE-labelled CD4+ T cells were added to the top chamber the next day. CD4+ T cells were stimulated 
with anti-CD3/CD28-coated beads in the transwell for 5 days. The concentrations of kynurenines in the 
supernatants were determined by comparing with the absorbances of known concentrations of L-
kynurenine at 492 nm. Each bar represents the concentration of kynurenines in cultures of MSC, Fb or T 
cells only or in transwells. Mean ± SEM of triplicates of three independent experiments is shown. **, 
p<0.01; ***, p<0.001 when concentrations of kynurenines were compared among the supernatants 
collected from transwells or cultures of MSC, Fb or T cells only. 
 
To investigate if IDO was important in mediating the suppressive effect of MSC and Fb, a 
competitive inhibitor of IDO, 1-MT, was added at a concentration of 0.1 mM or 0.5 mM to the 
transwell. The proliferation of anti-CD3/CD28-stimulated CD4+ T cells was determined by flow 
cytometry after 5 days. A plot of normalised proliferation index against concentration of 1-MT 
showed that there was a reversal of suppression in T cell proliferation by MSC or Fb (Figure 
4-30). The enhanced T cell proliferation was more significant at a 1-MT concentration of 0.5 
mM (p<0.05). T cell proliferation was restored to almost 100% in transwells with hESC-MSC 
when 0.5 mM 1-MT was added. A higher concentration of 1-MT was required to reverse the 
suppressive effect in transwells with BM-MSC or Fb since there was elevated IDO activity. 
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Therefore, IDO is clearly implicated as the key component responsible for the suppressive effect 
exerted by MSC and Fb on T cell proliferation. 
 
Figure 4-30. Reversal of T cell suppression by MSC and Fb with increasing concentrations of 1-
MT. 
2.8  × 105 mitomycin C-treated MSC or Fb were preplated in the lower chamber of a transwell and an 
equal number of CFSE-labelled CD4+ T cells were added to the top chamber the next day. Increasing 
concentrations of 1-MT were added. CD4+ T cells were stimulated with anti-CD3/CD28-coated beads in 
the transwell for 5 days and the proliferation determined by flow cytometry. Each bar represents the 
normalised proliferation index of CD4+ T cells in transwells. The proliferation index was normalised to that 
of the control CD4+ T cells in the absence of MSC or Fb without 1-MT added (2.49±0.05). Mean ± SEM of 
three independent experiments is shown. *, p<0.05; **, p<0.01; ***, p<0.001 when compared to the 
normalised proliferation index of stimulated T cells in the presence of the respective MSC or Fb with 
vehicle added. 
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4.4 Identification of potential suppressive factors 
As shown in 4.2.3, MSC and Fb could suppress CD4+ T cell proliferation in a transwell. 
Electrochemical analysis of the supernatants collected from transwells of MSC or Fb with 
stimulated T cells and cultures of MSC, Fb or stimulated T cells after 5 days showed that the 
suppression of T cell proliferation was not due to the depletion of nutrients or the accumulation 
of toxic waste products in the medium (section 4.2.6). In order to find out the possible 
suppressive factors produced by MSC and Fb in the presence of stimulated T cells, the Raybio 
antibody array was used to detect the differential factors in the supernatants collected. 
Supernatants were collected from transwells of MSC or Fb with stimulated CD4+ T cells and 
cultures of MSC, Fb or T cells only after 5 days of incubation and analysed for 507 proteins 
including cytokines and growth factors. The list of proteins can be found in the Appendix 1. 
4.4.1 How the antibody array works 
The antibodies for the proteins are printed on the array glass chip. The supernatants were 
dialysed and biotin-labelled (Figure 4-31). The biotin-labelled samples were subsequently added 
onto the glass chips and incubated. Fluorescent dye-conjugated streptavidin (cy3 equivalent) was 
used to visualize the signals. An internal control which is a spike-in protein mimicking the 
protein being labeled was used to normalise variations due to the biotin-labelling step. A 
representative image of a scanned array is shown in Figure 4-32. 
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Figure 4-31. How the antibody array works. 
The first step is to biotinylate the primary amine of the proteins in the supernatant. The biotin-labelled 
sample is then loaded onto the glass array chip and incubated overnight. Fluorescent dye-conjugated 
streptavidin (cy3 equivalent) is used to visualise the signals. A laser scanner is used to detect the signals. 
 
 

  
Figure 4-32.  Representative image of 
a scanned chip.  
The supernatant collected was 
analysed for 507 proteins including 
cytokines and growth factors according 
to manufacturer’s protocol. The median 
signal intensity of each protein was 
obtained from triplicate measurements 
in each chip and normalised to the 
internal control. The internal control is a 
protein which is spiked in together  
with the protein samples to be 
analysed. Therefore, it can be used to 
normalise the entire process. 

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4.4.2 Analysis method 
Triplicates of each antibody against the protein were spotted onto the chip. Signal intensity 
values which had coefficient of variance of more than 35% were discarded. The remaining 
values were then averaged to obtain the median signal intensity of the protein. To compare 
among arrays, a control sample of RPMI medium without cells added was incubated for 5 days, 
just like the setup using MSC or Fb. The signal intensity of each protein which was present in the 
control RPMI medium was substracted from the corresponding value in the rest of the 
supernatants as a form of background correction.  
Since MSC and Fb could suppress T cell proliferation in the transwell and that the supernatants 
collected from these wells could suppress T cell proliferation, it was possible that the additional 
factors which were produced when MSC or Fb were incubated with stimulated T cells could 
contribute to T cell suppression. To identify factors which were upregulated in transwells of 
MSC or Fb with stimulated CD4+ T cells, factors which were more highly expressed in the 
transwell supernatants compared to the corresponding cultures of MSC, Fb or stimulated T cells 
were identified. The signal intensities of the factors obtained in cultures of MSC or Fb and those 
obtained in the culture of stimulated T cells were subtracted from the signal intensities of the 
factors in corresponding transwell supernatants (Figure 4-33). Factors were considered to be 
upregulated if the resultant signal intensities were greater than zero. The lists of upregulated 
factors in the supernatants collected from various transwells were compared to give a combined 
list of upregulated factors found in all transwell supernatants.  
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(Median^ signal intensity in transwell*) – (Median^ signal intensity in MSC or Fb only) 
– (Median^ signal intensity in stimulated CD4+ T cell only) >0
^ From triplicates on the array
* hESC-MSC1, hESC-MSC2, BM-MSC or 
Fb with stimulated CD4+ T cellsList of overlapping upregulated factors in all transwells
 
Figure 4-33. Analysis work flow of antibody array. 
The list of upregulated factors in each transwell supernatant was obtained by identifying factors with 
median signal intensity greater than zero after subtracting the median signal intensity of the factor in the 
culture of MSC or Fb only and stimulated CD4+ T cells from the median signal intensity of the factor in the 
corresponding transwell. The four lists of upregulated factors were compared and a list of overlapping 
upregulated factors was generated. 
4.4.3 Candidate suppressive factors 
Using the approach outlined in 4.4.2, a total of 86, 67, 35 and 55 factors was found to be 
upregulated in the supernatants collected from transwells of hESC-MSC1, hESC-MSC, BM-
MSC and Fb with stimulated T cells respectively (Figure 4-34 and Appendix 2). A heatmap 
showing the distribution of upregulated proteins is shown in Figure 4-35. The lists of upregulated 
factors were compared and overlapping factors which were upregulated in at least three types of 
transwell supernatants were identified (Figure 4-34). 7 factors (EMAP-II, ENA-78, MIG, MIP2, 
sgp130, siglec-9 and VEGF-C) were upregulated in supernatants collected from MSC or Fb with 
stimulated T cells (Table 4-1). Other factors such as FGF-7, IL-8, IL-19, MCP-2, MMP-10 were 
upregulated in the supernatants of at least three out of four cell lines. Most of the upregulated 
factors are chemoattractants or play a role in the innate immune system. 
                                   
Figure 4-34. Venn diagram showing the number of upregulated proteins in the supernatants 
collected from transwells of MSC or Fb with stimulated CD4+ T cells. Venn diagram created using 
Venny (Oliveros, 2007). 
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Protein hESC-MSC1 hESC-MSC2 BM-MSC Fb   Intensity 
Activin A           >50000 
Activin C         >10000 
Activin RIA / ALK-2         >5000 
Activin RIB / ALK-4         >1000 
ALCAM         >500 
Angiogenin         >100 
Angiopoietin-2          >50 
Angiopoietin-4         >1 
Angiopoietin-like 1         0 
Angiopoietin-like 2         
Angiostatin            
AR (Amphiregulin)          
APRIL          
B7-1 /CD80         
BDNF           
beta-NGF         
BLC / BCA-1 / CXCL13         
BMP-3         
BMP-8         
BMPR-II           
Cardiotrophin-1 / CT-1          
CCL28 / VIC           
CCR1         
CCR4         
CD40 / TNFRSF5         
CD40 Ligand / TNFSF5 /CD154           
Chem R23         
Chordin-Like 1          
Chordin-Like 2         
CNTF          
CNTF R alpha         
CRIM 1         
Cripto-1          
Cryptic         
CXCL16           
CXCR3         
CXCR5 /BLR-1         
DcR3 / TNFRSF6B         
DR3 / TNFRSF25         
DR6 / TNFRSF21         
Dtk          
EDG-1         
EMAP-II            
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ENA-78            
Endocan          
Endoglin / CD105         
Eotaxin / CCL11          
Epiregulin          
ErbB3         
Erythropoietin            
FADD          
FAM3B         
FGF-6          
FGF-7 / KGF           
FGF-10 / KGF-2         
FGF-16          
FGF-23         
Follistatin         
Frizzled-5         
Frizzled-6          
Frizzled-7         
GASP-1 / WFIKKNRP         
GCP-2 / CXCL6         
G-CSF R / CD 114           
GDF1         
GDF3         
GDF-15          
GFR alpha-2         
Glucagon          
GM-CSF          
Granzyme A         
GRO          
GRO-a         
Growth Hormone (GH)          
HB-EGF         
HCC-4 / CCL16         
Hepassocin         
ICAM-1          
ICAM-2         
IFN-beta          
IGFBP-3          
IGFBP-6         
IGFBP-rp1 / IGFBP-7          
IGF-I SR         
IGF-II R         
IL-1 alpha          
IL-1 F5 / FIL1delta          
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IL-2           
IL-4 R          
IL-6         
IL-7 R alpha         
IL-8           
IL-9            
IL-10         
IL-10 R alpha          
IL-10 R beta           
IL-17         
IL-17B         
IL-17RD         
IL-19           
IL-20 R alpha           
IL-20 R beta          
IL-29         
I-TAC / CXCL11          
Latent TGF-beta bp1          
LECT2          
Lipocalin-1         
Lymphotoxin beta R / TNFRSF3         
MCP-1         
MCP-2           
MCP-3           
MFRP         
MIG            
MIP 2            
MMP-1          
MMP-10            
MMP-12          
Musk          
MSP alpha Chain           
MSP beta-chain         
NCAM-1 / CD56         
NeuroD1         
Orexin B          
Osteoprotegerin / TNFRSF11B         
OX40 Ligand / TNFSF4         
PDGF-AA          
PDGF-AB         
Progranulin           
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SCF R /CD117          
SDF-1 / CXCL12          
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Siglec-9            
Smad 4         
Soggy-1         
TGF-beta RI / ALK-5         
TGF-beta RII         
Thrombospondin (TSP)         
Thrombospondin-2         
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TIMP-3          
TRAIL R2 / DR5 / TNFRSF10B         
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WIF-1         
 
Figure 4-35. Heat map showing the expression of upregulated proteins in transwells of stimulated 
T cells with MSC or Fb. 
 
 
Table 4-1. Lists of factors upregulated in transwell supernatants. 
List of factors upregulated in all transwell supernatants 
EMAP-II 
ENA-78 
MIG 
MIP 2 
sgp130 
Siglec-9 
VEGF-C 
 
List of factors upregulated in transwells of hESC-MSC1, hESC-MSC2 and Fb 
Erythropoietin 
G-CSF R / CD 114 
IL-8 
IL-19 
IL-20 R alpha 
Progranulin 
MCP-3 
MMP-10 
 
List of factors upregulated in transwells of hESC-MSC2, BM-MSC and Fb 
CCL28 / VIC 
CD40 Ligand / TNFSF5 /CD154 
CXCL16 
FGF-7 / KGF 
IL-2 
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List of factors upregulated in transwells of hESC-MSC1, hESC-MSC2 and BM-MSC 
Angiostatin 
BMPR-II 
MCP-2 
MSP alpha Chain 
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5 Discussion 
5.1 hESC-MSC are MSC-like 
The MSC (hESC-MSC1, hESC-MSC2 and BM-MSC) and Fb used in this study were similar in 
surface antigen expression but differed in differentiation capability. They were positive for 
CD73, CD90 and CD105 but negative for CD34, CD45 and HLA class II molecules except for 
hESC-MSC2 which expressed CD34 (Figure 4-3). The surface expression of the haematopoietic 
marker, CD34, has previously been reported in AD-MSC (Cui et al., 2007; Roche et al., 2009). It 
was observed that the percentage of CD34 positive AD-MSC was downregulated from 17% at 
passage 2 to 2% at passage 5 (Cui et al., 2007). However, the authors did not report a significant 
difference in the immunosuppressive effect when AD-MSC were used as third party cells in 
MLR at both passages, suggesting that CD34 expression did not affect the immunosuppressive 
property of MSC (Cui et al., 2007). Since AD-MSC, which were derived from a source other 
than bone marrow, expressed CD34, the difference in CD34 expression between the two hESC-
MSC lines could be due to differences in the parental hESC used for the derivation. hESC-MSC1 
and hESC-MSC2 were derived from HuES9 (Lian et al., 2007) and ESI035 (materials and 
methods 3.1.2) respectively.  
The surface antigens expressed by the MSC and Fb when maintained in tissue culture flasks 
under standard culture conditions are in accordance with the putative MSC markers set forth by 
the MTSCC-ISCT (Dominici et al., 2006). Thus, based on surface antigen characterisation, MSC 
and Fb were indistinguishable. These results are in agreement with the literature describing the 
MSC phenotype of Fb from different sources (Haniffa et al., 2007; Jones et al., 2007). Fb 
isolated from the synovial membrane tissue (Jones et al., 2007), skin (Haniffa et al., 2007; Jones 
et al., 2007) and lung (Jones et al., 2007) have been shown to express the putative MSC markers. 
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Since MSC and Fb are similar in their surface antigen profiles, trilineage differentiation to the 
adipogenic, osteogenic and chondrogenic lineages was used to distinguish between the two cell 
types. As shown in Figure 4-5, BM-MSC differentiated to all the three lineages; hESC-MSC had 
limited differentiation capability while Fb failed to differentiate to any of the lineages. Although 
Fb are terminally differentiated, conflicting reports of the differentiation ability of Fb have been 
documented. Haniffa et al. (2007) were able to differentiate dermal Fb to the three lineages but 
Jones et al. (2007) demonstrated limited differentiation capability. Similar to our study, Wada et 
al. (2010) failed to differentiate foreskin Fb to any of the three lineages.  
In this study, hESC-MSC1 and hESC-MSC2 had limited differentiation capability and could 
only differentiate into adipocytes Figure 4-5. hESC-MSC1 which was obtained from Lian et al. 
(2007) had previously been reported to undergo both adipogenesis and chondrogenesis 
efficiently. Lian et al. (2007) showed that osteogenesis was minimal as exhibited by 1% positive 
von Kossa staining despite an upregulation of bone-specific alkaline phosphatase and bone 
sialoprotein expression by 2-3 fold. On the other hand, hESC-MSC derived by Trivedi et al. 
(2008) could differentiate to all three lineages. The differences in hESC-MSC differentiation 
efficiency suggest that the derivation protocols might affect the multipotency.  
It is also possible that the ability by hESC-MSC to differentiate has been reduced with prolonged 
culture, as demonstrated by the slight ORO staining of lipid droplets within the cells upon 
adipogenic induction (Figure 4-5). The morphology of hESC-MSC1 and hESC-MSC2 resembled 
an intermediate stage between the early and late passage MSC, reflecting a possible reduction in 
multipotency. Thus, only a small number of multipotent cells which could differentiate remained 
in the culture. To generate the large number of cells required for cell therapy, MSC are expanded 
ex vivo. However, MSC can only be expanded for 10-12 population doublings before they lose 
their multipotency (Siddappa et al., 2007). Siddappa et al. (2007) also reported that there was a 
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morphological change from thin and spindle-shaped early passage cells to large, flattened and 
irregularly-shaped late passage cells with a corresponding decline in osteogenic ability with 
increased passages.   
Many parameters such as the quality of fetal calf serum, basal medium, glucose concentration, 
plating density, plastic surface quality and supplements affect the expansion and multipotency of 
MSC. Reports have proposed plating MSC at low density to favour proliferation and 
multipotency (Colter et al., 2000). Low glucose concentration in DMEM-based media 
supplemented with glutamax instead of L-glutamine preferentially support MSC growth (Rider 
et al., 2008). Basic fibroblast growth factor 2 enhances proliferation but does not have an effect 
on osteogenic differentiation of BM-MSC and AD-MSC (Rider et al., 2008). Even the quality of 
the plastic affects the isolation and the proliferation capacity of BM-MSC to a great extent. 
When tissue culture flasks from Greiner, Nunc, Costar and Falcon were compared, more cells 
were harvested from the Falcon polystyrene flask (Sotiropoulou et al., 2006). Hence, multiple 
factors could have affected the proliferative and differentiation capacity of the cells. The culture 
protocols in the current study used media with high glucose concentration and L-glutamine, 
potentially leading to the lower efficiency in differentiation. The prolonged in vitro culture of 
hESC-MSC under suboptimal conditions might have also contributed to the loss of multipotency. 
In general, only BM-MSC fulfilled all the three MSC criteria of plastic-adherence, surface 
antigen expression and trilineage differentiation. hESC-MSC were MSC-like since they had 
limited differentiation capability. However, the reduction in differentiation capability was 
unlikely to have a consequence on the immunomodulatory potential of the cells as Fb which 
could not differentiate to all three lineages were still able to suppress T cell proliferation (Haniffa 
et al., 2007; Jones et al., 2007). This suggests that the immunosuppressive property appears to be 
shared by cells of stromal origin (Jones et al., 2007). Therefore, hESC-MSC was compared with 
  
135
BM-MSC (which was still multipotent) and Fb (which was terminally differentiated) to 
determine if they could suppress T cell proliferation. In addition, hESC-MSC1 are being 
investigated for the production of CM which can reduce the myocardial infarct size in the pig 
model (Timmers et al., 2007). Due to their therapeutic potential, it will be useful to know if the 
cells themselves can modulate immune responses and replace BM-MSC as an unlimited source 
of MSC for therapeutic purposes of immunomodulation.  
5.2 Immune phenotype of MSC and Fb 
5.2.1 MSC and Fb express HLA class I but not HLA class II molecules 
MSC and Fb were highly positive for HLA class I molecules (Figure 4-6). This is not surprising 
as all nucleated cells express HLA class I molecules which present intracellular antigens, 
including viral peptides, to CD8+ CTL. Although all the MSC and Fb expressed HLA class I 
molecules, the expression level of HLA class I molecules on hESC-MSC2 and Fb was twice that 
on BM-MSC and hESC-MSC1. Similar to the current study, Trivedi and Hematti (2008) also 
reported the variation in the expression of HLA class I molecules on hESC-MSC derived from 
different hESC lines. Hence, differences in the parental hESC used for derivation may influence 
the expression level of HLA class I molecules. In contrast, Gotherstrom et al. (2004) reported 
that the expression of HLA class I is lower in MSC from a fetal source compared to BM-MSC 
from an adult source. The expression of HLA class I molecules by MSC and Fb is important 
because it protects them from NK cell lysis. For instance, a major function of NK and NK-like 
cells is to kill tumour cells that have downregulated HLA class I (Ruggeri et al., 2001).  
Although MSC and Fb were positive for HLA class I molecules, they were negative for HLA 
class II molecules (Figure 4-6). The expression of HLA class II molecules is more restricted to 
cells such as B cells, DC and macrophages which present exogenous antigens derived from 
outside the cells to CD4+ T cells. The absence of HLA class II molecules gives MSC and Fb the 
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potential to escape direct recognition by alloreactive CD4+ T cells. However, the expression of 
HLA class II molecules can be upregulated during inflammation. BM-MSC expressed HLA class 
II molecules on the surface upon IFN- stimulation (Le Blanc et al., 2003a) but hESC did not 
(Drukker et al., 2002). This suggests that there are differences between embryonic- and adult-
sourced cells. Similarly, placenta-derived MSC did not express HLA class II molecules after 
IFN- stimulation (Chang et al., 2006)  and fetal MSC required a longer stimulation period for 
the expression of HLA class II molecules (Gotherstrom et al., 2004). Despite the expression of 
HLA class II molecules, BM-MSC were still unable to stimulate allogeneic T cells (Le Blanc et 
al., 2003a). This is similar to the non-responsiveness induced by parenchymal cells such as renal 
tubular epithelial cells expressing HLA class II molecules after IFN- treatment (Frasca et al., 
1998). Furthermore, the enhanced ability of BM-MSC to inhibit MLR after IFN- pretreatment 
suggested that IFN- played a role in the anti-proliferative effect of BM-MSC (Le Blanc et al., 
2003a). Despite the expression of HLA class I and possibly HLA class II upon IFN- stimulation 
on MSC and Fb, MSC and Fb could still suppress allogeneic T cell proliferation as shown in 
section 4.2. This suggests that they may not be inherently immunogenic. 
5.2.2 hESC-MSC and Fb express costimulatory molecules but BM-MSC do 
not 
Low levels of positive costimulatory molecules (CD80, CD86, CD40 and ICOSL) were 
expressed on hESC-MSC and Fb while BM-MSC did not express any positive costimulatory 
molecules (Figure 4-6). Similar to this study, there was absence of CD80 and CD86 on BM-
MSC, even in the presence of IFN- (Krampera et al., 2006a; Tse et al., 2003). On the contrary, 
other studies have reported the absence of CD80 and CD86 on hESC-MSC (Yen et al., 2009). 
The expression of CD80 and CD86 on hESC-MSC and Fb implies that the cells could potentially 
evoke activation of T cells by providing the costimulatory signal upon binding to CD28 on the T 
cells which is normally provided by APC. The other signal required to activate T cells involves 
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the engagement of the TCR with the peptide-MHC complex. The expression of low levels of 
CD80 and CD86 on hESC-MSC and Fb could potentially render them third party bystander APC 
and provide trans-costimulation. Trans-costimulation occurs when the costimulatory signal is not 
provided by the same cell which activated the TCR (Ding and Shevach, 1994). However, this 
slight expression of costimulatory molecules by hESC-MSC and Fb may not be significant since 
articular chondrocytes which expressed slight levels of CD80 could still suppress the 
proliferation of activated PBMC (Jones et al., 2007).  These low levels of expression might not 
be biologically significant when compared to APC. For example, the relative median 
fluorescence intensity of CD80 and CD86 expressed by monocyte-derived DC was more than 10 
when matured in the presence of GM-CSF and IL-4 (data not shown). Therefore, hESC-MSC 
and Fb might not act as efficiently as APC in providing the costimulatory signals for T cell 
activation. 
The absence of costimulatory molecules on BM-MSC implies that activation of T cells would 
not be achieved, resulting in anergy and contributing to tolerance. However, Chan et al. (2006) 
reported  that it was possible for BM-MSC to act as APC at low levels of IFN-. When antigen-
activated CD4+ T cells were incubated with BM-MSC preincubated with the antigen, 
proliferation of CD4+ T cells was absent, albeit at a lower level compared to macrophages. The 
authors suggested that the APC function of BM-MSC was dependent on the concentration of 
IFN- (Chan et al., 2006).  
When the expression of CD40 was compared, hESC-MSC and BM-MSC did not express CD40 
while Fb had low expression of CD40. The absence of CD40 on hESC-MSC (Trivedi and 
Hematti, 2008) and BM-MSC (Krampera et al., 2006a) has also been previously reported. The 
expression of CD40 on Fb implies that the expression of CD80 and CD86 on Fb might be further 
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enhanced, in a similar fashion as APC, by binding to CD40L on activated T cells (Durrbach et 
al., 2010). This might upregulate the antigen presentation capacity of Fb. 
Another positive costimulatory molecule expressed on B cells and non-professional APC is 
ICOSL (Greenwald et al., 2005). The absence of ICOSL on all the MSC and Fb implies that the 
cells are not capable of binding to ICOS on activated T cells, thereby modulating T cell 
responses (McAdam et al., 2000).  
When the expression of negative costimulatory molecules was examined, hESC-MSC and Fb 
expressed PD-L1 and PD-L2 while BM-MSC expressed negligible levels of the ligands. This 
suggests that hESC-MSC and Fb could deliver inhibitory signals to T cells via PD-1 ligation. 
The ligation of PD-1 contributed to T cell death (Chemnitz et al., 2004). Therefore, the 
immunomodulatory effects of hESC-MSC and Fb could be modulated through the PD-1/PD-
L1/PD-L2 pathway. Refer to section 5.5.2 for discussion on expression patterns of PD-L1 and 
PD-L2 by MSC and Fb in the presence of stimulated T cells. 
The costimulatory molecules discussed in the above paragraphs may bind to multiple receptors 
on T cells. An example is the B7 molecules, CD80 and CD86. Besides binding to CD28 on the T 
cells, B7 molecules bind to CTLA-4 as well. CTLA-4 is about 30% homologous with CD28 and 
exhibits stronger binding to B7 molecules compared to CD28. Binding of CTLA-4 to B7 
molecules delivers an inhibitory signal to the activated T cell (Alegre et al., 2001). Interestingly, 
hESC-MSC1, hESC-MSC2 and Fb expressed low levels of CTLA-4 while BM-MSC did not 
express any CTLA-4. Kaufman et al. (1999) showed that CTLA-4 was expressed on placentas 
derived from all trimesters of gestation as well as on cultured placental Fb which were in an 
environment without T cells. The authors suggested that CTLA-4 might have dual roles: an 
immunological role at the maternal-fetal interface in pregnancy and a non-immunological one. 
Similarly, the expression of CTLA-4 on hESC-MSC and Fb could play a role in tolerance. 
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In summary, although hESC-MSC and Fb expressed both positive and negative costimulatory 
molecules (Table 5-1), a net suppressive effect of hESC-MSC and Fb on T cell proliferation was 
observed in the current study.  
Table 5-1. Expression of costimulatory molecules on MSC and Fb. 
Cells 
Costimulatory molecules 
CD80 CD86 CD40 PD-L1 PD-L2 
hESC-MSC1  +  +  -  +  +++ 
hESC-MSC2  +  -  -  ++  +++ 
BM-MSC  -  -  -  -  - 
Fb  ++  ++  +  +  +++ 
+: Low expression     ++: Moderate expression     +++: High expression 
5.2.3 MSC and Fb do not express FasL 
As MSC and Fb did not express FasL (Figure 4-6), the reduction in the number of CD4+ T cells 
recovered after incubation with MSC or Fb for 5 days was most probably not due to FasL-
induced apoptosis. Similarly, the absence of FasL on BM-MSC has been reported (Plumas et al., 
2005). Apoptosis could have been triggered by other mechanisms. For example, the 
accumulation of kynurenines due to tryptophan metabolism by IDO, the ligation of PD-1 by its 
ligands and the lack of costimulation of T cells could induce apoptosis. 
5.3 Immunomodulatory effect of MSC and Fb 
5.3.1 MSC and Fb inhibit T cell proliferation in a dose-dependent manner 
Although the immunosuppressive effects of BM-MSC are well established, MSC derived from 
other sources including amnion (Magatti et al., 2008), adipose tissue (Wolbank et al., 2007) and 
umbilical cord (Chen et al., 2010; Wang et al., 2009) also exhibit various levels of inhibitory 
effects. In this study, we attempted to determine the immunomodulatory properties of hESC-
MSC.  All the MSC (hESC-MSC1, hESC-MSC2 and BM-MSC) and Fb investigated were able 
to suppress anti-CD3/CD28 stimulated CD4+ T cell proliferation in a dose-dependent manner in 
a 96-well plate (Figure 4-10C). Similarly, most of the literature also reported the suppression of 
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PBMC (Bocelli-Tyndall et al., 2007; Jones et al., 2007) and T cell (Haniffa et al., 2007; Li Pira et 
al., 2006) proliferation in a dose-dependent manner.  
The highest inhibition of proliferation (approximately 40%) was observed at a 1:1 MSC:T cell 
ratio by BM-MSC when the normalised proliferation index was compared (Figure 4-10C). In 
contrast, a 50% suppression of PBMC or T cell proliferation was reportedly achieved at a  lower 
MSC:PBMC/T cell ratio of 1:10 (Aggarwal and Pittenger, 2005; Beyth et al., 2005; Bocelli-
Tyndall et al., 2007; Jones et al., 2007; Krampera et al., 2006a). The difference in the number of 
MSC required could be due to variations in the proliferation assays. Firstly, the thymidine 
proliferation assay was used in the majority of published reports while the CFSE proliferation 
assay was used in the current study. The proliferation index in the CFSE assay measures the 
average number of cell divisions by actively dividing cells from the beginning of the experiment 
while the thymidine proliferation assay measures the amount of thymidine incorporation as an 
indication of DNA synthesis over a defined time frame. Secondly, there were variations in the 
experimental setup: the length of incubation ranged from 2 to 7 days (Jones et al., 2007; 
Maccario et al., 2005; Plumas et al., 2005; Yen et al., 2009); the type of stimulation used 
included anti-CD3 antibodies (Bocelli-Tyndall et al., 2007), anti-CD3/CD28 beads (Jones et al., 
2007), PHA (Wolbank et al., 2007) and inactivated stimulator PBMC (Batten et al., 2006); and 
lastly the type of responder cells could be pure T cell populations (Batten et al., 2006; Chang et 
al., 2006) or PBMC (Plumas et al., 2005). Despite the differences in the proliferation assays, the 
data in this study are consistent with the literature that MSC and Fb can suppress T cell 
proliferation. 
When studies which had a 5-day incubation period were compared specifically, the proliferation 
of PBMC or T cells was reduced by 30% to 75% when a MSC/Fb:PBMC/T cell ratio of 1:10 was 
used (Haniffa et al., 2007; Karlsson et al., 2008; Nasef et al., 2009). Likewise, BM-MSC and Fb 
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in our study could suppress T cell proliferation by 30% although hESC-MSC could not (Figure 
4-10C). The lower extent of suppression observed in this study could be due to the absence of 
accessory cells since accessory cells have been reported to be required for the optimal 
suppression of T cell by MSC (Cutler et al., 2010). When monocytes were depleted from PBMC, 
umbilical cord-derived MSC were unable to suppress the proliferation of T cells (Cutler et al., 
2010). 
5.3.2 hESC-MSC inhibit the proliferation of T cells to a similar extent as BM-
MSC and Fb in a 24-well plate contact system 
Initially, the coculture contact experiment was performed in a 96-well plate. However, it had to 
be scaled up to a 24-well plate for valid comparisons with the 24-well plate transwell used for 
investigating the effect of MSC or Fb on T cell proliferation in the absence of cell-cell contact. In 
the 24-well plate (Figure 4-13C), there was enhanced suppression of T cell proliferation by all 
the MSC and Fb as compared to the 96-well format (Figure 4-10C). Even hESC-MSC1 and 
hESC-MSC2 had comparable degree of suppression as BM-MSC and Fb. This phenomenon was 
not observed in the 96-well format.  
Similarly, hESC-MSC derived from HSF-6 hESC were also able to suppress proliferation of both 
CD4+ and CD8+ T cells to the same magnitude as BM-MSC when cultured in a 24-well plate 
contact system (Yen et al., 2009). However, the 2-day period of stimulation of the T cells 
appeared to be too short since most of the control T cells cultured in the absence of hESC-MSC 
had not proliferated as indicated by the prominent undivided peak in the CFSE profile (Yen et 
al., 2009). Therefore, comparing the CFSE profiles on day 2 did not yield substantial differences 
in the suppressive effect of hESC-MSC and BM-MSC (Yen et al., 2009). The ability of hESC-
MSC to suppress T cell proliferation to the same extent as BM-MSC in a 24-well plate contact 
system was also demonstrated by Trivedi and Hematti (2008). When the proliferation of CD3+ T 
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cells in a MLR was measured after 3 days, a cell concentration of 5 × 105 hESC-MSC per ml 
could suppress the proliferation of T cells (Trivedi and Hematti, 2008). Therefore, similar to this 
study, the cell concentration was approximately twice that of a 96-well plate system. As a result 
of the increase in cell concentration, the concentration of the secreted factors was also elevated. 
As such, the enhanced suppressive effect of hESC-MSC could be due to the increase in the 
concentration of suppressive factors as the scale-up from the 96-well plate to the 24-well plate 
system was not linear. 
5.3.3 Cell-cell contact is not critical in mediating the suppressive effect 
In order to determine if cell-cell contact was essential for suppression, the proliferation assay 
was performed in transwells where MSC or Fb were segregated from T cells. In the transwell 
system, all the MSC and Fb could still suppress T cell proliferation (Figure 4-14C).. In addition, 
the extent of suppression in the contact and transwell systems were comparable (Figure 4-13C 
and Figure 4-14C), suggesting that cell-cell contact was not critical in immunosuppression and 
that soluble secreted factors played a major role in the inhibition observed. These results 
corroborated with previous studies where hESC-MSC were reported to suppress T cell 
proliferation in a transwell system and that the degree of T cell suppression in the contact system 
was not significantly different from that in the transwell (Trivedi and Hematti, 2008; Yen et al., 
2009).  
In another study, when dermal Fb were cultured in the bottom chamber, separated from the DC 
and T cells in the top chamber, there was a 50% inhibition of T cell proliferation (Haniffa et al., 
2007). This extent of inhibition was similar to that observed in this study. However, Jones et al. 
(2007) did not observe an inhibition of PBMC when dermal Fb were cultured in the top chamber 
separated from PHA-stimulated PBMC in the bottom chamber after 3 days. On the other hand, 
when stimulated PBMC were also added to the dermal Fb in the top chamber, proliferation in the 
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bottom chamber was inhibited (Jones et al., 2007). Therefore, Jones et al. (2007) concluded that 
cell-cell contact was required for the subsequent production of soluble suppressive factors. This 
difference in conclusion could be due to differences in the experimental setup. Firstly, the length 
of incubation in this study was longer. The extent of suppression could be more pronounced with 
prolonged incubation time as shown in Figure 4-12. Secondly, the T cells in this study were 
seeded in the top chamber instead of the bottom chamber. With the T cells seeded in the smaller 
upper chamber, it is possible that they received more stimulation from the anti-CD3/CD28-
coated beads due to the enhanced contact between the beads and the T cells. Subsequently, more 
cytokines could be released by the stimulated T cells. The elevated concentration of cytokines 
might in turn trigger the activation and subsequent release of more suppressive factors from 
MSC and Fb which could inhibit T cell proliferation. 
The data from the current study demonstrated that soluble factors are mainly responsible for the 
suppressive effect since the inhibition persisted in the transwell where MSC or Fb were separated 
from T cells by the 0.4-µm semi-permeable membrane. The inhibition was comparable between 
contact and transwell system, although inhibition of T cells was slightly enhanced in the contact 
system in the presence of hESC-MSC. Close contact between MSC or Fb and T cells either 
mediates paracrine short-range acting mediators or provides an activating signal via direct cell-
cell contact (Jones et al., 2007). 
5.3.4 The immunosuppressive effect of hESC-MSC is lower than BM-MSC 
and Fb on a per cell basis 
If soluble factors are important in the suppressive effect of MSC and Fb, then the concentration 
of these suppressive factors will determine the potency of the inhibition. The concentration of 
suppressive factors will in turn correlate with the number of adherent cells, assuming that only 
live cells can produce the suppressive factors. It was observed that not all the pre-plated 
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mitomycin C-treated MSC or Fb adhered to the plate after overnight incubation (Figure 4-15). 
This could have been due to damage of the cells following irradiation and mitomycin C-
treatment to render them non-proliferative. Therefore, the MSC/Fb:T cells ratios used in the 
comparison of the immunosuppressive effect of MSC or Fb might not be totally accurate in 
previous studies since not all the MSC or Fb adhered after overnight plating. As such, it was 
important to relate the number of adherent cells to the percentage of T cell inhibition. 
Subsequently, the IC50 which is the number of adherent MSC or Fb required per 100 CD4+ T 
cells to inhibit the proliferation of CD4+ T cells by 50% was determined (Figure 4-16). The IC50 
showed that twice as many hESC-MSC1 as BM-MSC were required to achieve the same degree 
of suppression in the transwell system (Figure 4-17).  
The IC50 had to be extrapolated in some cases as the extent of suppression did not reach 50%. 
Therefore, IC25 which is the number of adherent MSC or Fb required per 100 CD4+ T cells to 
inhibit the proliferation of T cells by 25% was determined to give a more consistent and accurate 
measurement than IC50. IC25 could be determined directly from the best fit curve since a 25% 
suppression could be achieved in all the conditions tested. Similar to the IC50 results, hESC-MSC 
were shown to be less potent in suppressing T cell proliferation when compared to BM-MSC and 
Fb. This is in agreement with results from the contact and transwell systems showing that hESC-
MSC were less efficient at suppressing T cell proliferation when compared to BM-MSC and Fb. 
Although a greater number of hESC-MSC is required to achieve a similar suppressive effect, this 
hurdle is not difficult to overcome as they can be easily expanded in vitro. Therefore, the use of 
hESC-MSC for immunosuppression still remains a viable option. 
The embryonic origin of hESC-MSC could account for the difference in immunosuppressive 
effect. Conflicting reports of the immune properties of hESC have been published. In some 
reports, hESC were not immunogenic as injection of hESC into immune-competent mice did not 
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elicit an immune response (Li et al., 2004). Furthermore, undifferentiated hESC lines, H1, H7 
and H9, failed to stimulate proliferation of T cells cocultured with allogeneic DC (Li et al., 
2004). On the other hand, hESC line, HS237, induced an immune response similar to human 
dermal Fb when incubated with naïve CD4+ T cells only or in the presence of autologous DC 
(Grinnemo et al., 2006). Hence, the parental origin of the hESC line could contribute to the 
immunosuppressive property of hESC-MSC. 
When terminally differentiated Fb were compared with BM-MSC, Fb could inhibit T cell 
proliferation to a similar extent as BM-MSC (Figure 4-18). This anti-proliferative effect of Fb 
has been shown in other studies. In one study, both BM-MSC and dermal Fb inhibited the 
proliferation of CD3+ T cells stimulated with allogeneic DC or anti-CD3/CD28 beads to the 
same extent (Haniffa et al., 2007). In another study, Fb could suppress the proliferation of PBMC 
but the extent of suppression varied depending on the tissue of origin (Jones et al., 2007). 
Therefore, the immunosuppressive property might be shared by cells of stromal origin-whether 
they are mature Fb or multipotent MSC (Jones et al., 2007).  
5.3.5 MSC and Fb prevent T cells from dividing 
Besides inhibiting the proliferation of responder cohort T cells, MSC and Fb also prevented the 
overall CD4+ T cell population from dividing in both contact and transwell systems. There was a 
lower percentage of T cells dividing compared with the positive control of stimulated T cells 
only without MSC or Fb added (contact: Figure 4-10A, Figure 4-13A; transwell: Figure 4-14A). 
In addition, with the use of CFSE and counting beads, we showed that the cohort T cells which 
were initially stained with CFSE were prevented from dividing by MSC and Fb (Figure 4-13B 
and Figure 4-14B). The inhibitory effect on T cells by MSC and Fb was most evident after 5 
days of incubation (Figure 4-12). Similarly, Krampera et al. (2006a) showed that during the first 
3 days of cultures where BM-MSC were incubated with T cells stimulated with T cell-depleted 
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allogeneic PBMC, T cell proliferation was unaffected by the presence of BM-MSC. After 5 days, 
fewer T cells had divided in the presence of BM-MSC (Krampera et al., 2006a). The extent of 
inhibition was similar to that observed in this study.  
Similar to our observation, hESC-MSC and Fb have been reported to prevent the division of T 
cells and PBMC respectively (Jones et al., 2007; Yen et al., 2009). hESC-MSC inhibited the 
division of CD4+ T cells and CD8+ T cells in both contact and transwell settings (Yen et al., 
2009). The degree of inhibition by hESC-MSC was similar to that by BM-MSC (Yen et al., 
2009). Fb could also prevent the division of PBMC stimulated by PHA in a transwell (Jones et 
al., 2007). Cell cycle analysis demonstrated that PHA-stimulated PBMC were arrested in the 
G0/G1 phase with minimal percentage of cells in S and M phases upon contact coculture with Fb 
(Jones et al., 2007).  
In summary, MSC and Fb can prevent division of both the overall T cell population and cohort T 
cells added at the start of the experiment. 
5.3.6 The presence of stimulated T cells is required for the 
immunosuppressive effects of MSC and Fb 
Supernatants collected from cultures of MSC and Fb alone and then dosed at 0.75× to anti-
CD3/CD28 stimulated CD4+ T cell cultures failed to suppress T cell proliferation (Figure 4-20). 
On the other hand, when supernatants from transwells of MSC or Fb incubated with stimulated T 
cells were used, a reduction in T cell proliferation was observed (Figure 4-20). Similarly, 
supernatants collected from cocultures of MSC or Fb and stimulated PBMC have been reported 
to suppress T cell proliferation more than those from cultures of MSC or Fb only. The addition 
of coculture supernatant of BM-MSC and PBMC reduced the number of spots in the IFN- 
ELISPOT assay while BM-MSC supernatant upregulated the number of spots (Maitra et al., 
2004). Since a reduction in the number of spots reflects a lower level of T cell activation, this 
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implied that cross-talk between BM-MSC and PBMC enhanced the suppressive effect of 
coculture supernatant. Although supernatants collected from cultures of Fb could suppress the 
proliferation of T cells, the degree of suppression was enhanced with supernatants collected from 
Fb and MLR cocultures (Haniffa et al., 2007) and Fb and PHA-stimulated PBMC cocultures 
(Jones et al., 2007).  The results from our study suggest that the presence of stimulated T cells 
was essential for mediating the suppressive effect by MSC and Fb. Stimulated T cells may 
produce factors that activate MSC and Fb which in turn produce suppressive factors that inhibit 
T cell proliferation.  
A possible factor produced by activated T cells is IFN-. The concentration of IFN- in the 
cultures of stimulated CD4+ T cells was 8.8 ± 4.6 ng/ml (equivalent to 88 U/ml)as determined by 
ELISA when supernatants were harvested from the transwells after 5 days (data not shown). 
Since cytokine standards differ in their potency (as measured in international units per 
nanogram), an attempt was made to compare the concentration of IFN- measured in this study 
with the literature by standardising the concentration in terms of U/ml. At 88 U/ml of IFN-, the 
immunosuppressive effect of MSC was promoted instead of their potential APC property. 
Therefore, the MSC were observed to inhibit CD4+ T cell proliferation. Similarly, BM-MSC did 
not induce proliferation of allogeneic PBMC after pre-treatment with 100 U/ml IFN- (Le Blanc 
et al., 2003a). The APC property was only triggered after exposure to 500 U/ml of IFN- (Chan 
et al., 2008). 
Although transwell supernatants could inhibit T cell proliferation, the degree of inhibition was 
lower than that produced when MSC and Fb were incubated with stimulated T cells throughout 
the 5-day incubation period. Trivedi and Hematti (2008) also demonstrated that while CM could 
suppress proliferation of responder T cells, the extent of inhibition was lower than that produced 
when the hESC-MSC were in the contact or transwell systems. This suggests that suppressive 
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factors collected from the supernatants were not sufficient to exert a substantial inhibition. In 
addition, the interaction between MSC or Fb and T cells throughout the incubation period 
allowed MSC and Fb to replenish suppressive factors which might have degraded or been used 
up. However, in the study by Trivedi and Hematti (2008), CM from hESC-MSC cultures was 
used whereas supernatants from transwell cultures of T cells with MSC or Fb were used in the 
current study. 
Variations in the experimental setup between this study and that by Trivedi and Hematti (2008) 
might account for the difference in the suppressive effect of supernatants collected from cultures 
of hESC-MSC alone. Firstly, hESC-MSC in their study were conditioned in MSC medium while 
hESC-MSC1 and hESC-MSC2 in our study were conditioned in RPMI medium. Since RPMI 
medium was the optimal medium for T cell growth, the use of suboptimal MSC medium could 
inhibit T cell growth. Secondly, hESC-MSC1 and hESC-MSC2 were mitotically inactive but 
hESC-MSC used by Trivedi and Hematti were not. The actively growing cells could have 
consumed nutrients necessary for T cell proliferation, leading to the difference in results. To 
confirm that the mitotically inactivated hESC-MSC in this study did not deplete the nutrients in 
the medium, metabolism of the key nutrient components was determined in section 4.2.6. The 
results will be discussed in the next section 5.4.  
Although supernatants collected from the transwells exhibited a weaker suppressive effect on T 
cell proliferation when compared to the presence of MSC or Fb throughout the incubation 
period, the suppressive effect of the supernatants can be enhanced. Concentrating the 
supernatants is one way to increase the amount of suppressive factors. The effect of 
concentration is supported by the observation that supernatants added at 0.75× to secondary T 
cell cultures produced a greater extent of suppression compared to a 0.5× dosage (Figure 4-21). 
The concentration of the suppressive factors can also be augmented by prolonging the time 
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before harvest. As shown in a previous study, the inhibitory effect on MLR was only observed 
when supernatants obtained from cultures of human amnion mesenchyme which were 
conditioned for at least 4 days  were used (Magatti et al., 2008). The use of supernatants will 
obviate the use of cells, reducing the need for tissue-matching. 
5.4 Metabolism by MSC and Fb 
In order to exclude the possibility that the suppressive effect of the supernatants on T cell 
proliferation was not due to a depletion of essential nutrients (glutamine and glucose) or an 
accumulation of growth-inhibiting metabolites (ammonia and lactate), the supernatants were 
analysed for glutamine, glucose, ammonia and lactate. Glutamine has an important role in 
starting cell proliferation, namely as supplier of carbon in the form of mitochondrial oxaloacetate 
(for maintenance of citrate production in the tricarboxylic acid cycle) and nitrogen for amino 
acid synthesis (Newsholme et al., 1985). When RPMI medium was left in the 37oC incubator for 
5 days, there was substantial degradation of glutamine. Less than 25% of the starting glutamine 
(2 mM) remained (Figure 4-22). In cultures with just stimulated T cells, hESC-MSC or Fb, the 
concentrations of glutamine after 5 days were about 0.2 mM. On the other hand, BM-MSC 
consumed a lower amount of glutamine than hESC-MSC, Fb and stimulated T cells. Cultures 
from transwells had higher concentrations of glutamine remaining than the expected 
concentration derived from the subtraction of the individual concentrations of glutamine 
consumed by MSC or Fb and stimulated T cells only. This was most probably due to the 
inhibition of T cell proliferation by MSC and Fb, leading to the reduction in glutamine 
consumption. The concentrations of glucose in supernatants collected from cultures of MSC or 
Fb or stimulated T cells alone or in transwells were lower than that in the RPMI medium. Similar 
to glutamine consumption, cultures of transwells had higher concentrations of glucose remaining 
than the expected concentration derived from the subtraction of the individual concentrations of 
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glucose consumed by MSC or Fb and stimulated T cells only. This suggests that the inhibition of 
T cell proliferation might have reduced glucose consumption. 
As cells consume glucose and glutamine to produce energy, lactate and ammonia is produced. 
The metabolites could reach concentrations that inhibit cell growth. The sensitivity toward the 
metabolites is cell line specific and varies greatly. Growth inhibition by lactate is between 10 
mM and 40 mM and by ammonia is 0.5 mM and 12 mM (Hassell et al., 1991; Ozturk et al., 
1992; Schneider et al., 1996). For example, the inhibiting concentrations of lactate and ammonia 
are 35.4 mM and 2.4 mM respectively for human BM-MSC (Schop et al., 2009). The 
concentration of lactate in the supernatants collected was about 2 g/l (equivalent to 20 mM) 
while the concentration of ammonia ranged from 1.2 mM to 1.6 mM (Figure 4-22). Therefore, 
the concentrations of lactate and ammonia in the supernatants were most probably non-inhibitory 
to the growth and function of MSC. 
As shown in this study, the supernatants recovered were not nutrient limiting to the proliferation 
of fresh T cells. The growth limitation of the T cells was most likely not due to glucose or 
glutamine starvation since supernatants from cultures of hESC-MSC1 which had the lowest 
levels of glucose and glutamine resulted in a higher T cell proliferation compared to cultures of 
BM-MSC and Fb only. Furthermore, 25% fresh RPMI was supplemented to the secondary T cell 
cultures to replenish any components which could be possibly depleted. Although all the 
supernatants had similar concentrations of lactate and ammonia, there were differences in the 
suppressive effect on T cell proliferation. Therefore, the concentration of the accumulated 
metabolites was unlikely to be inhibitory to the T cells. 
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5.5 Mechanisms of T cell suppression 
5.5.1 MSC and Fb result in an increase in cell death but not apoptosis 
In addition to the inhibition of T cell proliferation by MSC and Fb, there could also be enhanced 
T cell death. When MSC or Fb were present, there was a 50% reduction in the number of CD4+ 
T cells recovered from the transwell after 5 days of incubation (Figure 4-23). On the other hand, 
there was a three-fold increase in the number of T cells in the control without MSC or Fb. This 
implied that MSC and Fb resulted in a significant degree of cell death. Similarly, Plumas et al. 
(2005) reported a 70% reduction in the number of PBMC recovered from a MLR after 6 days in 
a contact coculture.  
The enhanced cell death could be due to an increase in apoptosis. However, when the percentage 
of both annexin V positive and PI negative CD4+ T cells was determined, there was no 
significant difference in the percentage of apoptotic T cells in the presence or absence of MSC 
and Fb (Figure 4-24). Similar to our findings, when PBMC were stimulated with anti-CD3 
antibody for 4 days, there was no difference in the number of CD3+ annexin V positive T cells in 
the presence or absence of BM-MSC (Benvenuto et al., 2007). Under apoptosis-inducing 
conditions, BM-MSC and Fb could protect CD4+ T cells from apoptosis (Jones et al., 2007). 
When PHA-stimulated PBMC were cultured in low serum concentration to induce apoptosis, 
BM-MSC and Fb could reduce the proportion of apoptotic cells by half  (Jones et al., 2007). In 
contrast, BM-MSC induced apoptosis of T cells activated by anti-CD3 antibody within a day of 
incubation as shown by annexin V staining and activation of caspases (Plumas et al., 2005). It 
was possible that the window period where apoptosis could have occurred was not captured since 
the annexin V assay was performed after 5 days compared with 1 day by Plumas et al. (2005). 
The possibility that apoptosis might have occurred prior to 5 days could not be ruled out. 
Alternatively, cell death could have occurred by mechanisms other than apoptosis, such as 
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oncosis. The number of cohort T cells recovered did not indicate more cell death in the original 
population when MSC or Fb were present (Figure 4-25). Therefore, MSC and Fb did not mediate 
their suppressive effect via enhanced cohort T cell death. 
5.5.2 The immunomodulatory effect of MSC and Fb may not be due to the 
expression of PD-L1 and PD-L2 
PD-1 and its ligands, PD-L1 and PD-L2, negatively regulate immune responses. The PD-1/PD-L 
pathway has been utilised by microbes and tumours to attenuate immunity and facilitate tumour 
survival (Keir et al., 2008). To date, there are limited studies regarding the role of PD-L in the 
immunosuppressive activity of MSC. BM-MSC did not express PD-L1 (Figure 4-6). However, 
the expression of PD-L1 was upregulated when BM-MSC were cultured with activated T cells in 
a transwell (Figure 4-26). Chang et al. (2005) also reported that BM-MSC and placenta-derived 
MSC did not express basal levels of PD-L1. Contrary to our results, the level of PD-L1 was not 
upregulated in BM-MSC upon IFN- stimulation (Chang et al., 2006). A longer incubation 
period might be necessary for the expression of PD-L1 to be detected by the flow cytometry. In 
addition, other factors secreted by activated T cells might have led to the upregulation of PD-L1 
in our study. 
Both the hESC-MSC lines, hESC-MSC1 and hESC-MSC2, expressed PD-L1 constitutively 
(Figure 4-6). The expression of PD-L1 was strongly upregulated in the presence of activated T 
cells, especially in hESC-MSC2 (Figure 4-26). The differences in expression patterns between 
BM-MSC and hESC-MSC might be due to the origin of the cells. BM-MSC are matured in the 
haematopoietic stromal compartment while hESC-MSC are embryonic in origin. Fb which is a 
stromal cell has a PD-L1 expression profile similar to BM-MSC (Figure 4-26).  
The expression of PD-L2 is more restricted than PD-L1. Its expression can be induced on DC, 
macrophages and bone marrow-derived mast cells (Keir et al., 2008). Surprisingly, hESC-MSC1, 
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hESC-MSC2 and Fb expressed PD-L2 constitutively while BM-MSC did not (Figure 4-6). The 
binding of PD-L2 on DC led to an upregulation of proinflammatory cytokines, in particular 
TNF- and IL-6, by DC (Nguyen et al., 2002). Subsequently, naïve T cell proliferation was 
induced. However, the expression of MHC class II or B7 costimulatory molecules on DC was 
not affected (Nguyen et al., 2002). Similarly, factors secreted by T cells might bind PD-L2 on 
hESC-MSC and Fb and alter their cytokine profile to a proinflammatory one, similar to the 
proinflammatory effect on DC. However, in the presence of stimulated T cells, the expression of 
PD-L2 was slightly downregulated (Figure 4-26). This could reduce the amount of 
proinflammatory cytokines produced and the pro-apoptotic effect of PD-L1 on T cells could 
over-ride the proinflammatory effect of PD-L2.  
Although hESC-MSC expressed higher levels of PD-L1 than BM-MSC and Fb in the presence of 
activated T cells, they were not more effective in inhibiting T cell proliferation in the contact 24-
well plate. The high expression levels of PD-L2 on hESC-MSC could have abrogated the anti-
proliferative effect of PD-L1. In the transwell, PD-L were not able to bind PD-1 on activated T 
cells directly. Any effects on the T cells would be due to the indirect effects of PD-L, possibly an 
alteration in cytokine profile. Soluble forms of a number of B7-CD28 superfamily members like 
sCD28, sCD80, have been found (Kakoulidou et al., 2007; Simon et al., 2006; Zhang et al., 
2008). It is possible that soluble forms of PD-L which are anti-proliferative may exist, leading to 
the suppression of T cells in transwells. 
Preliminary data showed that the addition of anti-PD-1 blocking antibody did not lead to a 
reversal in the suppressive effect of MSC and Fb in the contact system (Figure 4-27). On the 
contrary, in mouse BM-MSC, the addition of anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies 
reversed the suppressive effect on T cell proliferation in a dose-dependent manner (Augello et 
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al., 2005). Species differences could account for the difference in immunosuppressive effect 
observed. 
The PD-1/PD-L pathway may not be important in human BM-MSC since the PD-L are 
minimally expressed. It may contribute more to the immunoregulation by hESC-MSC and Fb. 
More experiments to determine the importance of this pathway can be performed using 
neutralising antibodies against PD-L1 and PD-L2.  When anti-PD-1 antibody is added, PD-L1 
and PD-L2 may still bind other receptors (which have yet to be identified) and exert their 
respective downstream effects. Addition of either anti-PD-L1 or anti-PD-L2 neutralising 
antibodies will allow for the sole effect of PD-L1 and PD-L2 to be determined. Since a positive 
control was not included, we cannot rule out the possibility that the anti-PD-1 blocking antibody 
did not work. A positive control such as ascitic monocytes associated with tumours can be 
included. They are able to suppress T cell proliferation and the inhibition could be partially 
reversed when anti-PD-1 blocking antibody was added. 
5.5.3 Inhibition of T cell proliferation is partly mediated by IDO 
In the present study, the expression of IDO by hESC-MSC, BM-MSC and Fb was investigated 
following culture with anti-CD3/CD28-stimulated CD4+ T cells in a transwell. IDO was not 
expressed by hESC-MSC, BM-MSC, Fb or T cells when they were cultured alone (Figure 4-28). 
Plumas et al. (2005) also did not detect any intracellular IDO in BM-MSC at resting stage. 
However, IDO expression by the MSC and Fb was upregulated upon incubation with stimulated 
T cells (Figure 4-28). Similarly, Haniffa et al. (2007) reported that Fb did not produce IDO 
basally and IDO was induced upon exposure to a MLR. With the addition of anti-IFN- 
antibodies to the MLR, Fb no longer expressed IDO, suggesting that the production of IDO was 
dependent on IFN- released by T cells (Haniffa et al., 2007). TNF-, another proinflammatory 
cytokine, was not responsible for the production of IDO in BM-MSC (Ren et al., 2009). This 
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suggests that factors released by activated T cells regulated the expression of IDO in MSC and 
Fb. Further studies using blocking antibodies are required to verify that IDO expression in MSC 
and Fb in this study is dependent on IFN-. 
The immunomodulatory effect of IDO may be due to the depletion of tryptophan, an essential 
amino acid, required by T cells to proliferate (MacKenzie et al., 2007) or the accumulation of 
toxic downstream metabolites of tryptophan degradation (Frumento et al., 2002) or a 
combination of both. By measuring the concentration of kynurenines, downstream products of 
tryptophan degradation by IDO, IDO activity in the presence and absence of MSC or Fb can be 
determined. There was a significant increase in the concentration of kynurenines in the 
transwells while negligible amounts were measured in cultures of MSC, Fb or stimulated T cells 
only (Figure 4-29). This implies that the induction of IDO activity in the transwells was 
dependent on the presence of T cells. Plumas et al. (2005) also demonstrated the induction of 
IDO activity in MLR in the presence of BM-MSC. The authors showed that tryptophan was 
converted into kynurenine in MLR in the presence of BM-MSC. 
It was observed that BM-MSC and Fb transwell cultures with stimulated T cells produced higher 
concentrations of kynurenines (10 µM more) than corresponding hESC-MSC cultures. The 
higher concentrations of kynurenines measured in BM-MSC and Fb cultures with stimulated T 
cells suggested that BM-MSC and Fb exhibited greater IDO activities than hESC-MSC (Figure 
4-29). On the other hand, western blotting showed that a higher level of IDO expression in 
hESC-MSC was induced compared to BM-MSC and Fb instead (Figure 4-28). The discrepancy 
between the amount of IDO expressed and the level of IDO activity could be due to post-
translational modifications of IDO and substantial differences in the catalytic activity of IDO 
isoforms.  
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Post-translational modifications can influence the stability, function and degradation of the IDO 
enzyme. For example, the N-terminal methionine of IDO can be cleaved and alanine acetylated. 
In addition, tyrosine residues can be nitrated and inactivated by peroxynitrite (Fujigaki et al., 
2007). Peroxynitrite is generated during oxidative stress and activation of nitric oxide. Nitric 
oxide rapidly combines with superoxide to generate the highly reactive peroxynitrite. Therefore, 
we speculate that IDO produced by BM-MSC and Fb could be functionally more active than that 
by hESC-MSC since the extent of T cell inhibition by BM-MSC and Fb was greater than that by 
hESC-MSC. 
It was also possible that the IDO produced by BM-MSC and Fb was more potent at catalyzing 
the degradation of tryptophan. There are two variants of IDO, IDO1 and IDO2 (Ball et al., 2007). 
Primary tumour samples expressed various amounts of IDO1 and IDO2 and could inhibit 
immune responses (Lob et al., 2009). In an attempt to elucidate which isoform of IDO was more 
potent, knockdown studies using siRNA were performed (Lob et al., 2009). Knockdown of IDO1 
using siRNA completely abrogated the production of kynurenine, suggesting that IDO1 was the 
more active form. Since the anti-IDO antibody purchased in this study does not discriminate 
between IDO1 and IDO2, further experiments to determine the isoform expressed by hESC-
MSC have to be performed. hESC-MSC are speculated to produce more IDO2, which has a 
lower potency. Therefore, although IDO expression was upregulated in hESC-MSC, a lower 
concentration of downstream products, kynurenines, was measured.  
IDO can be inhibited by 1-MT which acts as a competitive inhibitor due to its structural 
similarity to tryptophan. Addition of L-1-MT reversed the suppressive effect of MSC or Fb on T 
cell proliferation (Figure 4-30). The addition of increasing concentrations of L-1-MT leads to 
enhanced T cell proliferation in the presence of MSC or Fb. These results show that the 
suppressive effect of MSC and Fb was partially due to IDO. Previous studies have also shown 
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the importance of IDO in mediating the suppression of T cell proliferation in BM-MSC 
(Krampera et al., 2006a; Plumas et al., 2005), periodontal ligament stem cells (Wada et al., 2009) 
and Fb (Haniffa et al., 2007). This is the first time that hESC-MSC have been shown to mediate 
the immunosuppressive effect via IDO. 
5.6 Identification of potential suppressive factors and mechanism of T cell 
inhibition 
One of the aims of the project was to identify possible T cell suppressive factors. Using the 
antibody array approach outlined in section 4.4 that detects 507 proteins, including cytokines and 
growth factors, among supernatants collected from MSC or Fb cultured alone and in transwells 
with stimulated T cells, seven factors (EMAP-II, ENA-78, MIG, MIP2, siglec-9, sgp130 and 
VEGF-C) were found to be upregulated in all the transwells (Table 4-1). 17 factors were 
upregulated in three of the transwells (Table 4-1). Among the commonly upregulated factors by 
all the transwells of MSC or Fb with stimulated T cells, most factors were already secreted by 
cultures of MSC or Fb only. hESC-MSC secreted all the seven common factors and ENA-78 has 
been previously reported to be found in hESC-MSC1 CM (Sze et al., 2007). BM-MSC secreted 
EMAP-II, ENA-78, MIG and MIP2. ENA-78 was also found in CM of BM-MSC (Wagner et al., 
2007a). Fb secreted MIG, MIP2 and sgp130 basally. This implies that the presence of stimulated 
T cells enhanced the production of these soluble factors by MSC and Fb. 
5.6.1 Abundance of chemoattractants in supernatants 
Eight out of the combined list of 24 upregulated factors are chemokines which serve as 
chemoattractants for leukocytes. These include ENA-78, CCL28, CXCL16, IL-8, MCP-2, MCP-
3, MIG and MIP2. The abundance of chemokines suggests that the innate system can be 
activated in addition to the interaction between MSC or Fb and activated T cells. It has been 
shown that MSC could prolong the lifespan of neutrophils (Raffaghello et al., 2008), mediate the 
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recruitment of neutrophils upon LPS stimulation through the secretion of MIF and IL-8 and 
sensitise neutrophils towards subsequent LPS challenge (Brandau et al., 2010). MSC could also 
respond to bacterial stimulation and TLR ligation. MSC expressed high levels of TLR2, TLR3, 
TLR4, TLR7 and TLR9 (Tomchuck et al., 2008). Stimulation of the TLR3 resulted in the 
greatest upregulation of chemokines and cytokines secretion and migration by MSC (Tomchuck 
et al., 2008). Therefore, it has been suggested that MSC could be a previously unrecognised 
player in immune responses (Stagg, 2007). 
5.6.2 Vascular endothelial growth factor-C (VEGF-C) 
VEGF-C which was found in all the transwell supernatants could possibly affect cells of the 
innate immune system. VEGF-C belongs to the VEGF family. The VEGF family consists five 
members in mammals: VEGF (or VEGF-A), placenta growth factor (PlGF), VEGF-B, VEGF-C 
and VEGF-D (Lohela et al., 2009). VEGF-A, PIGF and VEGF-B are involved in angiogenesis 
while VEGF-C and VEGF-D are involved in lymphangiogenesis (Lohela et al., 2009).  
Besides being involved in lymphangiogenesis, VEGF-C also plays a role in immune tolerance at 
the maternal-fetal interface (Kalkunte et al., 2009). Noncytotoxic uterine NK cells produced 
three to four fold higher levels of VEGF-C compared to cytotoxic uterine and peripheral blood 
NK cells.VEGF-C prevented killing of trophoblast and endometrial cells and this was due to the 
induction of antigen peptide transporter-1 (TAP-1) which is important in the assembly of MHC 
class I molecules. The enhanced surface expression of HLA-E on trophoblasts prevented NK 
cells from eliminating them since NK cells target cells which do not express MHC class I 
molecules. Similarly, MSC and Fb could escape NK cell lysis through the expression of VEGF-
C and subsequent upregulation of HLA-E (Figure 5-1). In addition, VEGF-C acts as a 
chemotactic factor for macrophages since a fraction of the cells express the receptor for VEGF-C 
(Lohela et al., 2009). 
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Figure 5-1. Upregulation of VEGF-C production by MSC and Fb and subsequent effects on NK 
cells and macrophages. 
5.6.3 Endothelial monocyte-activating polypeptide-II (EMAP-II) 
Besides affecting the innate system, one of the soluble factors, EMAP-II, produced by MSC and 
Fb has been reported to affect T cells. EMAP-II was first found in the supernatants of 
methylcholanthrene A-induced (MethA) fibrosarcomas in mice (Kao et al., 1992). EMAP-II has 
procoagulant activity and induces the expression of tissue factor in endothelial cells. It is also 
chemotactic for monocytes and granulocytes and induces inflammation upon injection into 
mouse footpads (Kao et al., 1992). Hence, the findings indicate that EMAP-II is a tumour-
derived proinflammatory factor and can potentially destroy the tumour vasculature. Therefore, 
the secretion of EMAP-II by tumours may appear to be non-beneficial as EMAP-II would aid the 
destruction of tumour cells. However, Tas and Murray (1996) suggested that EMAP-II serves to 
recruit neutrophils to eradicate the tumour cells which have undergone apoptosis, and monocytes 
and macrophages to phagocytose ageing neutrophils. Thus, the chemotactic activity of EMAP-II 
allows the tumour cells to recruit innate immune cells to remove dead cells accumulating around 
the tumour site (Tas and Murray, 1996).  
In addition, EMAP-II might inhibit cell-mediated cytotoxicity directed towards the tumour. 
Colorectal tumour cell lines produced minimal levels of soluble EMAP-II under normal 
conditions (Murray et al., 2004). Upon stimulation with TNF or IFN or under hypoxic 
conditions, maximal levels of approximately 0.5 nM of EMAP-II were measured in the CM of 
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colorectal tumour cell line, DLD-1, after 48 h (Murray et al., 2004). The CM obtained from 
DLD-1 was able to induce apoptosis in PHA-activated PBMC. Although HT29, another 
colorectal tumour cancer cell line, did not secrete EMAP-II, it was still able to induce the 
activation of caspase-8 and apoptosis in activated Jurkat cells in a contact culture system 
(Murray et al., 2004). The apoptotic effect of both the soluble and surface-associated EMAP-II 
was partially reversed by the addition of anti-EMAP-II antibodies (Murray et al., 2004). 
Similarly, hypoxia could induce apoptosis of tumour-infiltrating lymphocytes through EMAP-II 
in colorectal tumour cells (Youssef et al., 2006). Immunohistochemistry demonstrated the 
presence of active caspase-3 and cleaved Poly (ADP-ribose) polymerase (PARP) (indicators of 
apoptosis) in the samples of colorectal cancers (Youssef et al., 2006). Another type of tumour 
cells, hepatocellular carcinoma cells, also expressed EMAP-II and could induce caspase-8 
activation and apoptosis in Jurkat cells (Faisal et al., 2007). MSC and Fb could, in a parallel 
fashion, inhibit T cell proliferation through EMAP-II (Figure 5-2). Upon release of TNF or IFN 
by activated T cells, EMAP-II secretion by MSC and Fb could be upregulated. The enhanced 
secretion of EMAP-II could trigger T cell apoptosis. A point to note is that the concentration of 
EMAP-II appears to be critical in the modulation of innate and adaptive immunity. In patients 
with high grade GVHD, EMAP-II levels were found to be three-fold elevated after allogeneic 
stem cell transplantation (Nomura et al., 2009). 
                               
Figure 5-2. Secretion of EMAP-II by MSC and Fb leading to T cell apoptosis. 
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5.6.4 Sialic acid-binding immunoglobulin-like lectins-9 (Siglec-9). 
The interaction between activated T cells and MSC or Fb is most probably bi-directional. On one 
hand, factors secreted by activated T cells may trigger the release of T cell suppressive factors by 
MSC and Fb. On the other hand, factors produced by MSC and Fb may affect the T cells. For 
example, siglec expression on T cells can be upregulated, as evidenced by the elevated 
concentration of Siglec-9 in the transwell supernatants.  
Siglecs can recognise sialic acid-containing carbohydrate structures (Avril et al., 2004). Most 
Siglecs contain the immunoreceptor tyrosine-based inhibitory motifs (ITIM) which promote 
inhibitory responses. Upon ligation of the receptor, the ITIM recruit and activate inhibitory 
phosphatases such as Src homology domain 2 (SH2)-containing tyrosine phosphatase-1 (SHP-1) 
and SHP-2 and deliver inhibitory signals (Avril et al., 2004). Siglec-9 is highly expressed on 
monocytes and neutrophils but at lower levels in B cells, NK cells and T cells (Zhang et al., 
2000). Ligation of Siglec-9 can trigger apoptosis in neutrophils (von Gunten et al., 2005). The 
ability of Siglec-9 to recruit SHP-1 to the TCR complex on Jurkat cells resulted in a higher 
activation threshold (Ikehara et al., 2004). It might be possible for the stimulated CD4+ T cells to 
upregulate the expression of Siglec-9 which was subsequently shed into the medium after 
incubation with MSC and Fb (Figure 5-3). The enhanced expression of Siglec-9 could increase 
the activation threshold of T cells and inhibit their proliferation. To confirm this, expression of 
Siglec-9 on T cells before and after incubation with MSC or Fb can be determined using flow 
cytometry. 
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Figure 5-3. Factors produced by MSC and Fb may upregulate Siglec-9 expression on T cells. 
In summary, MSC and Fb might promote the activation of innate immune cells when they are 
infused into the body as they secrete chemokines capable of attracting neutrophils to the sites of 
transplantation. For example, VEGF-C is chemotactic for macrophages. However, the enhanced 
chemotactic activity did not affect their ability to suppress T cell proliferation in the current 
study. EMAP-II and Siglec-9 might play a role in the suppression of T cell proliferation. 
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6 General discussion 
6.1 Implications 
MSC are currently being evaluated in clinical trials for the treatment of a wide range of diseases 
(National Institutes of Health, 2010). For example, Osiris Theapeutics Inc. has completed a 
phase III trial evaluating their proprietary product Prochymal, consisting adult MSC from 
healthy donors, for the treatment of steroid refractory acute GVHD (Osiris Therapeutics Inc., 
2010). Results showed that Prochymal can improve response rates in difficult-to-treat 
gastrointestinal (88% vs 64%) and liver GVHD (76% vs 47%). Despite the clinical potential of 
MSC, primary sources can be limiting. Therefore, it would be useful to explore alternative 
sources of MSC, such as hESC-MSC, which can be more easily obtained and handled ex vivo. 
hESC-MSC have several advantages over adult tissue-derived MSC. The proliferation, 
differentiation potential and therapeutic efficacy of MSC are dependent on the age of the donor 
and the developmental stage of the tissue of origin. In general, MSC generated from younger 
donors and developmentally less mature tissues are more proliferative, have a more robust 
differentiation potential and greater therapeutic efficacy (Sethe et al., 2006). hESC provide a 
renewable tissue source for the generation of MSC and subsequently a more reproducible and 
consistent MSC batch. The hESC-MSC are homogenous and highly similar with each derivation 
(Yen et al., 2009). The similarity between hESC-MSC and adult tissue-derived MSC suggest that 
they could share similar biological activities. 
This work corroborates with previous observations that hESC-MSC can modulate T cell 
responses (Trivedi and Hematti, 2008; Yen et al., 2009). Similar to BM-MSC, hESC-MSC can 
inhibit the proliferation of CD4+ T cells in both contact and transwell systems. They can prevent 
cohort T cells from dividing and inhibit proliferation of T cells which have started dividing. This 
is demonstrated by the lower normalised cohort divided and proliferation index when compared 
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to control cultures with stimulated T cells only. However, hESC-MSC are less effective at 
suppressing T cell proliferation on a per cell basis than BM-MSC. Approximately twice the 
number of hESC-MSC compared to BM-MSC are required to inhibit the proliferation of T cells 
by 50%. Therefore, if hESC-MSC are to be used in cell therapy for immunosuppression, a larger 
cell number will have to be infused to achieve the same effect as BM-MSC. This large cell 
number can be generated easily due to the higher proliferative capacity of hESC-MSC.  
Beside investigating the use of hESC-MSC as an alternative source of MSC, Fb were also 
examined. Fb can be easily obtained from skin biopsies and cultured in vitro. As shown in both 
contact and transwell systems, Fb have similar suppressive effects as BM-MSC. These results 
are supported by previous studies where Fb from different sources have been demonstrated to 
suppress the proliferation of PBMC (Jones et al., 2007; Wada et al., 2010) and CD3+ T cells 
(Haniffa et al., 2007) to a similar extent as BM-MSC. The ability of Fb to immunesuppress 
suggests that the immunosuppressive property is shared by cells of stromal origin. Furthermore, 
it is difficult to distinguish Fb from BM-MSC based on their surface phenotype. The only 
distinction is that Fb are not able to differentiate to the three lineages-osteoblasts, adipocytes and 
chondrocytes. According to the MTSCC-ISCT, MSC should differentiate to the three lineages 
(Dominici et al., 2006). However, Fb from some sources such as the skin and synovial 
membrane tissues have also been reported to differentiate to the three lineages, suggesting that 
multipotent cells might persist depending on the origin of the cells (Haniffa et al., 2007; Jones et 
al., 2007). 
When the degree of inhibition of T cell proliferation was compared between the contact and 
transwell systems, MSC and Fb could still suppress T cell proliferation without direct cell-cell 
contact although cell-cell contact enhanced the suppressive effect by hESC-MSC. Similar results 
have been reported for hESC-MSC (Trivedi and Hematti, 2008), BM-MSC (Ren et al., 2009) and 
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Fb (Haniffa et al., 2007). Supernatants collected from cultures of MSC or Fb with stimulated T 
cells could suppress proliferation of fresh T cells while supernatants from cultures of MSC, Fb or 
stimulated T cells could not. Again, this suggests that soluble factors contribute to the 
suppressive effect of MSC and Fb and that the presence of stimulated T cells is required to 
mediate this suppressive effect. 
Since there was a reduction in viable T cells recovered from transwells after a 5-day incubation, 
we investigated possible mechanisms for enhanced cell death. It is possible that MSC and Fb 
secrete factors which may induce apoptosis of T cells. However, annexin V staining of the T 
cells did not reveal an increase in the apoptotic cell population. Although there was enhanced T 
cell death in the cultures with MSC or Fb present, it did not reach statistical significance. We 
cannot rule out the possibility that apoptosis might have occurred prior to day 5 as early 
apoptosis of activated T cells has been previously demonstrated (Plumas et al., 2005). At the 
same time, there are also literature describing that MSC and Fb have a protective effect on T cell 
apoptosis (Benvenuto et al., 2007; Jones et al., 2007).  
During inflammation, IFN- is released by activated T cells. IFN- can upregulate the expression 
of IDO. IDO activity has been demonstrated in BM-MSC (Plumas et al., 2005; Ren et al., 2009) 
and Fb (Haniffa et al., 2007). In this study, we reported for the first time that hESC-MSC 
expressed IDO when they were incubated with activated T cells as shown by western blots. 
However, MSC and Fb did not express IDO when they were cultured in the absence of activated 
T cells. IDO induction leads to the degradation of tryptophan which is an essential amino acid 
for T cell proliferation. At the same time, the accumulation of tryptophan metabolites-
kynurenine, 3-hydroxykynurenine, 3-hydroxyanthranilic can be toxic to cell proliferation. 
Interestingly, addition of 1-MT, a IDO inhibitor, reversed the suppressive effect of MSC and Fb. 
Despite hESC-MSC expressing elevated levels of IDO as determined by western blotting, they 
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inhibited T cell proliferation to a smaller extent compared to BM-MSC. The discrepancy 
between the amount of IDO and T cell inhibition could be due to the preferential expression of 
different isoforms of IDO. There are two isoforms of IDO, IDO1 and IDO2 (Ball et al., 2007; 
Ball et al., 2009). It is possible that hESC-MSC may express higher levels of IDO2 which has a 
lower potency than IDO1. This may account for the lower concentrations of kynurenines 
measured in the supernatants of hESC-MSC with activated T cells. 
IFN- can also upregulate the expression of PD-L1 and PD-L2 which have been demonstrated to 
be important in mediating the suppressive effect by mouse BM-MSC (Augello et al., 2005) and 
tumour cells (Keir et al., 2008). hESC-MSC and Fb express PD-L1 and PD-L2 basally while 
BM-MSC express negligible amounts of the ligands. Upon incubation with activated T cells, the 
expression of PD-L1 but not PD-L2 was upregulated on all the MSC and Fb, even on BM-MSC. 
This suggests that PD-1/PD-L1/PD-L2 pathway may mediate the suppressive effect of MSC and 
Fb. However, the addition of a neutralising antibody against PD-1, the receptor of PD-L2 and 
PD-L2 did not lead to a reversal in T cell suppression. Therefore, binding of PD-L1 and PD-L2 
to PD-1 is unlikely to be important in MSC or Fb-mediated suppression of T cell proliferation 
due to inter-species differences. Since the cytokines in the supernatants were not measured, it 
cannot be ruled out that other anti-inflammatory cytokines might be produced instead. 
In an attempt to identify novel suppressive factors, antibody arrays comparing the differences in 
cytokines and growth factors present in supernatants of MSC, Fb and stimulated T cells alone 
and transwells of stimulated T cells incubated with MSC or Fb were analysed. Most of the 
factors found to be exclusively upregulated in transwells of MSC and Fb were chemoattractants. 
This implies that the innate immune system will be activated in addition to the interaction 
between MSC or Fb and T cells. Among the factors identified, EMAP-II, VEGF-C and Siglec-9 
may be important in mediating the immunosuppressive effect of MSC and Fb. If the 
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immunosuppressive factors can be identified, they can be given to the patients directly, obviating 
the need for histocompatibility matching when cells are used. 
In summary, hESC-MSC can suppress the proliferation of T cells but are less potent compared to 
BM-MSC and Fb in both contact and transwell systems. Although cell-cell contact can enhance 
the suppressive effect, suppression of T cell proliferation still persists in a transwell. This 
suggests that soluble factors contribute to the suppressive effect of MSC and Fb. Factors 
produced by activated T cells are necessary in the induction of the suppressive effect mediated 
by MSC and Fb since only transwell supernatants are capable of immunosuppression. One 
possible inflammatory cytokine secreted by activated T cells is IFN-. The expression of IDO 
has been linked with IFN- stimulation and IDO plays a role in the suppressive effect of MSC 
and Fb. However, unlike murine MSC, human MSC do not induce T cell apoptosis via FasL or 
inhibit T cell proliferation via PD-L. Factors like EMAP-II, VEGF-C and Siglecs which were 
found to be upregulated in all transwells of MSC and Fb could play a role in the anti-
proliferative effect. 
6.2 Future work 
Since only two hESC-MSC lines were investigated, it would be useful to derive more hESC-
MSC lines for comparison with BM-MSC. 
One of the inflammatory cytokines released by activated T cells is IFN-. IFN- has been 
implicated in the upregulation of IDO by MSC and Fb. To test the importance of IFN- in the 
upregulation of IDO and the subsequent inhibition of T cell proliferation by MSC and Fb, a 
neutralising antibody against IFN- can be added to cultures of MSC or Fb with activated T 
cells. The effect on T cell proliferation in the presence of the neutralising antibody will be 
compared with the isotype control. In addition, western blots to compare the amount of IDO 
expressed by MSC and Fb can be performed to confirm that IDO is indeed downregulated in the 
  
168
presence of the neutralising antibody against IFN-. In addition, the preferred IDO isoform 
expressed by MSC and Fb could be determined. 
Similar experiments as above can be performed to determine the role of IFN- on the expression 
of PD-1, PD-L1 and PD-L2 on MSC and Fb. Before investigating the role of IFN-, more 
experiments with neutralising antibody against PD-1 have to be performed to confirm that the 
binding of PD-L1 and PD-L2 mediates the suppressive effect of MSC and Fb. A positive control 
such as a tumour cell line can be included to confirm that the concentration of neutralising 
antibody against PD-1 used is adequate in reversing the suppressive effect. Neutralising 
antibodies against PD-L1 and PD-L2 can be added to determine which ligand plays a more 
important part in the immunosuppressive effect of MSC and Fb. 
Using antibody arrays, potential suppressive factors produced by MSC and Fb when they were 
incubated with stimulated T cells have been identified. The importance of these suppressive 
factors can be tested individually by adding them into cultures of stimulated T cells only to 
determine if they can suppress T cell proliferation. Another approach is through the use of 
neutralising antibody against the suppressive factor and then determining if T cell suppression is 
reversed.  
Once the potential suppressive factor has been confirmed, their effects on T cells can be further 
determined: 
(a) The CFSE cell proliferation data shows that proliferation of T cells was inhibited with a 
majority of cells remaining in generation 0 (brightest peak). Cell cycle analysis can be done to 
determine the percentage of T cells in the S phase, G2 phase and G0/G1 phase. The specific 
point at which T cell proliferation is arrested by MSC can be evaluated. Western blot analysis for 
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the expression of cyclin D2, cyclin E and p27kip1 as G1 phase-specific markers can be 
performed. 
(b) Apoptotic T cells can be detected using annexin V staining.  
(c) The possibility of T cell anergy can be determined by the addition of exogenous IL-2. 
Classical form of T cell unresponsiveness can be reversed by exogenous IL-2 as T cells express 
normal levels of IL-2 receptor.  
(d)The levels of cytokines secreted by the T cells can be quantified using ELISA. Th1 response 
can be measured by an upregulation of IFN- and IL-2 production while Th2 response is 
characterised by an upregulation of IL-4 and IL-10 production. 
(e) MSC may favour a suppressive phenotype. A flow cytometry characterisation of the 
percentage of CD4+CD25+FoxP3+ Treg cells can be performed. 
These experiments will lead to the confirmation of novel factors which can affect T cell 
proliferation. The subsequent effects on T cell will complete the role of the secreted factors in 
immunomodulation. 
6.3 Conclusion 
The data presented in the current study have demonstrated that hESC-MSC are an attractive 
alternative to BM-MSC in cell therapy requiring immunosuppression since they are able to 
inhibit the proliferation of T cells. In addition, they have the advantage of being an unlimited 
source of MSC which can be consistently derived from hESC. Novel suppressive factors 
identified may be used in the future for immunosuppression. 
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Appendix 1.  List of 507 proteins that can be detected on the Raybio antibody array. 
1 6Ckine  43 BMP-15 85 CXCL16 
2 Activin A  44 BMPR-IA / ALK-3 86 CXCR1 / IL-8 RA 
3 Activin B 45 BMPR-IB / ALK-6 87 CXCR2 / IL-8 RB 
4 Activin C 46 BMPR-II 88 CXCR3 
5 Activin RIA / ALK-2 47 BTC 89 CXCR4 (fusin) 
6 Activin RIB / ALK-4 48 Cardiotrophin-1 / CT-1 90 CXCR5 /BLR-1 
7 Activin RII A/B 49 CCL14 / HCC-1 / HCC-3 91 CXCR6 
8 Activin RIIA 50 CCL28 / VIC 92 D6 
9 Adiponectin / Acrp30 51 CCR1 93 DAN 
10 AgRP 52 CCR2 94 DANCE 
11 ALCAM 53 CCR3 95 DcR3 / TNFRSF6B 
12 Angiogenin 54 CCR4 96 Decorin 
13 Angiopoietin-1 55 CCR5 97 Dkk-1 
14 Angiopoietin-2 56 CCR6 98 Dkk-3 
15 Angiopoietin-4 57 CCR7 99 Dkk-4  
16 Angiopoietin-like 1 58 CCR8 100 DR3 / TNFRSF25 
17 Angiopoietin-like 2 59 CCR9 101 DR6 / TNFRSF21 
18 Angiopoietin-like Factor  60 CD14 102 Dtk 
19 Angiostatin  61 CD27 / TNFRSF7 103 EDA-A2 
20 APJ 62 CD30 / TNFRSF8 104 EDAR 
21 AR (Amphiregulin) 63 CD30 Ligand / TNFSF8 105 EDG-1 
22 APRIL  64 CD40 / TNFRSF5 106 EGF 
23 Artemin 65 CD40 Ligand / TNFSF5 
/CD154 
107 EGF R / ErbB1 
24 Axl 66 CD 163 108 EG-VEGF / PK1 
25 B7-1 /CD80 67 Cerberus 1 109 EMAP-II 
26 BAFF R / TNFRSF13C 68 Chem R23 110 ENA-78 
27 BCMA / TNFRSF17 69 Chordin-Like 1 111 Endocan 
28 BD-1 70 Chordin-Like 2 112 Endoglin / CD105 
29 BDNF  71 Csk 113 Endostatin 
30 beta-Catenin 72 CLC 114 EN-RAGE 
31 beta-Defensin 2 73 CNTF  115 Eotaxin / CCL11 
32 beta-NGF 74 CNTF R alpha 116 Eotaxin-2 / MPIF-2 
33 BIK 75 Coagulation Factor III / 
Tissue Factor 
117 Eotaxin-3 / CCL26 
34 BLC / BCA-1 / CXCL13 76 CRIM 1 118 Epiregulin 
35 BMP-2  77 Cripto-1  119 ErbB2 
36 BMP-3 78 CRTH-2 120 ErbB3 
37 BMP-3b / GDF-10 79 Cryptic 121 ErbB4 
38 BMP-4  80 CTACK / CCL27 122 Erythropoietin  
39 BMP-5 81 CTGF / CCN2 123 E-Selectin 
40 BMP-6 82 CTLA-4 /CD152 124 Endothelin 
41 BMP-7  83 CV-2 / Crossveinless-2 125 FADD 
42 BMP-8 84 CXCL14 / BRAK 126 FAM3B 
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127 Fas / TNFRSF6 169 GDF3 211 ICAM-5 
128 Fas Ligand 170 GDF5 212 IFN-alpha / beta R1 
129 FGF Basic 171 GDF8 213 IFN-alpha / beta R2 
130 FGF-BP 172 GDF9 214 IFN-beta  
131 FGF R3 173 GDF11 215 IFN-gamma 
132 FGF R4 174 GDF-15 216 IFN-gamma R1 
133 FGF R5 175 GDNF  217 IGFBP-1  
134 FGF-4  176 GFR alpha-1 218 IGFBP-2  
135 FGF-5 177 GFR alpha-2 219 IGFBP-3  
136 FGF-6  178 GFR alpha-3 220 IGFBP-4  
137 FGF-7 / KGF 179 GFR alpha-4 221 IGFBP-6 
138 FGF-8  180 GITR / TNFRF18 222 IGFBP-rp1 / IGFBP-7 
139 FGF-9  181 GITR Ligand / TNFSF18 223 IGF-I 
140 FGF-10 / KGF-2 182 Glucagon 224 IGF-I SR 
141 FGF-11 183 Glut1 225 IGF-II 
142 FGF-12 184 Glut2 226 IGF-II R 
143 FGF-13 1B 185 Glut3 227 IL-1 alpha 
144 FGF-16 186 Glut5 228 IL-1 beta 
145 FGF-17  187 Glypican 3 229 IL-1 F5 / FIL1delta 
146 FGF-18  188 Glypican 5 230 IL-1 F6 / FIL1 epsilon 
147 FGF-19  189 GM-CSF 231 IL-1 F7 / FIL1 zeta 
148 FGF-20 190 GM-CSF R alpha 232 IL-1 F8 / FIL1 eta 
149 FGF-21 191 Granzyme A 233 IL-1 F9 / IL-1 H1 
150 FGF-23 192 GREMLIN 234 IL-1 F10 / IL-1HY2 
151 FLRG 193 GRO 235 IL-1 R3 / IL-1 R AcP 
152 Flt-3 Ligand  194 GRO-a 236 IL-1 R4 /ST2 
153 Follistatin 195 Growth Hormone (GH) 237 IL-1 R6 / IL-1 Rrp2 
154 Follistatin-like 1 196 Growth Hormone R (GHR) 238 IL-1 R8 
155 Fractalkine  197 HB-EGF 239 IL-1 R9 
156 Frizzled-1 198 HCC-4 / CCL16 240 IL-1 ra  
157 Frizzled-3 199 HCR / CRAM-A/B 241 IL-1 sRI 
158 Frizzled-4 200 Hepassocin 242 IL-1 sRII 
159 Frizzled-5 201 
Heregulin / NDF / GGF / 
Neuregulin 243 IL-2 
160 Frizzled-6 202 HGF  244 IL-2 R alpha  
161 Frizzled-7 203 HGFR 245 IL-2 R beta /CD122 
162 Galectin-3 204 HRG-alpha  246 IL-2 R gamma  
163 GASP-1 / WFIKKNRP 205 HRG-beta 1 247 IL-3 
164 GASP-2 / WFIKKN 206 HVEM / TNFRSF14 248 IL-3 R alpha 
165 GCP-2 / CXCL6 207 I-309 249 IL-4 
166 GCSF 208 ICAM-1 250 IL-4 R 
167 G-CSF R / CD 114 209 ICAM-2 251 IL-5 
168 GDF1 210 ICAM-3 (CD50) 252 IL-5 R alpha  
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253 IL-6 295 IL-23 337 MCP-4 / CCL13 
254 IL-6 R 296 IL-23 R 338 M-CSF 
255 IL-7 297 IL-24 339 M-CSF R  
256 IL-7 R alpha 298 IL-26 340 MDC 
257 IL-8 299 IL-27 341 MFG-E8 
258 IL-9   300 IL-28A 342 MFRP 
259 IL-10 301 IL-29 343 MIF  
260 IL-10 R alpha  302 IL-31 344 MIG 
261 IL-10 R beta  303 IL-31 RA 345 MIP-1a 
262 IL-11 304 Inhibin A  346 MIP-1b 
263 IL-12 p40 305 Inhibin B  347 MIP-1d 
264 IL-12 p70 306 Insulin 348 MIP 2 
265 IL-12 R beta 1 307 Insulin R 349 MIP-3 alpha  
266 IL-12 R beta 2 308 Insulysin / IDE 350 MIP-3 beta  
267 IL-13 309 IP-10  351 MMP-1  
268 IL-13 R alpha 1 310 I-TAC / CXCL11 352 MMP-2  
269 IL-13 R alpha 2 311 Kininostatin / kininogen 353 MMP-3 
270 IL-15 312 Kremen-1 354 MMP-7  
271 IL-15 R alpha 313 Kremen-2 355 MMP-8  
272 IL-16  314 Lck 356 MMP-9  
273 IL-17 315 Latent TGF-beta bp1  357 MMP-10  
274 IL-17B 316 LBP 358 MMP-11 /Stromelysin-3 
275 IL-17B R 317 LECT2  359 MMP-12  
276 IL-17C 318 Lefty - A 360 MMP-13  
277 IL-17D 319 Leptin R 361 MMP-14  
278 IL-17E 320 Leptin (OB) 362 MMP-15 
279 IL-17F 321 LFA-1 alpha  363 MMP-16 / MT3-MMP 
280 IL-17R 322 LIF  364 MMP-19 
281 IL-17RC 323 LIF R alpha 365 MMP-20  
282 IL-17RD 324 LIGHT / TNFSF14 366 MMP-24 / MT5-MMP 
283 IL-18 BPa  325 Lipocalin-1 367 MMP-25 / MT6-MMP 
284 IL-18 R alpha /IL-1 R5 326 LRP-1 368 Musk 
285 IL-18 R beta /AcPL 327 LRP-6 369 MSP alpha Chain 
286 IL-19 328 L-Selectin (CD62L) 370 MSP beta-chain 
287 IL-20 329 Luciferase 371 NAP-2  
288 IL-20 R alpha 330 Lymphotactin / XCL1 372 NCAM-1 / CD56 
289 IL-20 R beta 331 Lymphotoxin beta / TNFSF3 373 Neuritin  
290 IL-21 332 
Lymphotoxin beta R / 
TNFRSF3 374 NeuroD1 
291 IL-21 R  333 MAC-1  375 Neuropilin-2 
292 IL-22 334 MCP-1 376 Neurturin  
293 IL-22 BP 335 MCP-2 377 NGF R  
294 IL-22 R 336 MCP-3 378 NOV / CCN3 
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379 NRG1 Isoform GGF2 422 SCF R /CD117 465 TIMP-2  
380 NRG1-alpha / HRG1-alpha 423 SDF-1 / CXCL12 466 TIMP-3  
381 NRG1-beta1 / HRG1-beta1 424 sFRP-1 467 TIMP-4  
382 NRG2 425 sFRP-3 468 TL1A / TNFSF15 
383 NRG3 426 sFRP-4 469 TLR1 
384 NT-3  427 sgp130 470 TLR2 
385 NT-4  428 SIGIRR 471 TLR3 
386 Orexin A  429 Siglec-5/CD170 472 TLR4 
387 Orexin B 430 Siglec-9 473 TMEFF1 / Tomoregulin-1 
388 OSM 431 SLPI  474 TMEFF2 
389 Osteoactivin / GPNMB 432 Smad 1 475 TNF-alpha 
390 Osteocrin 433 Smad 4 476 TNF-beta 
391 
Osteoprotegerin / 
TNFRSF11B 434 Smad 5 477 TNF RI / TNFRSF1A 
392 OX40 Ligand / TNFSF4 435 Smad 7 478 TNF RII / TNFRSF1B 
393 PARC / CCL18 436 Smad 8 479 TRADD 
394 PD-ECGF 437 SMDF / NRG1Isoform 480 TRAIL / TNFSF10 
395 PDGF R alpha  438 Soggy-1 481 TRAIL R1 / DR4 / TNFRSF10A 
396 PDGF R beta  439 
Sonic Hedgehog (Shh N-
terminal) 482 TRAIL R2 / DR5 / TNFRSF10B 
397 PDGF-AA 440 SPARC  483 TRAIL R3 / TNFRSF10C 
398 PDGF-AB 441 Spinesin 484 TRAIL R4 / TNFRSF10D 
399 PDGF-BB 442 TACI / TNFRSF13B 485 TRANCE  
400 PDGF-C 443 Tarc 486 TREM-1 
401 PDGF-D 444 TCCR / WSX-1 487 TROY / TNFRSF19 
402 PECAM-1 /CD31 445 TECK / CCL25 488 TSG-6 
403 Pentraxin3 / TSG-14 446 TFPI 489 TSLP  
404 Persephin 447 TGF-alpha 490 TWEAK / TNFSF12 
405 PF4 / CXCL4 448 TGF-beta 1 491 TWEAK R / TNFRSF12 
406 PlGF  449 TGF-beta 2  492 Ubiquitin+1 
407 PLUNC 450 TGF-beta 3  493 uPA  
408 Pref-1 451 TGF-beta 5 494 uPAR 
409 Progranulin 452 TGF-beta RI / ALK-5 495 Vasorin 
410 Prolactin  453 TGF-beta RII 496 VCAM-1 (CD106) 
411 P-selectin 454 TGF-beta RIIb 497 VE-Cadherin 
412 RAGE 455 TGF-beta RIII 498 VEGF 
413 RANK / TNFRSF11A 456 Thrombopoietin (TPO) 499 VEGF R2 (KDR) 
414 RANTES 457 Thrombospondin (TSP) 500 VEGF R3  
415 RELM beta 458 Thrombospondin-1 501 VEGF-B 
416 RELT / TNFRSF19L 459 Thrombospondin-2 502 VEGF-C  
417 ROBO4 460 Thrombospondin-4 503 VEGF-D  
418 S100 A8/A9 461 Thymopoietin  504 VEGI / TNFSF15 
419 S100A10 462 Tie-1 505 WIF-1 
420 SAA 463 Tie-2 506 WISP-1 / CCN4 
421 SCF 464 TIMP-1  507 XEDAR 
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Appendix 2. List of proteins upregulated in transwells of MSC or Fb with stimulated T cells 
 
A. Transwell of hESC-MSC1 with stimulated T cells 
Protein Upregulation in signal intensity 
IL-8 70934 
GDF-15 51627 
Activin A  35124 
ENA-78 19324 
Thrombospondin (TSP) 17510 
MIP 2 16615 
Granzyme A 15287 
TIMP-1  14949 
Osteoprotegerin / TNFRSF11B 14053 
Siglec-9 9981 
GM-CSF 8152 
BMPR-II 7194 
MMP-10  5589 
Activin C 5507 
IL-17 5348 
CD40 / TNFRSF5 5256 
MCP-3 5253 
PDGF-AA 5165 
sgp130 5097 
Glucagon 4767 
Cardiotrophin-1 / CT-1 4534 
MIG 3973 
FGF-6  3969 
Angiostatin  3900 
CNTF R alpha 3646 
VEGF-C  3520 
IL-6 3462 
EDG-1 3363 
Angiopoietin-like 2 3255 
GRO 2978 
IL-19 2740 
BLC / BCA-1 / CXCL13 2493 
MSP beta-chain 2275 
Follistatin 2072 
GDF3 1658 
beta-NGF 1656 
Progranulin 1616 
IGF-I SR 1550 
MMP-12  1430 
IL-1 alpha 1351 
I-TAC / CXCL11 1329 
IGFBP-6 1227 
Orexin B 1213 
DR6 / TNFRSF21 1169 
Chem R23 932 
uPA  923 
Activin RIA / ALK-2 874 
APRIL  855 
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GRO-a 846 
Growth Hormone (GH) 750 
IL-1 F5 / FIL1delta 721 
Chordin-Like 1 689 
BMP-3 681 
IL-29 675 
Lipocalin-1 656 
IL-20 R alpha 649 
MSP alpha Chain 620 
FADD 579 
G-CSF R / CD 114 549 
Erythropoietin  548 
Frizzled-6 540 
FGF-10 / KGF-2 538 
ICAM-2 507 
MCP-2 483 
IL-17B 464 
IL-20 R beta 464 
VEGF 440 
MFRP 342 
Chordin-Like 2 333 
IL-9   332 
CNTF  273 
EMAP-II 262 
Epiregulin 248 
DR3 / TNFRSF25 193 
Musk 174 
Cryptic 165 
Frizzled-7 163 
ErbB3 146 
TIMP-3  119 
BDNF  115 
IFN-beta  104 
Angiopoietin-like 1 88 
Eotaxin / CCL11 72 
IL-10 R beta  60 
CCR1 55 
MCP-1 54 
 
B. Transwell of hESC-MSC2 with stimulated T cells 
Protein Upregulation in signal intensity 
IL-8 101616 
Activin A  79005 
TIMP-1  53458 
GDF-15 14407 
MIP 2 12827 
Siglec-9 8650 
uPA  6992 
Latent TGF-beta bp1  5228 
IL-19 5040 
IL-2 4329 
IGFBP-rp1 / IGFBP-7 3366 
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MMP-10  3014 
IL-10 R beta  2974 
MIG 2409 
sgp130 2330 
VEGF-C  2276 
BMPR-II 2001 
ICAM-1 1992 
GM-CSF 1960 
ENA-78 1756 
Erythropoietin  1517 
IL-10 R alpha  1459 
EMAP-II 1299 
Growth Hormone (GH) 1295 
CD40 Ligand / TNFSF5 /CD154 1204 
IL-1 F5 / FIL1delta 1172 
IL-20 R alpha 1122 
Angiostatin  1018 
Endocan 985 
IL-4 R 915 
MSP alpha Chain 889 
Angiopoietin-4 866 
IGFBP-3  787 
ALCAM 783 
CXCL16 780 
IL-20 R beta 777 
NCAM-1 / CD56 760 
Frizzled-6 725 
CCL28 / VIC 678 
GDF1 634 
Dtk 625 
MCP-2 605 
Progranulin 521 
FGF-23 433 
HB-EGF 383 
RELT / TNFRSF19L 380 
DcR3 / TNFRSF6B 352 
I-TAC / CXCL11 323 
Activin RIB / ALK-4 309 
FGF-7 / KGF 303 
FADD 291 
GASP-1 / WFIKKNRP 289 
Hepassocin 205 
Endoglin / CD105 198 
GCP-2 / CXCL6 193 
Angiopoietin-2 166 
G-CSF R / CD 114 141 
CXCR3 128 
WIF-1 107 
MCP-3 105 
HCC-4 / CCL16 90 
FGF-16 74 
Frizzled-5 66 
  
195
TGF-beta RI / ALK-5 51 
TGF-beta RII 18 
IGF-II R 11 
Angiogenin 9 
 
C. Transwell of BM-MSC with stimulated T cells 
Protein Upregulation in signal intensity 
ENA-78 14762 
Endocan 14708 
MIP 2 13307 
CXCL16 9171 
CCL28 / VIC 5958 
MIG 5631 
sgp130 5232 
CD40 Ligand / TNFSF5 /CD154 4496 
Angiostatin  3493 
MCP-2 3267 
Siglec-9 2915 
Angiopoietin-like 1 2728 
SCF R /CD117 2658 
FGF-7 / KGF 2610 
SCF 2533 
BMPR-II 2485 
IGFBP-rp1 / IGFBP-7 2189 
VEGF-C  1856 
FAM3B 1104 
SDF-1 / CXCL12 1035 
MSP alpha Chain 782 
PDGF-AB 613 
IL-10 609 
sFRP-1 566 
BDNF  536 
EMAP-II 488 
GRO 478 
CCR4 346 
AR (Amphiregulin) 300 
IL-17RD 282 
Musk 198 
IL-2 160 
OX40 Ligand / TNFSF4 113 
Chordin-Like 1 89 
B7-1 /CD80 55 
 
D. Transwell of Fb with stimulated T cells 
Protein Upregulation in signal intensity 
IL-8 29124 
ENA-78 21597 
IL-19 11437 
IL-2 10463 
Siglec-9 10182 
MCP-3 8754 
Thrombospondin-2 5608 
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MIG 5591 
MIP 2 3155 
sgp130 2528 
BMP-8 2481 
CXCL16 2471 
FGF-16 2399 
RANTES 2376 
Angiopoietin-2 2320 
CRIM 1 2309 
Erythropoietin  2268 
Glucagon 2030 
Soggy-1 1796 
G-CSF R / CD 114 1671 
VEGF 1650 
NeuroD1 1520 
LECT2  1423 
SCF 1413 
IL-4 R 1389 
FGF-7 / KGF 1327 
IL-7 R alpha 1222 
Lymphotoxin beta R / TNFRSF3 1214 
Smad 4 1208 
SCF R /CD117 1117 
IL-1 alpha 1038 
CD40 Ligand / TNFSF5 /CD154 1007 
PDGF-AA 955 
sFRP-1 931 
TRAIL R2 / DR5 / TNFRSF10B 787 
VEGF-C  769 
TREM-1 698 
Eotaxin / CCL11 676 
SDF-1 / CXCL12 651 
CXCR5 /BLR-1 643 
Orexin B 588 
Cardiotrophin-1 / CT-1 531 
MMP-10  523 
Cripto-1  514 
GFR alpha-2 317 
Epiregulin 302 
ICAM-1 298 
EMAP-II 291 
IL-9   290 
Dtk 280 
IL-20 R alpha 226 
Progranulin 185 
CCL28 / VIC 152 
MMP-1  55 
AR (Amphiregulin) 27 
 
